var title_f8_1_8208="Diagnosis male infertility I";
var content_f8_1_8208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Approach to diagnosis of male infertility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 620px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     T: testosterone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; ICSI: intracytoplasmic sperm injection.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8208=[""].join("\n");
var outline_f8_1_8208=null;
var title_f8_1_8209="Contents: Pediatric allergy";
var content_f8_1_8209=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric allergy",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric allergy",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Allergy pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/43/19129\">",
"           Increasing prevalence of asthma and allergic rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/41/20119\">",
"           Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/6/31848\">",
"           The biology of IgE",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17304\">",
"           The impact of breastfeeding on the development of allergic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/22/30056\">",
"           The relationship between IgE and allergic disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anaphylaxis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/15/17656\">",
"           Anaphylaxis induced by subcutaneous allergen immunotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/11/9401\">",
"           Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/29/35290\">",
"           Anaphylaxis: Rapid recognition and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/62/38888\">",
"           Differential diagnosis of anaphylaxis in children and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26777\">",
"           Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/45/42709\">",
"           Exercise-induced anaphylaxis: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/13/1241\">",
"           Fatal anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/17/34071\">",
"           Idiopathic anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/54/40809\">",
"           Laboratory tests to support the clinical diagnosis of anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/44/5833\">",
"           Long-term management of patients with anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18778\">",
"           Pathophysiology of anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23832\">",
"           Prescribing epinephrine for anaphylaxis self-treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/53/33625\">",
"           Unique aspects of anaphylaxis in infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma epidemiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15319\">",
"           Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7383\">",
"           Natural history of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20682\">",
"           Risk factors for asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34920\">",
"           Wheezing phenotypes and prediction of asthma in young children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26010\">",
"           Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25878\">",
"           Flow-volume loops",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/27/29112\">",
"           Overview of pulmonary function testing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/854\">",
"           Peak expiratory flow rate monitoring in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/41/1689\">",
"           Wheezing illnesses other than asthma in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11642\">",
"           Acute asthma exacerbations in children: Inpatient management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/16/33034\">",
"           Acute asthma exacerbations in children: Outpatient management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/44/22218\">",
"           Acute severe asthma exacerbations in children: Intensive care unit management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30746\">",
"           Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33354\">",
"           Alternative and experimental agents for the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/37/8794\">",
"           An overview of asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/24/20870\">",
"           Anticholinergic agents in the management of acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37354\">",
"           Chronic asthma in children younger than 12 years: Controller medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39670\">",
"           Chronic asthma in children younger than 12 years: Quick-relief agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31014\">",
"           Delivery of inhaled medication in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7114\">",
"           Major side effects of inhaled glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/854\">",
"           Peak expiratory flow rate monitoring in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/57/36760\">",
"           The use of inhaler devices in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11161\">",
"           Theophylline use in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18154\">",
"           Treatment of intermittent and mild persistent asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26745\">",
"           Treatment of moderate persistent asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/9/44184\">",
"           Trigger control to enhance asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/42/30376\">",
"           Use of medication nebulizers in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31991\">",
"           What do patients need to know about their asthma?",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15319\">",
"           Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma triggers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39944\">",
"           Aspirin exacerbated respiratory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1513\">",
"           Exercise-induced bronchoconstriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/42/34472\">",
"           Nocturnal asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/44/22216\">",
"           Treatment of recurrent virus-induced wheezing in young children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/15/2298\">",
"           Virus-induced wheezing and asthma: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bites and stings",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/16/24839\">",
"           Approach to the patient with a suspected spider bite: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/22/6502\">",
"           Bees, yellow jackets, hornets, and wasps: Avoidance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9271\">",
"           Bees, yellow jackets, hornets, and wasps: Biology and identification",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cutaneous disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26104\">",
"           Contact dermatitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/40/42631\">",
"           Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/40/3721\">",
"           Overview of dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/59/26551\">",
"           Role of allergy in atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnostic methods for allergic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/22/44391\">",
"           Overview of in vitro allergy tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/55/32633\">",
"           Overview of skin testing for allergic disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43097\">",
"           Allergic reactions to vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/46/23274\">",
"           Allergy to penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39944\">",
"           Aspirin exacerbated respiratory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/2/26663\">",
"           Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27209\">",
"           Clinical manifestations and diagnosis of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/17/41241\">",
"           Drug eruptions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2456\">",
"           Drug fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31305\">",
"           Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/57/43930\">",
"           Infusion reactions to systemic chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/5/1110\">",
"           Penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/40/8842\">",
"           Serum sickness and serum sickness-like reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/59/1978\">",
"           Vancomycin hypersensitivity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eosinophil-related disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24745\">",
"           Approach to the patient with eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27688\">",
"           Causes of pulmonary eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40632\">",
"           Eosinophilic meningitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32474\">",
"           Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eye disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34856\">",
"           Allergic conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37910\">",
"           Atopic keratoconjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20760\">",
"           Conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/60/5062\">",
"           Giant papillary conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/19/6452\">",
"           Toxic conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37352\">",
"           Vernal keratoconjunctivitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Food allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/52/11082\">",
"           Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14808\">",
"           Clinical manifestations of food allergy: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/12/5321\">",
"           Diagnostic evaluation of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/9/33944\">",
"           Egg allergy: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13223\">",
"           Egg allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/63/2042\">",
"           Food allergens: Overview of clinical features and cross-reactivity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/39/3705\">",
"           Food allergy in schools and camps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42759\">",
"           Food allergy: Impact on health-related quality of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/0/38920\">",
"           Food-induced anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/21/10585\">",
"           Future diagnostic tools for food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44057\">",
"           Future therapies for food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/17/26904\">",
"           History and physical examination in the patient with possible food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/30/20967\">",
"           Influenza vaccination in individuals with egg allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/37/25175\">",
"           Introducing formula and solid foods to infants at risk for allergic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37430\">",
"           Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/48/18185\">",
"           Management of food allergy: Avoidance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29640\">",
"           Milk allergy: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/9/40087\">",
"           Milk allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/56/23433\">",
"           Molecular features of food allergens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/51/7993\">",
"           Nutritional issues in food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/59/20409\">",
"           Oral food challenges for diagnosis and management of food allergies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/42/43689\">",
"           Pathogenesis of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/41/5785\">",
"           Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38457\">",
"           Peanut, tree nut, and seed allergy: Clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/27/9654\">",
"           Peanut, tree nut, and seed allergy: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32919\">",
"           Peanut, tree nut, and seed allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/55/38776\">",
"           Respiratory manifestations of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/61/16346\">",
"           Seafood allergies: Fish and shellfish",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/28/12746\">",
"           The natural history of childhood food allergy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypersensitivity pneumonitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/22/26985\">",
"           Approach to the infant and child with interstitial lung disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Immune complex disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40729\">",
"           Clinical manifestations and diagnosis of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/62/4070\">",
"           Hypersensitivity vasculitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28646\">",
"           Management of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/54/5993\">",
"           Renal manifestations of Henoch-Sch������nlein purpura",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insect allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7752\">",
"           Entomology and control of imported fire ants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/35/28216\">",
"           Insect bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/1/43031\">",
"           Prevention of arthropod and insect bites: Repellents and other measures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/51/7994\">",
"           Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mast cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/1/6170\">",
"           Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18650\">",
"           Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/22/44393\">",
"           Mast cells: Development, identification, and physiologic roles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41767\">",
"           Treatment and prognosis of cutaneous mastocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39817\">",
"           Treatment and prognosis of systemic mastocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/54/11110\">",
"           Assessment of mold in the indoor environment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/48/31496\">",
"           Chinese herbal medicine for the treatment of allergic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41895\">",
"           Control of secondhand smoke exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9785\">",
"           Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40070\">",
"           Latex allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17882\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33801\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/8/39049\">",
"           Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rhinitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/53/22362\">",
"           Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/17/30999\">",
"           An overview of rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/5/18519\">",
"           Atrophic rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12250\">",
"           Chronic nonallergic rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/39/6775\">",
"           Pathogenesis of allergic rhinitis (rhinosinusitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/60/37834\">",
"           Pharmacotherapy of allergic rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/18/20776\">",
"           Relationships between rhinosinusitis and asthma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sinusitis and nasal polyposis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/36/8775\">",
"           Fungal rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/4/30794\">",
"           Management of chronic rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11674\">",
"           Orbital cellulitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/6/27751\">",
"           Preseptal cellulitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urticaria and angioedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/22/15721\">",
"           Cold urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/52/19272\">",
"           Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33864\">",
"           Hereditary angioedema: Pathogenesis and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29658\">",
"           Hereditary angioedema: Prevention of attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33657\">",
"           Hereditary angioedema: Treatment of acute attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-5DEC244A40-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_1_8209=[""].join("\n");
var outline_f8_1_8209=null;
var title_f8_1_8210="Optic disc infiltration";
var content_f8_1_8210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukemic and lymphomatous optic disc infiltration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top: Leukemic infiltration. Bottom: Lymphomatous infiltration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8210=[""].join("\n");
var outline_f8_1_8210=null;
var title_f8_1_8211="Metagonimus egg";
var content_f8_1_8211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Metagonimus egg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Egg of Metagonimus spp from human.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the Web Atlas of Medical Parasitology. Copyright &copy; 2003 The Korean Society for Parasitology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8211=[""].join("\n");
var outline_f8_1_8211=null;
var title_f8_1_8212="Carisoprodol: Patient drug information";
var content_f8_1_8212=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carisoprodol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32693?source=see_link\">",
"     see \"Carisoprodol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Soma&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691274",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carisoprodol, meprobamate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with rest, PT (physical therapy), pain drugs, and other therapies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11764 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-1F4CD360AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8212=[""].join("\n");
var outline_f8_1_8212=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146360\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017066\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017065\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017070\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017071\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017073\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017068\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017069\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017074\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017075\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32693?source=related_link\">",
"      Carisoprodol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_1_8213="Eosinophilia";
var content_f8_1_8213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peripheral blood smear on the left is from a five-month-old boy with eosinophilia of unknown cause. Eosinophil granules are normal in number and size; nuclei are slightly hyperlobulated (ie, more than the usual two lobes). Eosinophilia gradually regressed, with no residual organ dysfuction. The peripheral blood smear on the right is from a 50-year-old male with hypereosinophilic syndrome and a three year history of eosinophilia, bone marrow failure and multiple end-organ involvement. The eosinophils show marked hypogranulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8213=[""].join("\n");
var outline_f8_1_8213=null;
var title_f8_1_8214="Rosacea keratitis - quiescent";
var content_f8_1_8214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61078%7EDERM%2F74260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61078%7EDERM%2F74260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The quiescent phase. An extensive vascularized corneal scar of moderate opacity is present. Corneal vessels are not actively dilated, and apart from the region of invading vessels, the globe is white.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Rosacea keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAdEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDt7mUc/N0rEvZsA/NVxlmuZRFChZj0A71zXiWZ9KZlvQYzjODXA77nv0oq9upS1rVVs43JPPavNNc1eW+lbLHZ9aXxHrj3sxVPuA+tYYl7YpJHavdViZMnrUvmBcY6iq4cnjFO+YDpViY+QlsljUYA6npSgZ+9mpMDHTAoElYTYWGKcEwMGnxEBfmxketNd1560xXGEdeagkb061IzEnAqMofSkTzEYyetO2k08YUdMmpQnGSKBNkAQ564pcHHIzU+zPU0112jgEmrUSOcqhQxJHSngACpfKZTuOAD2qOUqMgDmqjAzlUEAGck4prS44HSoJZgMgnPtVRpWfjoO1axpM5KuJS2LEtxjOW4qq9yCcDnNNaJmODnihYDnpW6p2OKWInIjeRznHAqA5Y9DV4WxzznmpEsxnuaq1jLVmaEyPlBNJsbkdK2EtT0FNlsySM9RQkHL3MoRZ4NJsxWkLfDDNDWvHFFtR8qsZ2wY5FOCgLVxrc4pfs/y9KLAUR0PanAZ71Y8nrxikWHPShomxHtIFJjOateSRjPFNaI5qS7aFYL6ikkHHpVhlPpUbr7UCaK+OOtAHSpCvbvTlTjJqiLakPPFKBTivNKV9KBjCKTuKfg88U3GDU2GA4znvSN0py9TS7RSsALxjNPHXikXgUAkk0WGmPB4zmp42bGarpx1qUNg5zgVm4nRTmWVkJ6ipAc96ro+7gjip0A/hrBo9CnO+xICRjFSrJ2NRUYzUG6bLSyYPGasxzkdTkVmBiGGDUquCfSpaNVI6XTNSmgIaKUjHau88PeL2XZHcMVPrXkUcpU8HBHStG01EqAJAT7ipcS2lI+k9J1+ORFPmA10tpfrKnWvmfTdcmtipjkJUdieldzoPjRSypKxU+5qVJxOSrg76xPafPX1orgf+Epg/56D86Kv2px/VZdinda6ukuZzxjj3IryTx74qn8QXxc5CKNoGe1O8W6499cFVYhAexrlmC845NK7aserClGD5upX29acsW6pAMmn7fQ0yhuAmB6Uobnml2Z981L5fy8YpgNUc8d6G469aPmQ5bFIwZmzjrQJsjdizAChYyzAdR3q1HEu0ZHJqVUwMAVRm2V1gVevNP8kY+WrCx45fNP2k/dT8qpIzcislrzk9aVYGZs/pV5MInzD5qPNSNQzEA+lXGJlKoU1hIck4wO1MuHji5xzTbu/wAkiJetZc3mTMSxNbKm2c066QtzebicZqozSSE4HFWFty3AHNWorRjhcfNW0aaRxzqzmZscBk+tTxWJZsCtiKxKEcda0rWxBPTrWiRNu5gw6aWHPX0qyunZBAGK6FLVU6DJBqybMlsgde1NLuHMkjlxYAHBWnf2fgggV0TWfXPUVM1l+7BA600hcyOZWz5IxTHtMZ4rq4tPLDgU2XTGCM200uUOdHGizz2xSG1OSMZrqTp5XBxxQNOJOSKOUd0coLTJ5WnmxxyB1rpl08qTxzUw04lehye2KGhpo49rI88UkFh1I5rqrjTWA6Hj2og09vL4XnNFg0vc5oWG4/SoZrEhuBn19q6trTBIUfpSfYgV9/pSURtpnJGx45GMVVktTk+1di9lkYx+lUZLE7sY6mlyiaRy/wBl71GYSBwK6g2Hy5IwM4qtLY+2KXLoJxOdMR7jio2THGOK25rUrwBVY2mPmNHKyWjMdCF4FRHGeK0pYd3aqrQgHA60rCZXVRnk07qakKYOO9IUxSDYjZTQD0FTFc9KQx7etArPcjbgCnEggU1jmmnPGKlq41KxPG2DwKtxNntiqCE1ajJxx1rOUTqo1GWxjvSn2qNM96lVeK5nE9OEroaVxTcnPTirGAahdfSpNUJweaVSQPvVHtIHWgHHegouxTMnTNaNlfbHG7HFYnm4HHNKsy55GD61DiVGp3Oy/tJfU/nRXJeeP79FTyl+0RoyDezL/EDk0hjIGOxqzIOAw6moiSSM1QDAgApyxq6BqV03AAGnqMHGOKBMQKoXgVHKQqnBNSSY6DihItxCnmmS2RRruOTmpdnzbscVcit8J0p4gymKaRnzkEceVBxUoiJIxU8cXAXPFTHZAuXNaxjcwnUsQJbno1SlkhQjIrOutTAJWMZNZ7SzzbskAVuodjmnU7ly7vuSExn2rOcyTSAPn6Vct7fKgt+dX0swUH96tVCxzSm5GZb2xA57dqmSz289Qa2Ut/lBZcCp/sx25AGK0SMr2MyCwJYHAA9KuW1qTcFVXJPQ1ZSKVFGKvaem6Q7uvFXbYnmSvYqR2nz4P41Zjt/KfOOK13stygqOTUsNm0gVCOversYup3M+K2RiNw96uJBzjFalrprFghHStL+yiu3jj1ppGUqqRzg08tLyvBqxBpxZWQjkfyrpLe1Cz7WAxV24tEEHmIdsi8j3FFupm6vQ5CbTzDEHTnHJFW7aCO4iUADB61qlFbjjDCqsNqYJSFPy5zQ11Q1O+jKF1pcRiOB361DFYxjA29K6Z4kKFRwcZrJ8ttxFSxxk3oym2kowLIuM0kdhhguK3bFgqbZBxUkqKHyvShNA5MwbrTlKniqJsQq5FdNcL8gJGRVK4hIB28AjpTbGpMxItL3SEgDFWBpCFc7MGtvTINqYdcnrk1pxxptAKjBPX0qlZkyqtbHET6Sem39KpDSD8x2/SvS57MMF2qNp/Wqt3ZJEm4KACOlDiJYhnm76VtAyuQe/vVG50xu4P5V6GbFZQVYgK3I9qqvpwZyrJux/F0qUlszZVup5lc6ewY/KcfSqjWWQ2R0r0m80kPIPLHA61nzaPsDnbQ49jWNZdTzqfTztJA6Vny2YxySPcCvQ7jSSY8Yx71lyaZtJUjik46DTTOMa2Oc8AVDLbZ7c11c+n7QflrOntSCSBUcmhRz8ke04HWoZlOM1tPZsWyRUDWrDtmk4E3MUg+lSKuOcVoNadTULwkdKhqwJFUrxT424xSupHWoxwelQ1cuLsXIySRVuM9apQnke9XI+DzWE4noUJ3JVSmyLt7VLHyM5p5XIOa52juiykwz2phXHWrOzk0xlwCDSuakBXimFRU7KD0qNhgjNAmiLaaKlyKKCeVG47MR6HtTUU5y3JqZlweRSBSR04qOpuIuBjFS7SRwM0sUWSMVfgjVcHv8ASmkRKVilHbS7lOAYyDnParsUIGNo7VbiiLYzwKsbEUYA6VrGJzymVFt9qZJpUj3ZHTFXGUmPgcVFI4iiOcZ7VqomEp2RSuZREpWsm4Z5Scng1blbzH5oEQI6VvGmc06hRitQOoqzBBh8Y4NX1i2gbuVqRUXaQo+lbJHPcpKm1DnsasxyYK+1P+ymQZBI9RTPs7A47iqSuS2WxKXGCOKlRSUBB6dqgg4HIqxGwUDB59K0UbGTdy5AQxGauJbbHEqHjvWdA3OW4xXQ2duZIgR36/Sna6M5SsWIISVG3v8ArW/pVgJEBK8jvUOkLHGgjuRsx91j0x6ZrqdMtwp2jpVJo4qkmiCDTo0mibHHQ1o39mkcGYx0q6YB8oOOtOnRRaNubpkYNIxcrnGSyIJR29aczBo85GR0/wA/hVLVsrI5SorORjHzycjvRsb8tx7Apldudpyce9S/Kw4IBx0qKZ/KnZdwIbkVTupcyqOmTzUvaxcVdl55VaIMpwcdaghdZGJYgdjVF32x7gTheMVA9xsxtPWptYtI1pJ0jQhR+NV3vcIB61TE4aNu+RVYkCMtnkHpVWGomxDerJbEMCcHGalaUSKuBy3FYlvKCm3PU9q2NLAd9pO4ChJEyXKrmsiqtrhl+9wDWlHpbPDG0Tr5Z6kkcVcg05XthKcqIwDgg8+tbNnZWiNCLtmCP8wwOlaNJHG5u+hUaG0tIVE7bjj+EdKwtRa2kCAEjjoa3NYtcs3lHcFJwfaubuE+ckqGJp9BRV2Nb7LGvzlSBULgSrthGAajNsm/Dj3q1bIoxtODSSNL2GW9h8mD1qN9PVmIK1rWzoueCT61M8QCCT1PShoXOzmrrSx5ZCxj61zt1pe1mZ0yPbtXpEq5TCrnjpWPqFspUjiixcariecy6b5vG3FZdzpK79v58V6MdNduAvX2ps2iiNMuvNOxsq55fPo7Ek4NUJdPMY5XkV6lPphYYVcL64rE1PT1AwFPFLlNYVkzzma2O7oBntWZcwHcdvbrXdy6WzszADArAu9NcyvtTNQ4GvNc5OWEkd6Z5XPTiuhfTyOoqNrTYMFc1lKJcV3MRRg8Vct1Y4PH41dWyOegGafHaHGFBJrCcDqpSs7EKggc4z7VJtJXpVj7OVXlSafHFg8iuSUT0oSuUgnGajkSrjIQeBULgnjFYWOlIqEegphXI5FWWQDrUTrSKsV9lFS7KKLisbpUE8cirEUeOo4pYUj27ieanhj8w/L0ppFSkCr2VasxrtAJ61LDBxxyPWrC2vdjWkUc8pIjjJYfKKtRQDG5jRFG2fRRUx+Vfl5rWKuctSViCYqin9KybnEjZ6YFX7kEgmqZUluAK6YROOUyksJLVYSHBFSqNrHI/KpS61tFGMmR+VnpTBG28KOD61bEisuOlSRqnBHNaWM+YW1B3sGHUUTQsMOtS4JH3cf1q/DaNMigZAPtTUehm521MqO3LnO3ApfsLmbC11Om6f5RAcZBrXutFiKh4xhuKtLuZSrK9kcjb2XA8wEV0NhBmNQB096svZsow0eePypLWICXKsQRVIylPmRrWRCsFlGUIwcjIra0smDP8MbMdh9KyIOQFlQ/7wrZg2tbshJCsMVEo63Ri30ZuK6zRqQcEd81malN5UbEn60y2uQI/kyGHUVRv3aaVv7posRaxSuIUuELKOTWX5XlE8celahIQHB4FZ9zKuW6EGm2axM/UJFI4FUXkPBJzjvUt6FOSD0FZk8pVDU2OmCJ5rnYp5+U1nfayWK5BIqndXOYzk8A1lvehXJzjHSpbN4Qub41HykPIyKgOobxnP4CuZvNSVYy2cMKopq0jt8v4mkrspxit2d3b3K7hk4rp/Dt0jTxq23hgT715pp9/wDODM3y+xrq9D1W2WVcsAKpbmVSF07H1XafZBptsTHGQ8Y2gLnJxUq6bbyoDPErN6EcCuI+HPiG0uoRBK5HlgeXv6V6Gk0bruV1K46g1y1FKLM6dpLVbHGeN7COzslltEKsxxx0FeayszMTJ97PXpxXpHxD1mKG1WCPDNuycV5VNdFi3HJ/Sumk246nPKKUny7Fl5VLGMDI/vULKACBwOlV7dwcZwM9fekMgMm1D+FW3YSjc37MRqi5YVanlDJha52GSUsAVGBV77fDApy2W9KtamLjbY1bcPIuCcUG1WRtuB9azLbVSzcIa0ReDgxjLVROpchtEiTOMsKrz25kBXaTVyBXkwzsQPSp3wvGSMVJN9TnprMgEEKB71i3unoT8y/jXWXIVu/FZ12sa9SefWmWmzh9QsXLYSIBT6CsqfSjuJlRVJ4yOtd5JEsx4fAB+lVb7TUdCyZPrmg3jUscBf6MsafKAQRnNYk+nnkBePWvSGtVkRocE7e5rPu9PTZjYQexqGdMKpwElkEQ7uvapLS2EZXeRk9q37u0WLOcMe1VobRixZwMehFZW1Onn0I309JE2wrulbsOlULvSpIZApBY4ycCu30aKFV3FQW9Ks3+mloGmZNoPqe1Z16V1dGlDEuMuU8wmsnB4UgeuKqS2xHFd+9l8pX7OSPU96xLvTJAGYIMegrzZRtsexTq9zkJrfA5qq8eBk1u3FlIp3PwOwxVOS3zWJ2RaMv86Kv+SKKVh3RqwQNKMnpWlBD5ajcPwqKE7MKvIq0d0jYFapGMmWoVPl5xx6VKu7HI4qaCMrDz1qeCDewyeK1SOOckiooZ2x0FBUKTWq8MSL8vWsq8OD8vWuiMbHHOpzaFCeTLcDg1CWGOmDUrjJ4pUgL/AFrdXMG0iqSckdM0BRjPerc1ts5bFVS3zFQK0SM27jR96rFsm5gBmoDGwOe3pVu0jcSAgcVqkRI3ILXfAOa2LeeGOJV2jcKxbGdgwR84qxPw+R0qrHNJX0OgtXWVuOvarwedCA3IFYFlJt27WOTW3BMc7c5PvTMJKzNy0EdxF86YJFR/Y7dHHyDOaZZzgABuMVe2LKoKnmlYyuT2rWqrzGOKS5a3OQg2jHWsqeYQsVf1qrPdgKShBU+9K9hqN9i8zmKYsuGXA3Adar37k/dOB1yKzRelW3FgPWoze5TGeKk0USzNjZv5xWFfTjzCB0q1NdPsOGGKxL6UnLEVi27nVTiiOe4+Ugnmsq9uwFIJ5ovJx1BwRWDqNydjE9hVc2h0RgRahdFUbB/WsC5u3kJCk59fWknnMg5JwTTAgJwOB61pCC3ZFSrfSI12aRQS3I7U5lYneTgEdBT/AC+eOQRSrkJjvVGLdyWyVyeuAa39Lj2zIpYqCwyfasSD5Dkc8VsWczEggg4FNF7HuHgq2ZYQkcqmNQGyeM/StXW/EYsH8iKZlyORuryTTdaeK3EaSuuFPQ1iXuqTyXJZpGfHqaHHqYKk3LU9P1HWnvBkvkD1rMW587fhu2a4ey1dpJCm/gjvWsLshAo9skd6m9tDX2Vtjo4rkxgfNu471asiplEjH8q5yEvM3GQMCtS1mMcexjx3pJEyj2Oj835MLndVPb+8LFQSaisXZwQBx2zVxYWU5YhRWsTlkrE9uufx7Vq2QG5QoH1z0rIV8A7GqzazOCoIGPWm2ZtHSpNsADNlvaoZHZmJkfHtmkiQqgJ789KWYJnOcHGalEWK8z8YQc+pqu8KvzJkn60+S4A+4p92YVAJAz8qzE0ykIfKB2jaPrTn2BNzE49BUbxqTkKBmnLEQcFs5HT0pWKuVXiBLOAFXH51kXpLkKxAjPUVv6igjtVUSYz3xWFcNGT8+7PqB1qJJWNabdzBv0j80+WhyOlUSjltxPH0rbmhlILRxHB7tWfNFcA/MFx1+Ws7rodkPMt6YuRhmwCOa3gIxAU3AggYBJOTXMWEn7wMsRYZx8x4JrqbFvOYGaIKAMAr0zUyldFKLUiHylkQCTczDso4qO40sSR/u4+Petq1t2LgRMuwHlTWobRmjPlhVwK43G50+15djzK90AyKSVFcbqVg0EzoRjFe7LpiGL5wC/XiuPvfD/2u6l+UAEmsJw7HfhsTq+bY8n+zGivSf+ER9xRWXs5Hb9Zp9zlYLc7AQBUiwvuyeMU9p9uFSrNojyHp1q0iHJj4Q77QK1IYzs6cilghWMAkVpWaBlyBW8EcVWehkyxE5znNYt4AMnuK6nUU27iOtcteDLn2rpscanczC53DjFWUkK4IHIoWPc3SpUgY4OMmrjcmTRFPM8h+71ohh+cEjFX0tSwzjmpYrbccHitUjFzKU0DYGyp7dWUjIq+kC4wCOKfsMZ6ZNaJGTmRxRhZFJGW9KvtCJY8gc1Tctnd0q1ZyOQOcGqM5dy1b2ZCdwatQMUYIx/Gm/aJQu3b+NME4jJMic0zJ3Zr27EDg5FaVtMY2BJ4rAhu4ioJ4qRr+MfLvx+NDM3Fs0dZi+0xko2DXKXS3MKbQWIrQuL9MYEhP41Xiv0dtu7dnjmsmrm1NOKM4NI4xk5q5DHIq4bNW1iCuHwpXrxSz3cap2zTLcm9EZsysOQcYqhckuhBx9anurtSTgVj3U4IPzYPpU3RtBMo6gwQGuU1K4yWQZ5FbWozcNzxXKSuTK2eTmoSuzeT5YjRzgk8fyqSHBYE05YCybv4ahB2sfQVucpeXaGaoyv7zFMjkIGW71P15zzRuMepCngfWrtqcDLGqcOFXB5JqUy4UDHFA0asNwqBhu5IqF5EZST1xistnJ6Z4oEgaPnOaaC6ElmaCcFTwK39LvvtGwE5I965yXBHY1Lo8rJcYHFZT7mlLV2PQra7+QBRz0zV+zVnfLt+Fc5ZOSwGa39Mfa4LUJimrHSWQbI8voO9aUjfINw3Gsyzm7fyrZQI8QLZzVo4ZoqxMGbBj+UelbOnW5cjb8nHBxkis0JGDkdvWrttdGJhzx7VTMmaBQQOTveWTGCXOB+VKVmmAyoI9aY0qSnftOTWhAT5OdpFK5JTawBGCxpv2QI2B0781PI0oY4OKrv5mN27g9TRcELLBtHyKuPWq4GeHIB+lSrMcAb+KV8Fc4o5irEUyxuoR0z6Gs26s8SqeAq85FXHk7AZyaVyskRRh196hvoXFW2Mi5aNkIx83tWNdw7yAWwPatma18tmG7gjp6VlXDKucHGB1NZyZ007lS3Um4CIMdvp711elsBEIiuWBwWPeuZ05w4OB3robUskiEtgAdcdam+lzWS1saEUospm+UBScjPetTzpJ4V2gJms0yLPGN6g88GtSy2tGEJ+YVzPe19DfSydtR28RqwYDzCMD3rHmsihZ43bnkit+WLcBwOPWkeGMRhypNZON3qa058q0OW+zN/eait/bH/zzNFLkRr7Zng9ihkbPUmt/T4mVuRTdKsQqgmtqOFU71MUdtSotkRKAASw4HtVu1cKAccGmlcKDT1YFeetbR3OOpsQaiA6kqc1zd2nzHiugvF2oWU1zl47NIc8V0nJFakUMTbsg8Vs2dqjKp71jQSYJFX7a4Mefmq4oio2zTYLH/CMVBNEZFPlgAmoxdBkPzZNWLa4ABzitEYO6KSW86Sgdu9WZNwbgH3qeS6Qjr+dEMykjfgitCG3uVxhQA5HNWYTCvO4U2WCKckjiqr2Koc7jTFozdgZHHGKdLEs3BwBVCxwmAWzVlpMj5exqjFqzGXVt5UGFAPvWLPAv3jKw9RW+8wKYcdqw9QkjjLZQ1LNKbY1GQLtAz9aUGJfurWcbht3yjA96bJO4U9M+1Tc3UTbhd2Q+Wxx6ZqKQOyndgis+2uHUDDYq2JHYYzmlcXLYq3AUZPOKxbwKd2FINdHPAWhySBWPfxFQeRUtI1gzldRJAPJwRXPBiWII5zXQakTnHPWsKQAOR3zSp66l1ehetplSAowyaozDEhIORSqCxHOKVlw2DWlzCw0H16VajycEmqygbc/xCrCMNpbvipvqVy6ErgKQV5zRKx4HBpgkLgEDimvkkntVLUl6AWbPWjODweKbnimnOTmmSSKQw9CO9Nsn2XgHU1GrbGznIPUVPAhW5BUfL1rOezNaerTR1VizMq7eDXR2UbHac1z2l42DcefaulsNo24zURNamht2JIbBrpbCLcnzNjHasPTY1ZgepHrW6hwM9BWiPPqMshI3+QLk1btrWMAArVFLmJUIKkEd6v6ezPjrg07mLRYSJFOccU55i9zhTiONfuj+ImlfKRnK5rPkbE2Q2Ff9Kl3YRLskzlTtXJqnNJLsI2U8xuFBVvxzUExcgqW2+pBqxEMCPnEhVR7mrCn5wgkTHpmqEkavysjNg1B5UYYnLAjvmlcuxekLRyEKAOetQW77ldickNgmq0u4rlGYnoOagjnjSSaJGJXIOffvWcnqaRTswvrjbISWzisa+uN7bUAGeuRV29jYEsGBFZEuZG3dTUSR0Uie03pIDFtYHqDxW/aXSPGvmjD5xgc1z1sQIzjOTxWvZv8AczGMjgY4NZylyqyOiMObU1IX3y+WG+XPQ9a34AnHmBlkAwDnrXNRyKsyqcJIDnJ610FvBvA3SBm6jmuRs6HGyRbe9ZF2lA2Biopb0kbU646elV4lL3hjlII9fWtS2tlCEhBu9cVCcpFtRgrtGb9pn9B+VFbGz/ZH/fNFPkfcPbR7HkluGUAdKvxrn3qk7hSNvStK2ZTEM9as6JLqRN8hxng05sbfSnSRbuSTx2qIx7/unj37U4mE7NGfezAKQvOK5+6Ys5OK2tQRkzisWUk5BrdS7mPL2KjlRhjnI96esxYgZOO9SCHeuBjHrTGiCIWUg1tF3MnZExkVQMZzR9qkAwKo5YnJNWYQccc5rWJnJdywLjPUGl+0MGXBwKgct071JCNxGVArQhovfaJFXqQaja4kbgljnpSje5GORVpIQyjGN1UZNpBaCcyhcfuivLZ71YvFuUhzACTjmrdnCQBnrXR2OnLNHnPJFO2hi6lmebteXqOTJu47YqS3vhO22ZMk16Hc6PDtO9AfcisqTTbWDMhjQY7kVNi1Wi+hzF3ZuVDRL8vaqDW0/cYro77U4UUqiZI6YFY01/JM3yrtFSzaLkS6dYqzr5mcVqS26Rjci57YrO0+eVWGcHmtSWUlFUrgk54qXYTvcy71vKU/uwB7Z5rDvbgldvGAOK2dXmIQhRuNc7cpnnNZtm9NGFqQMgbHBrBY4dg3Y10V0ByR0rAu1KynjrSpysy60bq4ICelWCm764qvCauqwMZyBuA71q2YJEKoAhyOtOjG3GDnip5MeUoPfFQS4XIU8ioKHMdnUc1GW3HGKAc9TTWrVGbG4JJHQU5wNuM/jTF+mDQ4IA96ZI0oeSD9a1dPjDIm7r2+lZseeeOK3dPh5UkEHGRWVR9DooLqbelooYDiums0wRgVz1hCGwehHeuo0uNxtOc1MWFU3dMjyBwc9q15VCRg7ayrSViwAwMGtSV98WxjkHkEVSkcUkyq0ytlDxziul0l8qmMYAxXLrEr3MaL8pzuOe+K6LS1aPJBHWlu7kyXu2Nl0DA7wAOtZV9DHFtkVQQGwauyuWQ+awwOwqiXFxPMpOIVbG0dz3qXJ7Exj1EnuEVflUbR0rEubk+YW9eABV68dVjYk85IArFuG/fKmDgDJNFSemhpSp3ZI7EAgEhjioWeVWc5UqB0xTRIXHAJGetVfPChtp2sCc+9ZOZ0xgTrK5+ZCee3YVTsJh+8LctvOcDrSgEADzDhjnFVLM+Vv3MRgk5PapUndGjgrMt3UrOf3TZB6rjms9y2QAjrz1PSoprueRhLbQhUB6nq1WLG5+1glkw4ONpPFNT5nYr2fIr2LNlboQWYsCDkHtWvhXQNkDHcdabbwqmAxDEjt0qG8faPkIBB4xWVR2NaS5mWra4aS5HmxgoOAcdfrW/BGpcv5ajjAANYMM+xEDg7vcVsjUBbWZeSMs/YDvXOmup0uEtFFFmW2FvF5sYLSjnGc8U+21ZZVEaMY5D69qrWerrebTEpG4bTnsazNXaKOQ4b96vOUGalzS1ib06Lk+WotTofMuf+flaK4/7bP6y/lRU+1Zr9SMyO3BAyDz0qxCu0gDirccagDPWlMfPy4rdqxzc/MMk+WM9vemW4OwmpZY2aPaSKijIjOxh2qoPUyqK8TM1MNhj2rm7ohW5rp9UPynaO1cxdD5uTk1ve5hBMbBMUI3Dj6ZqeeQXACKoH4VUB28VajZcj5evetYrSxnPe5GtkC4DEmpGgSIjaatZKru6immJZAHU/MDyK2ikjByb3IBGWOQKmWAIfm6VeWJdgIqcRRsOeT9K0M3Ir2kQcgKtWo7YK4Ynp2q1bhY1+QYJoLIrerVVzJu5ds1DEDFdDZ4iizzXOWdyVfGMCtOO+BGMcdTQYyWpoX1yiQljnAHeuD1q8mkLqrbUPaulupWuSCcCMchfXFc3ewSXMzScAMeMVjOWtjeiktzDB2ck5+tGQ3PAq1dWZUDOaiSBgcBTVHRdFiABBnNWwWlyV6VmOHXG6r9vcEJ8+B7VOgmmQXUeFORWDfR7WLEZFdLKnnZzwBWbfQqEbJ7VEjSDOTni3KSeKyL2Eg/KueK6eWIGLJHSsm6jOcg8fSs+h0qz0Ofj4xnPWrC/dc9R9aW4tyj5TPPrVmxtGu5EhjX943GapzVrmPs2noV2bcAB0AGaY+eM1v6voj6aqkjgCsSVQDiiLurky0IlGT7UmDvIFSIvzDA70SLljkc1qnoZuJEATJT36YFSIoBBJqaJFd+ATRKaQ4wb0G2cOXBJ/Ct20ibAxmoLa3XHAwa2bSMxhCcHHasW76nQlyqyLtgu0BWHHrXR6evACHntWVaoN3GNprbtwI2jYEZPA+tVexhU1NK2O4OQASuD+NWGnwR8vQZ496pKQqqqsdx+ZiKnBB+X1/iFNM55Ic06AKVB8zcMGt62ucqwK87evvXNNA32qNV9Cc/TFa1lId0aOcc8k1K1uxSSsjTmu3EKRAANIvU9h61FFKI0EcbAnO5mqO4uInvo0zlYQc7eck9v0pksyyTMFGzI6HArNP3rjcdNiHU3UryPmJ4IrCuLh1Lhlyc8n2rTu5BkAnkdKzZljKs3UnrUVHfY6KMbLUiiuOThuCMgemKQTR7s/KW7iqBJidjGDk+3SkgfzHLMwMgHAxWKmdjpdUXbpmKExMox7Vn3FqhVi0rfMMtz1qcI3kkTHBPQ0rRxomZCrYHQmi92NR5VoVrc7bdUG4gDAOO1SacjW0pMuMfeXjrTnu4YVDAAYHIHeqs2oR3LfuwT6AU5TSLp0ZSb00Z0UN8m0u46elVYrq2admkkCkdNxrBuby4mXYkWwdCKbbIGxvtpC/c9axlVudtPCJK7Z2lpeWzIMzKzA+nSpL7U4Zk+z2x8yYjACjpXMySTi0ChNq5G4he1W7C62ONkQ29BxjNc8ql9DphhVH3jStrK9iQRiUR5OTWjHZTREsQkhx1qpbXzyOEdAY88kHpWul8gG23iZ+3PSpTQ6kp32Knl3H/PMfnRVrzLr+5HRS5kT73kYYmA4xmmG5A3DoakmRYlJP4Vlu+6U4HFdkpNHHTgpGl5pMeRzVSeV5BlRyKlRwI8GolkCnAHWkmTKPWxSnMrKQw61gXI8uUhhXWXOdnA5rndTgLbi3XtW99DnVrmUx+bNSxBtwNMiKjg9RV62i3sCDhRWsJGVSNiVYi0JYtgVatkVUOR1FNSMSOFB+QdTUhkWE9MiuiLucctNBhk/dkKPmHFRJPKGAzVgyx+cSAACM0wlCcnAzWkWQyWBpnkyG4rTW3yAzcmqEciJHlauQXJddoFWmZSuW8KBwOKkaQiLC9McVXTJOKtA4jAx1OBxQ3oZ21GozsqCmRIGiAC5YEjHvWtbwKYwSRz+n0qAHyb4NxtfCk4/LPvUSdmmOLvdIrHTi8YZlDEc9KrPCvzAqB+FdSfkjJ4z6VmXVmWYuOc9hVbMlSfU5LULclWZUxgVnRW8nmAsTggV2F3aZjwM4PBrMh2RxEMmQpI+tQ17x0RqPlKaIVUKV596zp4TKr7ugOOK15nVuXyfYVTkxjCqcCs5GsGYjQ/KVI+ZT09qzb2AFmOMD6V1D2KyAs+Mnnis27tlUBlBKg4IzUao3jJM5S4hHTHHrVeCSSzm8yI4cd/SuiuoF27wP3fasxrUtuJAANTLdI2i7q4anrc1/arHONzAYBrEOWHrn9K1GsixwRxUSWZX5R61a91aGfImUkTaPelbL5+XFa0dpnP0oFp86nBpKXUpwWxmwWhdhnODWpbWQUgc1o29m2On0q1FAVbkdKrVkaR2K0FqykEgAA1qQ225XJxlTUjxh4wR2qzLEfIDKCeckDuKlu1xXuT2EZIR2GAa0SgWdVOCEG5fcmoYABGu304+lTuvmkGEYdehNDWhi3qXoF24ULlmP6VfhiQnkFX/AErKspneRmO3cnB9auiTk88Dn3pqStoZSg76k1zblwCDiVORg9RVi18uSJWIAy21geoNMEwLDaQMjPNMgf8A0m5kUApuH51nfUq2moiFfPmmhbyznYCB1xTblpkTKyqwyOGFQTzi3uN2G8p854zzUNzK2EaFjg4ODjFZN2VjZRu0yG9llLl9nz+o5BqpHcJInlyoUeprqUs2DIyufyrPujO25Mx7l5Dd6xlLU7KVO61AkxAuWyg602Irvby+M9DSusrW5RUGwgZz1J9amt7YIGY52ntUa3OiyS1LDKBGpZi4xzmqs0sEafMB64oaN853k+tUrpGQuWwQemafM0VGmpdRbkm4QEMqK3QKKyC720pWJjx2rXiSKXaAcAD9aivYohKWUZyKiTudVFKL5WUUu50kLEZyM8VsWOpb1UIGV++az/sW9VcBlz71JNCYcCPOfX0rJycTsVOnU0OpaSNrdd2d2Pm96hDJHIqsR5ePlI7e1YBuLiUKhfAA5qSLIP7xy3tWMpNs2hh+VWudXbywQWpMhXJPrVzT28y081Zscn5R3rA0yJHkDOu5fQnpWoIJLI+ZasrKf4TSuZSpq9rmh5snqaKzPt99/wA8V/SilcXsfMS63yDaBUAt9oGcVZE3PIFDcg4NehozyruK0KzJ0FOEHGcU7aVOTzUyuMcVKCTdtCrOxIwo5rLvocoS/wCFa0jbRnFVLoqyds1vBnLNWOSkAhlyRwakWXCcHFWb2IMrcfjWJLujfGeKr4R25zcjuVSP5evrVSa5JbO6qKs7DGeKs28Iz83WtozbOeVNLVj4J2eQNyR3q6q+auAcc1UQFG9jVqCVVbBHNbRdjGSvsX7YFkCha0ra3HGGwap2LjbyMVr26hgOmK0WxyzdmNljmI+XA+gp9tHK86P5h2oeV9auu6w252rk9BUYIgXDD5sA1L1Yk9C6JAYwqtg9waZdBHgLqV3Jhjg9hVfzBJh5Fx6Yp3nQSRmMIOeC1DTaIVk0zUhZGjDFiSRkVOY0jQSN1PUHvWBpt15SmF23PGcKfUVqoWmAMjcH17U1LmRMoOLINTlRE2xruZuFA7e9ZU8UcNtsUZfODnuTVwjdcySgkr91T6e4qG82hFkHJRhk+tK99S0re6YMyhHAYduKYyAqApz3qe6QGUselRptc4Tr2oNkxUwykIMtVS4g4wR96tGLEaYx8/emP8zZIyvr6VL1KTszl7iLdOtu5xGPmz60PbAjhcbv5Vp6na77beh+ZAWBFLpyCeNJCM5FZRXvanS5XhdGa1gQuTVZrP5gQOM9a6eSHjpxUEsAaJiOCO1aMzUzDt7X52GBwMGrSWQ+U4zjtV6O2bJaIjJz1HWpxazMjN5irkY6VneyLb1KdvAEwcAgE8UpjGSVAwSavWRUqFkUb8EDH8VWjaDAIGDimnczk7PUzI4wIxuxye1WbVCJfLkGTjIOeDU7QAINo+YHk9qjK71fPyuoJAzSbGncWEeTL5ZGQeRirYOGBqsyO6xyICZMc9s1IsyIEaZSvuec0lK24nHm1JNLYAyOOWZyfwq7ldxZgfn4qlaD90uzhs/lWg2FU7sZ7j1FQ37o2rSEDpHCXYZCjnNNtpJLWFGPKS/Ng84JpYIka2kZwWBBwpPQdqrxRlrdDKWYdsHoKi7vcqysy28nysCenrWYWzAmxgCCfl70s4j+6jHceck1XmYuvIUSx4PHelJ3NKcbIlllR9rOAG6c1Wu/LcLkZkPRl9KQBmRmkYY5OQM1SSd9yrIGBxwTWUnbQ66UL6o07WUGDY4+ZTTZCzSfJIQvpREqBBnOTScADb7ipuWlqQTyb02hyP8AaqFkZV+95mBST5G5QQGzTXYqMKdoxUNnVTj2I4onZyAQu3n86kmyAFbGagjbfcgc4IxkVpR2qlx5h56gVnfsdNrO7Kcc8ikllyoHT0qS0Kzf60kAmrFxAsk6xQ8Hq1Wo9PB2g8EVmzeMopX2Ixbw4G0gYqLyViuOBkGr8Vr5co3fcJ5q5LaJvJXG3HIqWjRVLdSrZyorYyPpVxHaf5UAx6k1JaafbkqfWtFrWG22tGpYd6RDnG+hnfYpv74/OitX7Qn/ADy/Wilcz9pIw7UiUKaklPl5rEt7toVxmraXfmg5ruUjilSd7iteHcVA4qzbv/ETVMpuyRU8LYQjqRU31CUVbQtsVfPA5qle2ylCQcVaSQbRnrQ6l0JxxW0GcVWLWpy8wYBlPIrPuLcEZx1robqMbiMYrNeIlivY1qZrVmGW8ttpOKs2fzDLNUk1nvQ8YI71BHKIxhgBinHTcc0mtCy4wR3FTQEMc447VUVgwJHep7aXgA9q1jLU55RdjUtZCPlrUhlKECsMSbSGXkVahnMg+8VFac/Q53T6m0bs4CLgkA80rzAqnJOP51nwyLHk7sk9zTBISxBbDdfrT5iPZmlLOzLtyQO1Rwna3XPs3eqqyDeCd2B61M8gGGP3TVJ3IcbaC3BNtNHMB8rHkLWmL17lAi4jjcdT1NY6uZ7vk5EQ+Qe9WuYlLYHl7vmB/nWXe2xckmknua1wVSJdpBwMACsi7lZom2nHqPxFXZDvBCYHoRVWeHfBIjfexwfU1o3oZxWpRuAzscEVJbxBYy2RnB5qe1hEqhiOMdadJHsixkY3AdKObS5XWxSyXmBGTxkmmXDMrBV/GtdrZAvyDaMYxWbeRhMYB+tLoNO7M+5kby2jH3W4ApuiFUtyuOVYigkNIc5wvNRWHy30iISVZc/jWbdpJnQleDRtKyEHjBFQSpjJHpk04McHK8Z60qksWGeMda0b6GC0G6cmImBGGz+hoKK8jNu3IvUZpiXQjkZQrEqpVsDP0ptvItwiLEpCqcucYzWDlfQ35Xq2XNNto0RGZB3xn61PcR4bdGxXnvyKcBjHHB7VMqkgbhnPBrRJWsYybbuVzjqU2+voapTiMN82QfYHNayLsDBuMdM96qXYhd9z844GOtRKWhUI3ZStZAvnKWOFw2D17025kM0sAKnaFBA96W4RopI7iNRgcMp6kVZmWKW3MgOOMr7VhKTasdUYpNMnR1byyQAWyDj14q0x8uZGdeMbc4zWRaM6x+Y43A9AKnmuA6AKzAZGaXOJ0tdCyXBhYhyIgSDmm2hYRLG2d6jP4VnylzcBesC/NtFSmaRS+HwQRnjtS5rsbp2RJdIoOWChvUVnOH3EpjcOuaumQzKyzZO3065qrhmlVj0PU45oZcFbcjyVICDk8EVDPE7yhl5ZR0FPuYyJsrJhh0pIZPKB3k7jnLe1ZSZ2U1omiwhUwA5yx7elLFKBuUjA65qpC2JG2EFP4fapGDyNzjA7ipuacmtgnTeCRx3zUO9ZQAwzgc1Md3lk4I655qvhVlAOcEdqmTN6asV4ztuF2cAGtlAZGGSBxxisqeKNhuiYh1qxaSyOgKD5RwazvY6nHmV0XYpBb3u4gEHjNabXEeQUbjHasUfvGKMvXuKbYP5cpHLLnGKhstUr6m6kqEsDkMOatl8xLjGW4wKyJGLAjGPSp7EMo+9z2pXD2elzorOKKGMFsEmtFniW1wyjA5rnhcCLAPzGrdxKZIh5YPPUGk2YOm29Sz5lr/corN3t6CikX7M46cFZMVfto8qKq3S4bHNW7WdVUA9vWulGc7uOhLcMYo+Kq2NyzyZ7ZxSX1x5nyr61JZRlOT37UJ3YWtDU2Io/M5qdQPLIqO1chhmp5SFbPQVvF2PNqq+hl3EILcismaI+cQOBnrXQTsjgkHmsqdljfJ4zWikjFQepUNvlj3FZl/ZjJKituMgy89DVe+UKOOtbJpoyalGRzzjyyAOKlVlYgZovQWzgjNVYGIfacZqb6mnLdGnGVGewpUc7hzxVYHnmpwCyAqOlHMZ8pbV+x5P1qaE7m6jPrVXcFjy+B9KfEw2jBx3qua5k4WLzONuBxijzTI3Xt09Krb8ncxAHpTl+8WUEcfnVqRHIT6e2LxwSeQDW5EwZNpAIPPPcVy8RYXLE55HQVctr8ByCGDAYC0oTVtRVKbbujZt5hAfJlIG3hCf4hTWly7blIaqctzlBHInmZGcAcimwSTxhpFiBiHVHPzYp8/QzdO6uXrHcH2qf3e4hW/KrFygCMScA9PY1SsJEmJbIWLcSozVlmWRDtxgHgZzRGV0KcbSFhbehBb5hVC5fzZSpwOw5q40JkYGM7WA5PrUDW7LcFHCnK5+tDkwikncyfKK5HY9D6ijTIv8AWoRiRTn6itC5UKrBgCUPy/SqUj+VdxXEZ+9wwqXpZm8byTRobD5e7GcVTmm+TKMM9AAepqW/kfyliQkea3UdhSpaRKEMSD13Hk0SbbsiIpJXY20tvKaRWyzOdxPpT3iMZIUbNwAB9anUiO4UYzuBpZSBLCr8IGzyetKVkrDTcnctxQKu04OcZJz1qycDgDr1FQySldsZ5LZOBTo2H3TkN2zS51sTyvdiyxKxAk5x0NRTKrbWRAMH05qxJsKZLZOP1rOmusHazck4B6YrOTLhFvYW4CyAY6981jurZcmQxp/dxV+Vwo3K2SDlhmq16Uk+cHhxxz0rOWp10lylixJESFuQc9aMIVDE4yTgVQtmcny3Y7VHFWgwVdrNnuCaLlSjZkcbsszBRuOMVad1OQVABH61QjcM5wrbm6H2qXa67gFBGMj2pKVinTUmAmaCZmjAk3Hp6VJFNsA80DJHWsq7uzp4Acbg/II7VIt0t0PkfBIGPahTLdB79C5OpkcFQBx3rJupCJhE3Ck8mka6kS5EfnGQd/ao4E82dxK29s5/Cs5STOqhScdWWuI2G0A+gFPtnKkgluvQ1GEEcihiQDQ0gVioP41FzdRuSO6MWQsVzU5XhRHggLjJrMc4lAPOe9STS+VGFzyOeO9TfuaqltYnYA/KRg+tPtHEETrnIzUCT+Yme5FLA+0ncualnRGGlmSPcMWHlI2T1NaVvalNj5XcetV7cSSKCNoGegrRMRRMvncKz3NG0tEWJLdooy7kMMcYqvpz4dmdePSm3d4YoNgbcf5VRWRwmDIQD1pN2FGDa1OgF9ZiXng47c1bGqW5jIyKw7SWziXaSHb1xVlAlwCYkXb7ChNkulHqXPtkHtRVH7E3oaKfMw5IFFow64PUUwWwAIxzinPJ5dKkyykHJBHpXTY41eJXhtz5g3DIrSijXZuH0qKM/vBjtV9kHljBpozqSbHwHA4pbiQMCF60yE7R1qGZxuNX0OfluxFXKkk1lXS7n2BiR6mrzyMEIqnEoZ2bqfWhPoCja8iFR5bAk5qKeQSHC1NcICAMY5qAYSXaOlWp2M3C+pUa2JY5HWoJbMDkce9a0gyRt603AdQDjNaJmDujHFu5O8vkdMVZjV0UKpAX3q6YgnBAqOQrjGBxQ0JScio7oAwfOcU5G2xrk5OOKivCpOIsmQ8e1ZVxPJaSY3b3H8Pas+flNo0OdWN1JAxBxnnpVgSgjGG61y8E91NI0m/yVxxmtbR9R85CkmDKDjNVComRVwzgrrU0MAybkYgj1poabzB/CeufWpvOiODwW9qcHUkYX61rbsct7bou2cyxtuYku3U4q4X+UkHOeDWK+ZJGVZdqjBHFWrdpUHzBGB9DzWkZX0MZw63JdOcxPJCVyAd2ParUZ2ByRhc8VQnYh1nhJWROqnqRViNxMisoJQcfU1K00CSv7xpW1yiNvG9s44x7UyYmVWmIKtuwoPpSJIQDgcinL88bcfMR1odyNOhDfnfF0GWGKyLplcrbRLmQYyfTFSqp1G5Kb3SCLj5e5qWK1FuGYcsTgk9TUXcjZJU/UhnEphDbxui+Ye9Xo3YoW4QHoBVdl3W8ox2OKWArK0auR5YXPPFU3Zk25kTwAyzbyDtXj61buQvlKpH3iMDvUEbMqkptVBzim25xumdix/h56VDfQaWtyd4haSLNGSX+6cnrmpHu0ZSmw5+lZ9zMZZE2twOatSKr7S3Jxng4qV5FuO3MMkd04JJU98VAZCY8SHdn2qyHXyzsIOO1ZqlpGfnAznmoka01cWTHJ3deKhQlB84DpkYx2qSTGMMcA/zqK4YRbShAPUg1JvHXQjklzLkFs8+1SOuQrAnkjPNRXMu6UMAp46AVNG48knOG9MUirWSZCjYOWYjHGBVsT4wGAIxVRjjDZxn1FR/aI451MmW3cGpehqo8wzVUjuiFBwR0xWRayyWc8gHPODV68kKSsI1x35qEoDbkY+duSxqHqzspx5Y2ew65jZUjbIO7kYFMlPlvHIQQehAqymWgCPk4HX0qpMzRwMZAT6ZqWy6avoTzXalgpb5ByDTZLy3HzdT3ArPt7bzkG8kZ6VL9hWJgWGR2IqLs6VTgtLkiTmViI84PTNaVpbgrmU5b0qvHCvlZQ1atmwOpJHY0Icnde7oOCqrYCH2xT8NsyUwBVmN90Y28PViGISq2D81K41K25nbnh+aPIqX+05ZFIIy3Sp5bdpAUPHvWYbd0lKI2KhyZ0R5ZblyyjLTBpAxHc1oyxs4zGgA+nWqls08PysBIPTFbOnySTqNiDAOCD2qeYmo7alS0sNsgZkXI7EVeEQST91mMnrir74tmXzMEH9KW5nt9m5QC3tRc55TbK3lz/wDPSipPti+n6UUaEe92OUkkyOTUUcm1uDTZQVOKhTlvQV03Y+W6Na2bcQa00YYAPesa0baRk1fR8jrWkTlqx1LMmADiqxjJGQadG5YEHmgjB9Kb1MkrDZwPJOT2qtZL8p4qa4fKAdqWJwkdK4OPu2KV0p3/ACnmqMhKyZzyKu3DMGZu1UmKs3NTzFRhZEyzKqhjyfSmGeM8nioyEIPt0qPYGHatFJmLpR3LMkylM7hWe053HABHvUoQKTnGKryDzHwNoFNybFGlFCtNsB+UCQ9KggiRZC86/MxySRVtUUFeMnuaR080kNk47U9xPRaFW/SO6iK2/DH9KzLN/spaKQYK87q21iWFcquWPes+fT/OuS27AbtSad7oqjKNnF7Fuy1G3OAVw/qe9a0cykZ4I9KwP7Ka3AkDhm96tWlw0cwSZApPQ1tCbWjOetQhLWmawOZQcYA9akyc9cD2qKJhjJJJqQEk/McDtWxwtFpGAA3YOOhPWqxY2cpkjJeEnLJ6fSnxn5ivBp5KmLccdemOtKWupMfddnsX4JhIoEZyG5zUl6xhsJXRvmUcYrEE7WM3y8wtyV9KtXmoQraSgSglk4Apc9077j9i+ZW2LWkMsVlGANzN8zH6093B3fXNZdm8sFnGA+XIzginRNI+5yx3Hg1Kl0LnTu2y9LJHEjFj8uM1n2MPnqjSltp6DPQVVuHYym3yGZu57Cr4eOOILz8o6ile7Hy8kdOo8QFi4ywjXgDPWmwlpD5cXyqOD71H5+2FtpIB6E1PaJ5YznBIz+NK2ug1dK7JYLYGI8Ec8mng70JXORx1phlZYiueTSRlI8CRwD160mrArvUSRnZMooA7sOKhjkLbx6Dk097oMf3fzDPTtUQADM54z1XtUM3itNRsjo6BNw+tMvCrwAKfmHINNZFUseCM8ZomZSoEY6j73pUGsVqQRjg5Y8jOafbTcfMVKiq8m6IgjBX0NQTSDf8AIowetK9jdQ5i/NKX+YD5B+tUW8uRmkY5UfdHvQlzvjMUakjuaY0SQxZZ8n+761LdzenT5dx1u/mTndzuGM1JJhomRhnFVvPijUBBz1qJ7s/w8nORU81jb2Tk72L0MgKHIww/Ws+8k+0XCxpnHpUbXTOxJXB6cVPp8eJRIwye1S3c2jT5PeNEQhYwAOAOaNilcdakdty45G2pEYHAABpuxmrkSQKDgcZ61KbZQu6MtuHrT3j/AIkPNT27l/lZeBWbZqr7lRGL4bdtboRWraAJHlWIJ45qlNb4lBQc9xV6wCSjY+VbtmpuaTtbQWFygbzBuGetQmBftCyA8McVburR0hPlsMe9RWasQC4yB6Unogi+qL0VqisCT071Jbzi0vWXGUcdahRmDhNvynmpntzJgoPmFQ+6Jb6SH3kpuDtCn0pUt2jiAZBz3qe3lVSPNjK9q0JpIXj+X04pWuZOfLokZf2Z/wDZoqfefSimPnZyEybgSKrbcE9qtnpUEgx0FdTFFixbhjuKuoSRknH0rPjlwcHoauRt6dKqLImixG2O5yKnDg9aqbsDI601pfmOKdzJxvsSTtuJAqtLMqMiO21m+6PWrCHIJIqCRA8oOF3DOCRnHFJlJdAdxINowcHBxUE1pkEipoUKHAHJOTVpiQMGkKTtojDaPZwTUO/acVq3CKwOBj3rNkhI5AyKV7DSvuQyyZ4FSW8O4Z6ZqSG2ycmpghjBABJq0zOemiE2KowetQt1OBUsQJHz5De9MnkCDBOT2xV3OaSexE2TjPWlXAwWPzVAzNyc4x0ohcMdzMOKpMlw0LBBMgLkkelQamN5Vk5Knk09rpfoajcFgckgGnzLoTGDTTZJFdI23YSG+tXBIpAZskisK4jMQyFP4VPpu5gd7MBj7tONR7Dnh4uPMjZ84Y3HC4/WljmDtxkD3qKCLKhhjA7Gq9zP5Epkx0HAq3LqzmVNPSJoXMiGRCcZAOc+lZuhpG8dxI8YYbztJ9Kqp5t9IGd9qnPC1oArHCLeIFQOpNRe7ua8ns48nUmjuMhuSccDIqzFIY1BI4I/WqW5Am3ODUjXMcUf7xzjtxVJ2MpQvokQ37MkqzxkL/C2OeDVl7cCMZmdkIzxWfNcm4BijjbLdyMVb3GGFUkGcDGR3pKzuXJSSS6j4H2TZdtwA+UGp5LhVPzOOe1Zt3IkcZmjYbgOhNV7SQH/AEiUksR0NLmtogjS5veZsCR7lxuO1BU2IlOepHc81n2t0jtgyDaexqeaVF4QggjtU82hTpu9izHKWP7pVxnripGXcx3AZxVG3fanXGe9PjkZCWySehz3ouDhZ6AwDMWJOB2qKaRViOeKR3CsQx98Vn385CEDgGobOinTcnYjuL5OdqknpVaO53SHdkD0qS2jymcA/WphEm45UZrPU7kox0sReYVAEXeiOGWQHfnPpUjIByvBojchuWbntS9S09NASHcmFXLdDUi2giVuQcVPGSpwpwT3pzxHYGYjPfmnZC5n3KYWPyyNvzVImEQY4xS7Q/bHvT0QYIxmoNExYnyfmzzViIOk454qDHGB8uKswSPtywyPWpuXYl8zcxHSrMTKqY/iqJEjZDlcH1qssrQtyCR2qLmiimtC9bybnJYHOeuamluE+1p2AqtYzqTgqD9anuIEmG4Daw9KTCyvqaEuZo92cDFMsmAXb0PWq9ndiH93OuV7GlE6ifCD5TTeouVrSxbu7gwSxkMOT2q1bzZberHOetUbi0WUBmbp+lA22u3MmVaos7ismtDXu5lEILkMtWLG7s3RQgBPpWZE8M6bQd3rzUtjpEst4ptgQh5yaaWuhi4xtaTsa++P+5RV3+xJv+ei/mKK19lLscvtIdzzplwOaqykgEGr7HrxVW5TgkcVrJG0GUSw6dcU8TlQKgdWDUHkDPGKi7N7Jl6K4GOacZVJNZcm5VyKiaV1PXrRzCVJM2fN4wpPNOR+etZcMpbnNTxSMG56U0xOBqW7ZkBJxVq4zt6Vn2zhmFXywZRVo55qzKvl5+lMeHPHarJIHfFMc+9K2pJV2FSMGnmQAYOM0knJoaNWAJqkKSvuZ1wxBJBqrIVUbiea05YQB2OelULiMBjmmTZMqOzyn5RxSlEUfMCPWnSOEAwOKrF2kcf3fSlcOV9NiZVDt8owB39atr8oGOtQRnAAA4qReWH607kyjfcWU7gRjJqDHkOrtnB/SrcjBcKuM1UvT+4Y9TVK+5mrbF5ryJI+ufaqF1P5ikspXj5fxrPsWPmfNznpmtOYKbbDckY5p8zkgdKNOVifS0EFrlhyT1p9w6rJvz+dAkTyFPAGKztQmWR1RRuAPOKpuyMowc53ZJNcl5f3KbzjHsKs29s+Q8pDsfXoKdbeX5QEYCr61YI3AbSRRGNyZztolYkVQBjjPsKSQuFxgkdqFOF5bpUTXkaEhnBH1q9DFRbeiuUdQkjSCRpR2wB71z4lnuGVQ5AAxgVc1q8WY7IxkZq7p1nGlosjbCx5x3rmm7uyPXoxVKneS1IbfTpyobdipmjniONxIrVtyoQFTwf4aJEO0Lt496LEe2k3ZmXHdSJ978KtrfsxHQYpwgUcMMmgWqSEheDRqNuD3RFJKD8zuCfWqsriVsLgipJrI5O1vzqFYXi5I/D1qWzaEY7plqFiFAAH4VIu0k5OCaoiRlONpWpYs7SQSc0rjdMfJkjAOaaqgnJzxUiAsny9qkgTHDg59qW5cdCxFaStErJks3AqSe0aHHmscetOivGij2qcj0NRtcvKwDsSB0zVPlsSlJsa8SggICPWnbcYxj8KZKnPzElT3zU0O0suzP41k2bKLERVZ8OKenytgNx6U+OIPcBSeT3ouIvKbaTnHSpNVbYswZCbSMjHHtTvLXADgYotLlQgG3OKU75JNwjO0VLYle40RJ5gVSAKteVNGSRytVyechMEVpR3eIsMB6UA20VFIlYq0eaq4eC6CH7jdD6Vt27KnBXJI9KhvIVuQoUck9cUPyJjUV7PYQW8kiYD0kmnyFSuCxxxWzo2jXUgBnPlxjv610EemxwR7sEkdGI4q405SMJ4lQdkzA0HQ2hjDXJ25GSBXZrPFbxW6wgEL17ZrOnd5F6hDjsKZl/JOWDbeuR610Rjy7HHVk6msi95sf8AeH/fVFZ+U/55p+dFVzmHI+xwBGQcgj61FKoOfSp5M4AoK5HPfpSsdidjGuFCsRVc44rTu4ueKzpEZM96yaOiMrkTMeVPNMdQQcdaazVC8hDcVLNopk0Iw3HSrqAN1qpbjNXFwOooRM2SAGMhhwKvQzfJ6mqDkFCCKiS48vAxVJ2MnHmRpsxY9aaxx3qslyGBOcU4TB8U7kclh+8E4qVR71AM7ugxntU0pxyKaYnG+hFPyMH8KqyxqI2YdqnY7xyaqXDYITP1ocgVMypFLy5PSpo48HgZzU8kO/7lTwW7AL3pIc1ZFcxkdOKZPMsZCp1qzdMBGQFwaxp2LNgdaZEY33LSzBnzTLpiYGxUSkRqM0TzxmIheatPQz9k+a6QmnFAATyf5VduGBhJWs233RxnP8VSysVtiM0J2QThzTuRtK8gCopPHJqe24UDAz3qGCRVAUH5varsUWVBJ60J6lzjyq1ixgLGAvWo7y8NsgwwyR0ptzIIYid3Irn7l5LqbHOM8U5TtsZ0cNzu8tixJqFxdPsTPPpT0sLuTr0q3pto0IzgbvWtZN7pjcAfUVK13Nak/Z6U0jmo7URXO2f6iultY4pYo2CjgY+lZd7EftgY8kDHNW4pikWFH5VKaQqnNNJmi8flEBcZ68VHKSRkEn60sMySEMCdwHNIVySeuadzK2uobSwXg8Ui4RiRT9vBKuQP51EVXb15ouUo3FlcsQduDTlt1YZJIb1NOSM7NzHn0xVnZnAcY4zQh7aIy57VZBwePWols2UblfGO3rWpIF3EKOBUR4IyBgVNkbwk7WKSOEfDdDxVxFSNMnOD3qtdwh8bP0pqO8agPyBSvY35Lq6J9vJyKaEUsOORT0y/INQ3chiU54JqGzSMLuxM8yKpV+fT2qOO6CgAkAVWjQuu5uc1agt1bqBzUXNuSKVi0lwmAyEZp7TJKo3EZqu1rCvXr7VUaF0csmSKVwUIvY1rVShOwblzkj1rXhuYpI9oGDXMwXzKQpGCeM1ch81Xyw4PcUrk1Kd9zWMRUls5FRRqJp9udtRwMX6OSR2NaekaRPdXSucrH6+tVFNvQxlJRTuy1a2cjyBEywrrPDmiRwyiaYB26AEdKm0yyjtggAy3cmteMiNiec4+XFdVOko6s8mviHLSJWuCC5WPgj5cDpRFGyoUkJaMDO0npUE/EhBJOeSQMGrMdu5i4YnI49au6uZbLcYkaBGwu8n26VRvIpSuy1UM/wDFgZzXQXCxDSY1iQCcHJbNFnbLDafaY3GH4ZV6iqtfQzVW3vHI/Zm/umiul8iL+9+lFT7E1+tnlt1bMhG4YqHBGPWvQNZ0PereWATXG3djLAxDDpQ1Y1hUUkZc2DwetULiPjpV+VcE5qtJmpaudMWY08foKqspDdK2JFB61UmQZ4rJxsdMZjbc4x2q2rDHNU0UrzVqHBHzUJCn3HE4agIC2cdakI4B9aVU460WM7kUkIxkVVf90cg1oMMCqzxhgSaTVi4SvuEU4bGetTySbxjGBWePlkAHSrORjk0rlyih2/bwOnrUIIduRn3qOSTPAqRCFUUrj5SwgRMcc1biI2ngVRjG9uKlkJjXrzVxMJwuU78fOQBxWc0JA3YrUZSyFs1VnwsWO9Uyox6GJcsWfFJ9nZY99X7a18yXpV6a2TaVP4VNmzSUlCyRjwMXG0mkugWjCirBtyj8VJ5YyMDJouLlV7lS0tjs8wnkVaDsq85FW0j+UYHGal8lX7cCmkxOSe5gXrSyvhc4q5plnIuGkAFbEVgo+YCrvloyDauMU+VkSrJLliUYoivOcml3HaSE5q8YNqhlqWKGLPz9D2p2ZzuS3MORRIm5+o7YpqQkOccpjpWlcxL9o29j0NSx23yN61NjXmSRQhwMbBtPvVna6tnACj0olRUOD1PSpSWKBe1Gwmr6oaQXwRUkduhG4jn1ojTZ1OauxneAoGAB1oJemxEYiV+TJApzMGUb+q8VdgYLGQRmqV3GMlx37U27ExXNoyOQDbkKM1VkG8dPwpzErhTmpEK45GahyOmMOUpeU4PBAHpTGhbnPStNwuzIHNVn3SEAEgd6hm8HczZDJAwKHIqKV5LpwCOBWt5CgYkqCaARkMgJNQzeMkMgV1X7mQBVpcSgLGuGxzUsUbvGCAangspPlKId/sOtO3YhyXUpSwSKiuAeDU1mQSRKh57YrpNOsFuyFnZVXOCD1r0rw94F0+Ox8xtPaaRhlWmbBNawoub0OKvj4UVaR4Vd2cYYlOD2qO0knjmWEI0gPTAr2fxIbO1gfTotHt45mGDLwStYmi6JbW/70xgyjpu6CiVHW1x08wUoc0kZOheH2UrcXn3j0X/Guzto4olVY1xt6jFNOOF4Ge4qSJGBb0HeumnTUdEedWrSqasmIG/KjrUgO4KME496IwojC9Sec0qYjB3ZyOlacpzXHPEmT2JHOTWtoMqo7GRCVCEE4zWBK8hc4K7TzU8Nw/SIlWx0B7VFrSuE480bFm6kNzLxGVUdD0zUEkjIjCM/L0wKmuHZoRu+UjuBnNVDHI24hSRxyO1VJWFHsLh/U0U3bJ6H8qKXMWaUjZXJ5rIvrKOYHcvJram+5VKeqkZwdnocVqei/eKLXN3djIj7drflXp04HlngVmBEN0Mqp/CsWjthVaRwC6LdyLvWNtv0rPmtHjcq4wele1hFFvwoHHpXn/idFExwoHPpScTSjiJT0ZyRt+xqGaFlVfL555rSTkc+9QT/AOsh+ppWN+dplIOQeSanSTI6VHcAZ6dqhTqak1tdFtnzgZFRSfdPNRselRsTzzSYRjYhLYY45pwBIJJ61B/y0NWx9wVmbvQjVADnNPUbmqJutWoO1ANk0SiNSSO1QyyfMOn41Yk/1ZrLnJz1rS9iFG+5aecMMYAPpVCfLMSOlObrSpz1pNlqKRNZggYXj1qVwR1og4YYqWfpSuZS1ZU2gt83elSOMNwM0g+/ViEDB4pA3YswpHsAxjNNaIIDjpTk6UXP3T9K0TMLXZJD0Ug8U7lJTgZWobPmPmrkf3qdyJKzsQAmRtvSlaPrg8io5SRdDBxVhPvmlcbjYhkjU7DzmhA67hnjtVmUdKYfvik2F7oz7hCXA70yQTIoOeKuTj/S0+h/pTrn7i1JtFkMR3R7m+hFWoXw6jBAxVSAcfjV9BQOUUOkkJGBikK44zwaB/FTv4aQKKI3h8wZAzUBi2jg1bhJ9afIBs6Ck0UnYrwLnAPSgwMZuFOD7VfslBdcgdRW1dgBug6UJXQpVOVmdbaOZYAWXDHue1JNp1tFOqSzIB7VaZ2yg3Nj0zVXTI0lvLrzEV8dNwzjrT0MozlK7vsPkk020XajtI3TA6U+yiuL0SSwiOGIep5rPnRRJwqjn0q/p5Pl4zxk8UQd3qOonGN+pe0BfsWqRzKVl2kE7+lejXfjOd4vLtoVQkY3ZriNPRfL+6PyrptKijNuSUUn1IrphdKyPOxMYzalJXMg7552mnYvITkmrCndgNwpqS+AEZwAOvSobXkJn1ppW0Fe6JZAoACDFTEDyTtY8jHNNkAwOB1NCdx2rSKMm7ksMKxQZkZjxwaDKjEbwdgX86i3E4BJI54zTH+8fpTuJK+42SYSsPL4B4ya2NKs4omWa6nQRngiuej/ANZ/wKtiFj9kuOT92s4vW46t0rI1mELJJAJVVOqk9xVO1EbEgOWIPQnGabF87rv+b90OvPrToFUQuQozg9q1Wpha10S7Yf8ALUVSxRTsiLn/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Heavy neovascularization and mild opacity are present on the lower half of the cornea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8214=[""].join("\n");
var outline_f8_1_8214=null;
var title_f8_1_8215="Clindamycin (systemic): Pediatric drug information";
var content_f8_1_8215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clindamycin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/46/41704?source=see_link\">",
"    see \"Clindamycin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/49/35604?source=see_link\">",
"    see \"Clindamycin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8007987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8008032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cleocin HCl&reg;;",
"     </li>",
"     <li>",
"      Cleocin Pediatric&reg;;",
"     </li>",
"     <li>",
"      Cleocin Phosphate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8008033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clindamycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Clindamycin;",
"     </li>",
"     <li>",
"      Clindamycin Injection, USP;",
"     </li>",
"     <li>",
"      Clindamycine;",
"     </li>",
"     <li>",
"      Dalacin&trade; C;",
"     </li>",
"     <li>",
"      Mylan-Clindamycin;",
"     </li>",
"     <li>",
"      PMS-Clindamycin;",
"     </li>",
"     <li>",
"      Riva-Clindamycin;",
"     </li>",
"     <li>",
"      Teva-Clindamycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10533166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Anaerobic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.M., I.V., Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &lt;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;2000 g: 10 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 15 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &ge;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1200 g: 10 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200-2000 g: 15 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 20-30 mg/kg/day divided every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10533179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/46/41704?source=see_link\">",
"      see \"Clindamycin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Mild to moderate infections:15-25 mg/kg/day divided every 6-8 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Severe infections: 25-40 mg/kg/day divided every 6-8 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Children and Adolescents 1-16 years: 20-40 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Mild to moderate infections: 10-40 mg/kg/day divided every 6-8 hours; maximum daily dose: 1800 mg/day; not appropriate for severe infection  (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Hydrochloride salt (capsule): 8-20 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Palmitate salt (solution): 8-25 mg/kg/day divided every 6-8 hours; minimum dose: 37.5 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Anthrax, treatment:",
"     </b>",
"     I.V.: 30 mg/kg/day divided every 6 hours; used as part of a multidrug regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Babesiosis:",
"     </b>",
"     Oral: 20-40 mg/kg/day divided every 8 hours for 7-10 days plus quinine  (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bacterial endocarditis prophylaxis for dental and upper respiratory procedures in penicillin allergic patients",
"     </b>",
"     (Wilson, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.:  20 mg/kg 30 minutes before procedure; maximum dose: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 20 mg/kg 1 hour before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria; uncomplicated, treatment:",
"     </b>",
"     Oral: 20 mg/kg/day divided every 8 hours for 7 days plus quinine (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria; severe, treatment:",
"     </b>",
"     I.V.:  Loading dose: 10 mg/kg once followed by 15 mg/kg/day divided every 8 hours plus I.V. quinidine gluconate; switch to oral therapy (clindamycin and quinine, see above) when able for total treatment duration of 7 days.",
"     <b>",
"      Note:",
"     </b>",
"     Quinine duration is region specific; consult CDC for current recommendations (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      MRSA, treatment",
"     </b>",
"     (Liu, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cellulitis: Oral: 40 mg/kg/day divided every 6-8 hours for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Complicated skin/soft tissue infection: I.V., Oral: 40 mg/kg/day divided every 6-8 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Osteomyelitis : I.V., Oral: 40 mg/kg/day divided  every 6-8 hours for a minimum of 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pneumonia, hospital-acquired or community-acquired: I.V., Oral: 40 mg/kg/day divided every 6-8 hours for 7-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Septic arthritis: I.V., Oral: 40 mg/kg/day divided every 6-8 hours for minimum of 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Primary prevention of rheumatic fever (treatment of streptococcal tonsillopharyngitis) in penicillin-allergic patients (&gt;3 years)",
"     </b>",
"     : Oral: 20 mg/kg/day divided every 8 hours; maximum dose: 1.8 g/day  (Gerber, 2009;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Toxoplasmosis, secondary prevention (HIV-exposed/positive):",
"     </b>",
"     Oral: 20-30 mg/kg/day divided every 6 hours and pyrimethamine plus leucovorin (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 1200-2700 mg/day in 2-4 divided doses; doses as high as 4800 mg/day have been given I.V. to adults in life-threatening situations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 150-450 mg/",
"     <b>",
"      dose",
"     </b>",
"     every 6-8 hours; maximum daily dose: 1800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Babesiosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 1200 mg twice daily for 7-10 days plus quinine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 600 mg 3 times/day for 7-10 days plus quinine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bacterial endocarditis prophylaxis for dental and upper respiratory procedures in penicillin-allergic patients",
"     </b>",
"     (Wilson, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 600 mg 30 minutes before procedure",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 600 mg 1 hour before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cellulitis due to MRSA:",
"     </b>",
"     Oral: 300-450 mg 3 times/day for 5-10 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Osteomyelitis, pneumonia, complicated skin/soft tissue infection due to MRSA:",
"     </b>",
"     I.V., Oral: 600 mg 3 times/day (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"     900 mg I.V. every 8 hours with gentamicin (conventional or single daily dosing) for 24 hours after significant clinical improvement, followed by 450 mg orally 4 times/day to complete a 14-day course (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing  adjustment in renal impairment:",
"     </b>",
"     No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Systemic use: No adjustment required. Use caution with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8008168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride [strength expressed as base]: 75 mg, 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin HCl&reg;: 75 mg, 150 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin HCl&reg;: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for solution, oral, as palmitate hydrochloride [strength expressed as base]: 75 mg/5 mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin Pediatric&reg;: 75 mg/5 mL (100 mL) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as phosphate [strength expressed as base]: 300 mg (50 mL); 600 mg (50 mL); 900 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin Phosphate&reg;: 300 mg (50 mL); 600 mg (50 mL); 900 mg (50 mL) [contains edetate disodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as phosphate [strength expressed as base]: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin Phosphate&reg;: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL) [contains benzyl alcohol, edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8008035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10533497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Capsule should be taken with a full glass of water to avoid esophageal irritation; shake oral solution well before use; may administer with or without meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Administer by I.V. intermittent infusion over at least 10-60 minutes, at a rate not to exceed 30 mg/minute; hypotension and cardiopulmonary arrest have been reported following rapid I.V. administration; final concentration for administration should not exceed 18 mg/mL; pH: 6.0-6.3 (usual); 5.5-7.0 (range)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8008095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, anakinra, anidulafungin, aztreonam, bivalirudin, caffeine citrate, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, fentanyl, fludarabine, foscarnet, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, labetalol, levofloxacin, linezolid, magnesium sulfate, melphalan, meperidine, midazolam, milrinone, morphine, multivitamins, nicardipine, ondansetron, oxytocin, pemetrexed, piperacillin/tazobactam, propofol, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, azithromycin, caspofungin, doxapram, filgrastim, idarubicin, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Drotrecogin alfa, fluconazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Amikacin, aztreonam, caffeine citrate, dimenhydrinate, gentamicin, heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone, pantoprazole, tobramycin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10533175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infusion solution in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W solution is stable for 16 days at room temperature, 32 days refrigerated, or 8 weeks frozen. Prior to use, store vials and premixed bags at controlled room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). After initial use, discard any unused portion of vial after 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Do not refrigerate reconstituted oral solution (it will thicken). Following reconstitution, oral solution is stable for 2 weeks at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10533167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active against most aerobic gram-positive staphylococci and streptococci (except enterococci); useful against",
"     <i>",
"      Fusobacterium",
"     </i>",
"     ,",
"     <i>",
"      Bacteroides",
"     </i>",
"     species,",
"     <i>",
"      Actinomyces",
"     </i>",
"     , and certain anaerobic gram-positive organisms. Use for treatment of infections of the respiratory tract, skin and soft tissue, and female pelvis and genital tract; sepsis and intra-abdominal infections due to susceptible organisms (FDA approved in children and adults); bacterial endocarditis prophylaxis for dental and upper respiratory procedures in penicillin-allergic patients; perioperative prophylaxis for head and neck surgery (incision through oral mucosa), colorectal surgery, appendectomy, or surgery for ruptured viscus; treatment of babesiosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8007988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cleocin&reg; may be confused with bleomycin, Clinoril&reg;, Cubicin&reg;, Lincocin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clindamycin may be confused with clarithromycin, Claritin&reg;, vancomycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8008066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest (rare; I.V. administration), hypotension (rare; I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme (rare), exfoliative dermatitis (rare), pruritus, rash, Stevens-Johnson syndrome (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, esophagitis, nausea, pseudomembranous colitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia (transient), neutropenia (transient), thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice, liver function test abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Induration/pain/sterile abscess (I.M.), thrombophlebitis (I.V.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Polyarthritis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal dysfunction (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10533168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clindamycin, lincomycin, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10533171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with severe renal and/or hepatic impairment; use with caution in atopic patients; use with caution in patients with previous pseudomembranous colitis, regional enteritis, or ulcerative colitis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10533169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use can cause severe and possibly fatal colitis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     characterized by severe persistent diarrhea, severe abdominal cramps, and possibly, the passage of blood and mucus; discontinue drug if significant diarrhea occurs. Antiperistaltic agents, such as opiates or diphenoxylate with atropine, may prolong and worsen the condition. Not appropriate for use in the treatment of meningitis due to inadequate penetration into the CSF.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Capsule contains tartrazine which may cause allergic reactions in susceptible individuals. Injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; use clindamycin injection products containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8008069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): Lincosamide Antibiotics may diminish the therapeutic effect of Erythromycin (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the absorption of Lincosamide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8008047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8008048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Clindamycin crosses the placenta throughout pregnancy and at term, but use during pregnancy has not been shown to cause adverse fetal effects. Clindamycin pharmacokinetics are not affected by pregnancy. Clindamycin therapy is recommended in certain pregnant patients for prophylaxis of group B streptococcal disease in newborns, prophylaxis and treatment of",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     encephalitis, or for the treatment of",
"     <i>",
"      Pneumocystis",
"     </i>",
"     pneumonia (PCP), bacterial vaginosis, or malaria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10533498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for changes in bowel frequency; during prolonged therapy, monitor CBC with differential, platelet count, and hepatic and renal function tests periodically.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10533176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly binds to 50S ribosomal subunits preventing peptide bond formation, thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10533177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: 90% of clindamycin hydrochloride is rapidly absorbed; clindamycin palmitate must be hydrolyzed in the GI tract before it is active",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: No significant levels are seen in CSF, even with inflamed meninges; distributes into saliva, ascites fluid, pleural fluid, bone, and bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Premature: 8.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Full-term: 3.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants 1 month to 1 year: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adults with normal renal function: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Within 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Within 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Most of the drug is eliminated by hepatic metabolism; 10% of an oral dose excreted in urine and 3.6% excreted in feces as active drug and metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10533499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/49/35604?source=see_link\">",
"      see \"Clindamycin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., I.V.: Report any burning, pain, swelling, or redness at infusion or injection site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Take each dose with a full glass of water. Complete full prescription, even if feeling better. You may experience nausea or vomiting (small, frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help). Report dizziness; persistent GI effects (pain, diarrhea, vomiting); skin redness, rash, or burning; fever; chills; unusual bruising or bleeding; signs of infection; excessive fatigue; yellowing of eyes or skin; change in color of urine or blackened stool; swelling, warmth, or pain in extremities; difficult respirations; bloody or fatty stool (do not take antidiarrheal without consulting prescriber); or lack of improvement or worsening of condition.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/1/8215/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Diagnosis and Treatment of Malaria.\" Available at",
"      <a href=\"file://www.cdc.gov/malaria/diagnosis_treatment/index.html\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/diagnosis_treatment/index.html",
"      </a>",
"      . Date accessed: October 21, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/1/8215/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/1/8215/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al, \"Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute",
"      <i>",
"       Streptococcal pharyngitis",
"      </i>",
"      : A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(11):1541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/1/8215/abstract-text/19246689/pubmed\" id=\"19246689\" target=\"_blank\">",
"        19246689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/1/8215/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Drugs for Parasitic Infections,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 783-816. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/4.10",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Group A Streptococcal Infections,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 616-28. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/3.125",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, \"Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/1/8215/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, \"Prevention of Infective Endocarditis. Guidelines From the American Heart Association,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115:1-20.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Workowski KA, Berman S, and Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/1/8215/abstract-text/ 21160459 /pubmed\" id=\" 21160459 \" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15953 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8215=[""].join("\n");
var outline_f8_1_8215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8007987\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008032\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008033\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533166\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442269\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533179\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008168\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008035\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533497\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008095\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533175\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533167\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8007988\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008066\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533168\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533171\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533169\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299057\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008069\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008047\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008048\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533498\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533176\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533177\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533499\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15953\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15953|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/46/41704?source=related_link\">",
"      Clindamycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/49/35604?source=related_link\">",
"      Clindamycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/46/5862?source=related_link\">",
"      Clindamycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/21/2389?source=related_link\">",
"      Clindamycin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/21/38229?source=related_link\">",
"      Clindamycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_1_8216="Coronary collateral circulation";
var content_f8_1_8216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary collateral circulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8216/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8216/contributors\">",
"     Bruce D Klugherz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8216/contributors\">",
"     Daniel M Kolansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8216/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8216/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8216/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/1/8216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anastomotic channels, known as collateral vessels, can develop in the heart as an adaptation to ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. They serve as conduits that bridge severe stenoses or connect a territory supplied by one epicardial coronary artery with that of another [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/3\">",
"     3",
"    </a>",
"    ]. Collaterals therefore provide an alternative source of blood supply to myocardium jeopardized by occlusive coronary artery disease, and they can help to preserve myocardial function in the setting of a chronic total coronary occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two classes of collateral vessels have been recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Capillary size collaterals, in which smooth muscle cells are absent, may be observed throughout the myocardium, although they have a predilection for the subendocardium.",
"     </li>",
"     <li>",
"      Larger, muscular collaterals, which develop from preexisting arterioles, are typically located epicardially [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF RECRUITMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and pathophysiologic determinants of collateral recruitment are poorly understood. Although primarily thought to be initiated by ischemia, appreciable collateral perfusion is present in some patients who do not have coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of transient coronary occlusion during balloon angioplasty have found that the following independent clinical and angiographic variables are correlated with increases in collateral flow [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/4,7-9\">",
"     4,7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Longer duration of angina",
"     </li>",
"     <li>",
"      Greater level of long-term physical activity during leisure time",
"     </li>",
"     <li>",
"      Greater lesion severity",
"     </li>",
"     <li>",
"      Proximal lesion location",
"     </li>",
"     <li>",
"      Greater duration of lesion occlusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Collateral recruitment may be diminished in older adults. In a study of over 1900 patients undergoing angiography within 72 hours after an acute myocardial infarction, the prevalence of collaterals decreased from 48 percent in patients &lt;50 years of age to 34 percent in patients &ge;70 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying mechanisms by which ischemia induces collateral vessel formation are unknown. Several endothelial and smooth muscle cell mitogens have been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. As an example, markedly elevated levels of basic fibroblast growth factor (bFGF) have been demonstrated in the pericardial fluid of patients undergoing coronary artery bypass grafting for unstable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/11\">",
"     11",
"    </a>",
"    ]. In patients with coronary disease undergoing angioplasty, intracoronary concentrations of bFGF and vascular endothelial growth factor (VEGF) are associated with a directly-measured index of collateral flow; the concentration of VEGF is influenced by the degree of coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, increased expression of VEGF has been shown in animal models of acute myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/12\">",
"     12",
"    </a>",
"    ] and in patients with an acute myocardial infarction; levels are higher in those with, compared to those without, improvement of left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/15\">",
"     15",
"    </a>",
"    ]. VEGF induces or stimulates collateral vessel formation and improves the impaired endothelium-dependent relaxation of collaterals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/16\">",
"     16",
"    </a>",
"    ]; the induction of coronary collateralization by VEGF requires the production of nitric oxide, which is an important regulator of collateral growth [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although suggestive, these studies do not directly prove a causative role for these molecules in the induction of collateral vasculogenesis. On the other hand, inhibitors of angiogenesis, such as protamine, interfere with collateral vessel development in dogs subjected to transient left anterior descending artery occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a canine model of collateral development, gradual occlusion of an epicardial coronary artery resulted in collateral vessel growth sufficient to provide approximately 80 percent of the blood flow to normally perfused myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/18\">",
"     18",
"    </a>",
"    ]. Although collateral vessel blood flow after epicardial coronary occlusion may be adequate to meet myocardial needs at rest, collateral circulation is generally",
"    <strong>",
"     not",
"    </strong>",
"    sufficient to meet myocardial demands during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/19\">",
"     19",
"    </a>",
"    ] and may not prevent myocardial ischemia during coronary occlusion. This was illustrated by one study of 450 patients, which found that 67 percent did not have enough collateral flow to prevent myocardial ischemia produced by balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quantitative radionuclide myocardial perfusion imaging with positron emission tomography has added to the understanding of blood flow regulation in collateral circulation in humans. Applying this technique to patients with single vessel coronary occlusion, blood flow to collateral-dependent myocardium was shown to increase by nearly 35 percent during atrial pacing-induced tachycardia, a condition that increases myocardial oxygen demand [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/20\">",
"     20",
"    </a>",
"    ]. This degree of flow augmentation, however, was far less than that observed among normal controls.",
"   </p>",
"   <p>",
"    The precise mechanisms underlying exercise-induced augmentation of collateral blood flow are not well understood. Coronary collaterals exhibit vasoconstrictor activity both early [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/21\">",
"     21",
"    </a>",
"    ], when vessels are thin-walled and nearly devoid of smooth muscle, and late, when vessels have developed further and have a thick muscular media [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, endothelium-dependent relaxation is reduced early after the development of collaterals and may require up to several months to become normal, suggesting a possible increased propensity for vasospasm early after collaterals have formed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial release of nitric oxide&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/24\">",
"     24",
"    </a>",
"    ] and activation of beta-adrenergic receptors, whose existence has been demonstrated in collateral vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/25\">",
"     25",
"    </a>",
"    ], may be responsible for vasodilation of coronary collaterals. In contrast, alpha-adrenergic receptors have not been identified in isolated rings of collateral tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in animal models have shown that beta blockers induce vasoconstriction of coronary collaterals during exercise, thereby reducing collateral blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/27\">",
"     27",
"    </a>",
"    ]. A similar effect can be induced by inhibitors of nitric oxide synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/28\">",
"     28",
"    </a>",
"    ] and by a platelet activating factor which causes platelet aggregation and the release of the potent vasoconstrictors thromboxane A2 and serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/29\">",
"     29",
"    </a>",
"    ]. These observations may have clinical implications in patients with collateral-dependent myocardium, especially during episodes of ischemia and subsequent platelet activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary collaterals have been traditionally assessed using selective coronary angiography; this technique offers direct visualization of collateral vessels exceeding 100 microns in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. A classification system for collateral flow from patent vessels to the occluded vessel was developed by Rentrop [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0 &mdash; No visible filling of any collateral channel",
"     </li>",
"     <li>",
"      Grade 1 &mdash; Filling of the side branches of the occluded artery, with no dye reaching the epicardial segment",
"     </li>",
"     <li>",
"      Grade 2 &mdash; Partial filling of the epicardial vessel",
"     </li>",
"     <li>",
"      Grade 3 &mdash; Complete filling of the epicardial vessel by collaterals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intracoronary flow velocity, flow capacity, or pressure measurements obtained during routine catheterization and angioplasty can also provide an accurate and quantitative method for assessing the collateral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=see_link\">",
"     \"Clinical use of coronary artery pressure and Doppler flow measurements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients undergoing angioplasty, the Doppler-derived or pressure-derived collateral flow index (CFI), which is defined as the ratio of flow during balloon inflation divided by resting flow, may be calculated. CFI is a useful measure for assessing the effects of various pharmacologic agents, such as adenosine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , on coronary collateral perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/34\">",
"     34",
"    </a>",
"    ]. Pressure-derived CFI was recently shown to predict left ventricular dilatation one year following thrombolysis for acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/35\">",
"     35",
"    </a>",
"    ], making this measurement a potentially valuable clinical tool for prognostication.",
"   </p>",
"   <p>",
"    Myocardial contrast echocardiography, which for this purpose involves the selective coronary injection of sonicated microbubbles, is an alternative diagnostic tool for the assessment of coronary collaterals. This technique may more precisely identify the spatial extent of perfusion via collateral vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/36\">",
"     36",
"    </a>",
"    ]. However, FDA-approved agents for cardiac imaging are contraindicated for intraarterial injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=see_link\">",
"     \"Contrast echocardiography: Contrast agents, safety, and imaging technique\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myocardial contrast echocardiography and angiography appear to differ in their ability to detect the functional significance of collateral beds [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/30,37,38\">",
"     30,37,38",
"    </a>",
"    ]. Surprisingly, there is a poor correlation between the presence of well-visualized collaterals at angiography and the preservation of segmental wall motion in patients with chronically occluded epicardial coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/30\">",
"     30",
"    </a>",
"    ]. By comparison, myocardial contrast echocardiography more reliably reflects wall motion in these patients, perhaps due to more precise delineation of microvascular perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial contrast echocardiography can also be used to predict functional recovery after revascularization of collateralized myocardium. In one series, for example, improvement in left ventricular function correlated with successful angioplasty of the infarct-related artery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/38\">",
"     38",
"    </a>",
"    ]. Among patients in whom angioplasty was successful, those with &gt;50 percent of the infarct bed perfused by collaterals, as demonstrated by myocardial contrast echocardiography, had superior baseline wall motion and wall motion one month following revascularization compared with those whose infarct beds were &le;50 percent perfused by collateral flow.",
"   </p>",
"   <p>",
"    Other noninvasive techniques can assess the collateral circulation. The severity of 99m-technetium-sestamibi tomographic perfusion defects, for example, has been shown to correlate closely with absolute collateral flow as measured by radiolabeled microspheres in animal models of coronary occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/39\">",
"     39",
"    </a>",
"    ] and with collateral fractional flow reserve, an index of collateral flow in patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .) Spiral computerized tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/41\">",
"     41",
"    </a>",
"    ], magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/42\">",
"     42",
"    </a>",
"    ], and positron emission tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/20,43\">",
"     20,43",
"    </a>",
"    ] have also been validated and may ultimately prove clinically useful in the assessment of myocardial collateralization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;During brief episodes of coronary occlusion produced by angioplasty, the presence of recruitable collaterals reduces the severity of regional myocardial hypoperfusion in some patients, as evaluated with radionuclide myocardial perfusion imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/44\">",
"     44",
"    </a>",
"    ]. In the setting of acute myocardial infarction, thrombotic occlusion of an epicardial coronary artery results in downstream myonecrosis, with resultant segmental abnormalities of regional wall motion. Preexisting collateral vessels have the potential to reduce the severity of injury by providing blood flow to the threatened segments.",
"   </p>",
"   <p>",
"    Specific beneficial effects observed in the presence of collateral vessels include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced infarction size &mdash; In a canine model of electrically induced left circumflex coronary thrombosis, infarct size as determined histochemically was smaller among dogs with contrast echo-detected collateral perfusion than among those without collaterals (4 versus 11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/45\">",
"       45",
"      </a>",
"      ]. In the TIMI trial, infarct size, as determined by serum creatine kinase, was smaller among patients with collateral vessels compared to those without such vessels (20.6 versus 31.4 CK gram equivalents, p =0.001) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Greater postinfarction ejection fraction &mdash; Smaller infarct size should translate into a greater postinfarction left ventricular ejection fraction (LVEF) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. One study found that, in patients with sufficient collaterals, left ventricular recovery after reperfused myocardial infarction is primarily determined by the amount of collateral blood flow and is less dependent upon the time to reperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/49\">",
"       49",
"      </a>",
"      ]. In one series of patients with occluded culprit arteries after fibrinolytic therapy, the presence of significant collateral flow (as determined angiographically) was associated with a significantly higher postinfarction LVEF (60 versus 54 percent for those with lesser collateral flow) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/48\">",
"       48",
"      </a>",
"      ]. Preservation of left ventricular function has also been observed following the late administration of fibrinolytic therapy to patients suffering from acute myocardial infarction who had a collateralized infarct-related artery [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced risk for rupture &mdash; The presence of collaterals can reduce the risk for rupture of papillary muscle, myocardial free wall, or interventricular septum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"       \"Mechanical complications of acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreased aneurysmal dilatation &mdash; In one series of 47 patients given fibrinolytic therapy within six hours of a first myocardial infarction, the incidence of left ventricular aneurysm was 4 percent in those with successful reperfusion and, among those with unsuccessful reperfusion, was much lower in patients with significant collaterals to the infarct-related artery (10 versus 58 percent in those without collaterals) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSTIC SIGNIFICANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141866190\">",
"    <span class=\"h2\">",
"     Acute myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of collateral circulation to the infarct-related artery may be an independent predictor of mortality in patients with an acute myocardial infarction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 1059 patients undergoing primary percutaneous coronary intervention (PCI) for ST elevation MI, increased collateral flow was associated with a lower incidence of Killip class &ge;2 at presentation, less need for intraaortic balloon pumping after PCI, better myocardial blush grade after intervention, and smaller enzymatic infarct size [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 180 patients undergoing primary PCI for anterior ST elevation MI (STEMI), the in-hospital mortality rate was substantially lower in those with demonstrable collaterals as determined by angiography (8 versus 23 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/53\">",
"       53",
"      </a>",
"      ]. This difference was primarily due to a lower frequency of cardiogenic shock among the patients with preexisting collaterals.",
"     </li>",
"     <li>",
"      There also appears to be a long-term protective effect of collaterals when present early after an acute infarction. Although early evidence did not show this, more recent studies have been quite suggestive about the benefit of collaterals [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/54-57\">",
"       54-57",
"      </a>",
"      ]. In the study with the longest follow-up (median of 797 days), and which included 227 patients with STEMI, the presence of extensive coronary collateral flow before primary PCI was associated with a significantly lower mortality (4.4 versus 13.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indirect support for a long-term protective effect of an adequate coronary collateral circulation in patients with acute MI comes from a study of 845 individuals with either stable (739 patients) or no important coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients underwent quantitative, coronary pressure-derived collateral measurements and were followed for a mean of five years. Patients with a high collateral flow index compared to those with a low index had significantly higher cumulative rates of 10-year overall survival (88 versus 71 percent) and survival free of cardiac death (97 versus 89 percent). A limitation to these data is that the authors were unable to control for all potential confounders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     In diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with coronary artery disease who have diabetes mellitus have a less favorable outcome than those without diabetes. In addition, they have a higher mortality and are more likely to experience a complication after myocardial infarction, such as postinfarction angina or congestive heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=see_link\">",
"     \"Treatment of acute myocardial infarction in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This increase in risk may be attributable to fewer collaterals. One study of 306 patients with diabetes who underwent coronary angiography found that these patients had a lower mean collateral score compared to nondiabetics (2.41 versus 2.6), suggesting poorer development of collaterals in diabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism for impaired collateral formation in diabetics was evaluated in a series of 16 diabetics and 14 healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/59\">",
"     59",
"    </a>",
"    ]. The cellular response of monocytes to VEGF-A, an important step during collateral formation due to regional myocardial ischemia, was attenuated in the diabetic patients. The expression of vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF-1alpha), a transcriptional activator of VEGF, was measured in ventricular biopsy specimens from patients undergoing coronary bypass surgery. Patients without diabetes had statistically significantly higher levels of VEGF and HIF-1alpha than diabetic patients, suggesting reduced expression of these angiogenesis factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     THERAPEUTIC POTENTIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recent attention has been directed toward therapies that might augment the natural supply of collaterals through myocardial neovascularization. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=see_link\">",
"     \"Therapeutic angiogenesis for management of refractory angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serotonin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serotonin can reduce coronary artery collateral flow by vasoconstriction, possibly via platelet activation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    .) In a small study of 22 patients, the administration of a serotonin receptor antagonist improved exercise duration and the double product at ST segment depression and reduced the severity of ischemia on radionuclide myocardial perfusion imaging among patients with well-developed collaterals, but had no effect in those without collaterals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Angiotensin converting enzyme inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angiotensin converting enzyme (ACE) inhibitors improve the endothelial dysfunction seen in atherosclerosis, suggesting that they may have a role in angiogenesis. Support for this comes from a study of rabbits with hindlimb ischemia that found that quinaprilat, an ACE inhibitor with high tissue affinity, augmented angiogenesis to a degree similar as VEGF;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , an ACE inhibitor with low tissue affinity, and placebo were ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong evidence supporting the angiogenic potential of statin therapy. A recent clinical trial measuring collateral flow index (CFI) among 500 patients undergoing coronary intervention found no difference in quantitatively determined collateral flow between patients being treated with statins (n = 186) and those who were untreated (n = 314) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMPACT OF DRUG ELUTING STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and rapamycin coatings on some drug-eluting stents may impair the development and function of coronary collaterals after their placement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8216/abstract/64\">",
"     64",
"    </a>",
"    ]. This study raises the possibility that if subsequent stent thrombosis occurs after drug-eluting stent placement then collateral protection could be impaired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anastomotic channels known as collateral vessels can develop in the heart as an adaptation to ischemia. They serve as conduits that bridge severe stenoses or connect a territory supplied by one epicardial coronary artery with that of another.",
"     </li>",
"     <li>",
"      Two classes of collateral vessels have been recognized: capillary size collaterals, in which smooth muscle cells are absent, may be observed throughout the myocardium, although they have a predilection for the subendocardium; and larger, muscular collaterals, which develop from preexisting arterioles, are typically located epicardially.",
"     </li>",
"     <li>",
"      Coronary collaterals can provide substantial blood flow to resting myocardium, but are generally insufficient during increased demand (exercise).",
"     </li>",
"     <li>",
"      Collaterals may: reduce infarct size after myocardial infarction; reduce postmyocardial infarction complications such as rupture of a papillary muscle, myocardial free wall, or interventricular septum; and reduce aneurysmal dilatation.",
"     </li>",
"     <li>",
"      The absence of collateral circulation to the infarct-related artery may be an independent predictor of mortality in patients with an acute myocardial infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with diabetes have less well-developed collateral vessels.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/1\">",
"      Fujita M, Sasayama S, Ohno A, et al. Importance of angina for development of collateral circulation. Br Heart J 1987; 57:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/2\">",
"      Tayebjee MH, Lip GY, MacFadyen RJ. Collateralization and the response to obstruction of epicardial coronary arteries. QJM 2004; 97:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/3\">",
"      Levin DC. Pathways and functional significance of the coronary collateral circulation. Circulation 1974; 50:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/4\">",
"      Werner GS, Ferrari M, Betge S, et al. Collateral function in chronic total coronary occlusions is related to regional myocardial function and duration of occlusion. Circulation 2001; 104:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/5\">",
"      Schaper W. Collateral vessel growth in the human heart. Role of fibroblast growth factor-2. Circulation 1996; 94:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/6\">",
"      Wustmann K, Zbinden S, Windecker S, et al. Is there functional collateral flow during vascular occlusion in angiographically normal coronary arteries? Circulation 2003; 107:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/7\">",
"      Piek JJ, van Liebergen RA, Koch KT, et al. Clinical, angiographic and hemodynamic predictors of recruitable collateral flow assessed during balloon angioplasty coronary occlusion. J Am Coll Cardiol 1997; 29:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/8\">",
"      Senti S, Fleisch M, Billinger M, et al. Long-term physical exercise and quantitatively assessed human coronary collateral circulation. J Am Coll Cardiol 1998; 32:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/9\">",
"      Pohl T, Seiler C, Billinger M, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol 2001; 38:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/10\">",
"      Kurotobi T, Sato H, Kinjo K, et al. Reduced collateral circulation to the infarct-related artery in elderly patients with acute myocardial infarction. J Am Coll Cardiol 2004; 44:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/11\">",
"      Fujita M, Ikemoto M, Kishishita M, et al. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation 1996; 94:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/12\">",
"      Shweiki D, Itin A, Neufeld G, et al. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993; 91:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/13\">",
"      Kersten JR, Pagel PS, Warltier DC. Protamine inhibits coronary collateral development in a canine model of repetitive coronary occlusion. Am J Physiol 1995; 268:H720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/14\">",
"      Fleisch M, Billinger M, Eberli FR, et al. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation 1999; 100:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/15\">",
"      Hojo Y, Ikeda U, Zhu Y, et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 2000; 35:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/16\">",
"      Takeshita S, Isshiki T, Ochiai M, et al. Endothelium-dependent relaxation of collateral microvessels after intramuscular gene transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia. Circulation 1998; 98:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/17\">",
"      Matsunaga T, Warltier DC, Weihrauch DW, et al. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000; 102:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/18\">",
"      Foreman BW, Dai XZ, Bache RJ. Vasoconstriction of canine coronary collateral vessels with vasopressin limits blood flow to collateral-dependent myocardium during exercise. Circ Res 1991; 69:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/19\">",
"      Bache RJ, Schwartz JS. Myocardial blood flow during exercise after gradual coronary occlusion in the dog. Am J Physiol 1983; 245:H131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/20\">",
"      Sambuceti G, Parodi O, Giorgetti A, et al. Microvascular dysfunction in collateral-dependent myocardium. J Am Coll Cardiol 1995; 26:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/21\">",
"      Kinn JW, Altman JD, Chang MW, Bache RJ. Vasomotor responses of newly developed coronary collateral vessels. Am J Physiol 1996; 271:H490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/22\">",
"      Hautamaa PV, Dai XZ, Homans DC, Bache RJ. Vasomotor activity of moderately well-developed canine coronary collateral circulation. Am J Physiol 1989; 256:H890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/23\">",
"      Rapps JA, Myers PR, Zhong Q, Parker JL. Development of endothelium-dependent relaxation in canine coronary collateral arteries. Circulation 1998; 98:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/24\">",
"      Frank MW, Harris KR, Ahlin KA, Klocke FJ. Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary collateral vessels. J Am Coll Cardiol 1996; 27:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/25\">",
"      Feldman RD, Christy JP, Paul ST, Harrison DG. Beta-adrenergic receptors on canine coronary collateral vessels: characterization and function. Am J Physiol 1989; 257:H1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/26\">",
"      Harrison DG, Chilian WM, Marcus ML. Absence of functioning alpha-adrenergic receptors in mature canine coronary collaterals. Circ Res 1986; 59:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/27\">",
"      Traverse JH, Altman JD, Kinn J, et al. Effect of beta-adrenergic receptor blockade on blood flow to collateral-dependent myocardium during exercise. Circulation 1995; 91:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/28\">",
"      Traverse JH, Kinn JW, Klassen C, et al. Nitric oxide inhibition impairs blood flow during exercise in hearts with a collateral-dependent myocardial region. J Am Coll Cardiol 1998; 31:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/29\">",
"      Kinn JW, Bache RJ. Effect of platelet activation on coronary collateral blood flow. Circulation 1998; 98:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/30\">",
"      Gensini GG, Bruto da Costa BC. The coronary collateral circulation in living man. Am J Cardiol 1969; 24:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/31\">",
"      Rockstroh J, Brown BG. Coronary collateral size, flow capacity, and growth: estimates from the angiogram in patients with obstructive coronary disease. Circulation 2002; 105:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/32\">",
"      Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/33\">",
"      Seiler C, Fleisch M, Garachemani A, Meier B. Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol 1998; 32:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/34\">",
"      Billinger M, Raeber L, Seiler C, et al. Coronary collateral perfusion in patients with coronary artery disease: effect of metoprolol. Eur Heart J 2004; 25:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/35\">",
"      Sezer M, Nisanci Y, Umman B, et al. Pressure-derived collateral flow index: a strong predictor of late left ventricular remodeling after thrombolysis for acute myocardial infarction. Coron Artery Dis 2006; 17:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/36\">",
"      Mills JD, Fischer D, Villanueva FS. Coronary collateral development during chronic ischemia: serial assessment using harmonic myocardial contrast echocardiography. J Am Coll Cardiol 2000; 36:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/37\">",
"      Vernon SM, Camarano G, Kaul S, et al. Myocardial contrast echocardiography demonstrates that collateral flow can preserve myocardial function beyond a chronically occluded coronary artery. Am J Cardiol 1996; 78:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/38\">",
"      Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/39\">",
"      Christian TF, O'Connor MK, Schwartz RS, et al. Technetium-99m MIBI to assess coronary collateral flow during acute myocardial infarction in two closed-chest animal models. J Nucl Med 1997; 38:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/40\">",
"      Matsuo H, Watanabe S, Kadosaki T, et al. Validation of collateral fractional flow reserve by myocardial perfusion imaging. Circulation 2002; 105:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/41\">",
"      Pearlman JD, Laham RJ, Simons M, et al. Extent of myocardial collateralization: determination with three-dimensional elastic-subtraction spiral CT. Acad Radiol 1997; 4:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/42\">",
"      Jerosch-Herold M, Wilke N. MR first pass imaging: quantitative assessment of transmural perfusion and collateral flow. Int J Card Imaging 1997; 13:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/43\">",
"      Akutsu Y, Hara T, Michihata T, et al. Functional role of coronary collaterals with exercise in infarct-related myocardium. Int J Cardiol 1995; 51:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/44\">",
"      Sand NP, Rehling M, Bagger JP, et al. Functional significance of recruitable collaterals during temporary coronary occlusion evaluated by 99mTc-sestamibi single-photon emission computerized tomography. J Am Coll Cardiol 2000; 35:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/45\">",
"      Cheirif J, Narkiewicz-Jodko JB, Hawkins HK, et al. Myocardial contrast echocardiography: relation of collateral perfusion to extent of injury and severity of contractile dysfunction in a canine model of coronary thrombosis and reperfusion. J Am Coll Cardiol 1995; 26:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/46\">",
"      Habib GB, Heibig J, Forman SA, et al. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation 1991; 83:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/47\">",
"      Blanke H, Cohen M, Karsch KR, et al. Prevalence and significance of residual flow to the infarct zone during the acute phase of myocardial infarction. J Am Coll Cardiol 1985; 5:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/48\">",
"      Nicolau JC, Pinto MA, Nogueira PR, et al. The role of antegrade and collateral flow in relation to left ventricular function post-thrombolysis. Int J Cardiol 1997; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/49\">",
"      Lee CW, Park SW, Cho GY, et al. Pressure-derived fractional collateral blood flow: a primary determinant of left ventricular recovery after reperfused acute myocardial infarction. J Am Coll Cardiol 2000; 35:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/50\">",
"      Rentrop KP, Feit F, Sherman W, et al. Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial. J Am Coll Cardiol 1989; 14:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/51\">",
"      Hirai T, Fujita M, Nakajima H, et al. Importance of collateral circulation for prevention of left ventricular aneurysm formation in acute myocardial infarction. Circulation 1989; 79:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/52\">",
"      Elsman P, van 't Hof AW, de Boer MJ, et al. Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. Eur Heart J 2004; 25:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/53\">",
"      P&eacute;rez-Castellano N, Garc&iacute;a EJ, Abeytua M, et al. Influence of collateral circulation on in-hospital death from anterior acute myocardial infarction. J Am Coll Cardiol 1998; 31:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/54\">",
"      Nicolau JC, Nogueira PR, Pinto MA, et al. Early infarct artery collateral flow does not improve long-term survival following thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1999; 83:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/55\">",
"      Antoniucci D, Valenti R, Moschi G, et al. Relation between preintervention angiographic evidence of coronary collateral circulation and clinical and angiographic outcomes after primary angioplasty or stenting for acute myocardial infarction. Am J Cardiol 2002; 89:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/56\">",
"      Desch S, de Waha S, Eitel I, et al. Effect of coronary collaterals on long-term prognosis in patients undergoing primary angioplasty for acute ST-elevation myocardial infarction. Am J Cardiol 2010; 106:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/57\">",
"      Meier P, Gloekler S, Zbinden R, et al. Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation 2007; 116:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/58\">",
"      Abaci A, O��uzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/59\">",
"      Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000; 102:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/60\">",
"      Marfella R, Esposito K, Nappo F, et al. Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes 2004; 53:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/61\">",
"      Tanaka T, Fujita M, Nakae I, et al. Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. J Am Coll Cardiol 1998; 32:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/62\">",
"      Fabre JE, Rivard A, Magner M, et al. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999; 99:3043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/63\">",
"      Zbinden S, Brunner N, Wustmann K, et al. Effect of statin treatment on coronary collateral flow in patients with coronary artery disease. Heart 2004; 90:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8216/abstract/64\">",
"      Meier P, Zbinden R, Togni M, et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 2007; 49:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1523 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8216=[""].join("\n");
var outline_f8_1_8216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF RECRUITMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSTIC SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141866190\">",
"      Acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      In diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      THERAPEUTIC POTENTIAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serotonin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Angiotensin converting enzyme inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMPACT OF DRUG ELUTING STENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=related_link\">",
"      Contrast echocardiography: Contrast agents, safety, and imaging technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=related_link\">",
"      Therapeutic angiogenesis for management of refractory angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=related_link\">",
"      Treatment of acute myocardial infarction in diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_1_8217="Initiation of breastfeeding";
var content_f8_1_8217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initiation of breastfeeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8217/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8217/contributors\">",
"     Richard J Schanler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8217/contributors\">",
"     Debra C Potak, RN, BSN, IBCLC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8217/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8217/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8217/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8217/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/1/8217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human milk is recognized as the optimal feeding for all infants because of its proven health benefits to infants and their mothers. The World Health organization (WHO), the American Academy of Pediatrics (AAP), the American College of Obstetricians and Gynecologists (ACOG), and the United States Preventive Services Task Force all recommend breastfeeding for the first six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=see_link\">",
"     \"Maternal and economic benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, the Goals for Healthy People 2020 include the initiation of breastfeeding in 82 percent of newborns, and any continued breastfeeding in 61 percent of six month old infants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/5\">",
"     5",
"    </a>",
"    ]. Successful achievement of these goals is dependent upon health care professionals providing antenatal and postnatal breastfeeding education and support. In particular, the delivery and hospital experience should promote and support initiation of breastfeeding to enhance the probability of successful breastfeeding.",
"   </p>",
"   <p>",
"    The initiation of breastfeeding during the birth hospitalization will be reviewed here. Factors that influence parental decision on whether to breastfeed, parental educational and supportive programs for breastfeeding, the composition of human milk, and complications of breastfeeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6727?source=see_link\">",
"     \"Nutritional composition of human milk for full-term infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"     \"Common problems of breastfeeding and weaning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HOSPITAL ENVIRONMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the birth hospitalization, higher initiation rates of breastfeeding occur in facilities with clinical practice policies that promote breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/6-12\">",
"     6-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These policies are best summarized by the Ten Steps to Successful Breastfeeding developed by the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) as criteria for a Baby-Friendly Hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/4,7,13\">",
"     4,7,13",
"    </a>",
"    ]. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have a written policy on breastfeeding that is communicated routinely to all staff.",
"     </li>",
"     <li>",
"      Train all health care staff in the skills needed to implement the policy.",
"     </li>",
"     <li>",
"      Inform all pregnant women of the benefits and management of breastfeeding.",
"     </li>",
"     <li>",
"      Help mothers start breastfeeding within one hour after birth.",
"     </li>",
"     <li>",
"      Show mothers how to breastfeed and maintain lactation, even if they are separated from their infants.",
"     </li>",
"     <li>",
"      Give newborns only breast milk, unless other feedings are medically indicated. Hospitals must pay a fair market price for formula and feeding supplies.",
"     </li>",
"     <li>",
"      Allow mothers and infants to remain together at all times (continuous rooming in).",
"     </li>",
"     <li>",
"      Encourage breastfeeding on demand.",
"     </li>",
"     <li>",
"      Provide no pacifiers or artificial teats to nursing infants.",
"     </li>",
"     <li>",
"      Foster the establishment of breastfeeding support groups and refer mothers to them.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adoption of these policies has increased the rate of breastfeeding in different parts of the world. Studies have demonstrated increased exclusive breastfeeding rates in infants during their birth hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ], and at 6 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/10\">",
"     10",
"    </a>",
"    ] and 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/11\">",
"     11",
"    </a>",
"    ]. Hospital policies have a major role in the success of breastfeeding. One study reported that 30 percent of mothers whose intention was to breastfeed exclusively were not successful in reaching this goal. Reasons cited for not meeting their goals included hospital supplementation with formula and lack of skin-to-skin contact in the delivery room [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a significant number of births facilities in the United States continue to have clinical practices that interfere with breastfeeding. This was illustrated by a 2007 survey by the Centers of Disease Control (CDC) of all hospitals with maternity services and birthing centers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/14\">",
"     14",
"    </a>",
"    ]. Responses from 2690 hospitals and birth centers (82 percent response rate) demonstrated the following interfering practices and the percent of facilities that reported their use. Based upon a state-by-state analysis, states with a higher prevalence of practices that interfered with breastfeeding also had a lower rate of breastfeeding. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distribution of gift bags containing infant formula samples &ndash; 70 percent",
"     </li>",
"     <li>",
"      Limiting duration of suckling at each breastfeeding &ndash; 65 percent",
"     </li>",
"     <li>",
"      Pacifier use &ndash; 45 percent",
"     </li>",
"     <li>",
"      Supplementation of something other than breast milk &ndash; 24 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a follow-up national survey conducted in 2009, most hospitals in the United States still do not fully incorporate the Baby-Friendly policies compared with hospitals surveyed in 2007 (3.5 versus 2.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/15\">",
"     15",
"    </a>",
"    ]. Although most hospitals provide prenatal breastfeeding (93 percent) and postpartum education on breastfeeding techniques (89 percent) and feeding cues (82 percent), few hospitals have implemented model breastfeeding policies (14 percent), limited supplementation (22 percent), or supported breastfeeding mothers after discharge (27 percent).",
"   </p>",
"   <p>",
"    In order to increase breastfeeding rates, the AAP and ACOG have recommended that all birthing centers adopt care practices similar to those of the",
"    <span class=\"nowrap\">",
"     WHO/UNICEF",
"    </span>",
"    Baby-Friendly criteria that include a written policy (recommending early initiation and maintenance of breastfeeding and restricts supplementation and pacifier use), and required education and training of all professional staff to implement the written policy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DELIVERY ROOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after birth, the infant should be given to the mother for skin-to-skin contact, unless there are medical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/4\">",
"     4",
"    </a>",
"    ]. Physical contact between the mother and the infant in the immediate postpartum period, and contact between the infant's lips and the nipple are associated with increased initiation and duration of breastfeeding. Breastfeeding should be started as soon after birth as possible, preferably within the first hour after delivery. Professional staff should be available to help instruct the mother.",
"   </p>",
"   <p>",
"    Weighing, measuring, and routine care for the infant should be delayed until the first feeding is completed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/4\">",
"     4",
"    </a>",
"    ]. The infant should stay with the mother through recovery and room-in with the mother to enhance infant-maternal bonding and to facilitate subsequent feedings, which should be on demand. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Demand feeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18294243\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that the initiation rates of breastfeeding are lower in infants born by cesarean delivery compared with those born vaginally [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a meta-analysis, the rate of initiating breastfeeding was lower after cesarean versus vaginal delivery (odds ratio [OR] 0.78, 95% CI 0.76-.078). There was no difference in the rate of breastfeeding at six months of age between infants born by vaginal and cesarean delivery.",
"   </p>",
"   <p>",
"    In this systemic review, a subgroup analysis suggested that the decrease in early breastfeeding was primarily due to infants delivered by elective cesarean delivery, as infants born by emergency caesarean delivery had comparable rates of breastfeeding initiation to those delivered vaginally. Similar results were noted in an Italian multi-center study, which reported exclusive formula use in 7, 8, and 19 percent of infants born by vaginal, emergency cesarean, and elective cesarean delivery, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, a population-based study from Ontario, Canada, found that breastfeeding was less common for both infants born by elective (50 percent) and non-elective cesarean delivery (48 percent) compared with vaginal delivery (68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General anesthesia for cesarean delivery and some types of analgesia may decrease alertness of the infant and interfere with initiation of nursing; however, this is an infrequent problem, as most cesarean deliveries are performed under regional anesthesia. Most infants delivered by cesarean delivery can be given to their mother for skin-to-skin contact in the operating room. Mothers who undergo cesarean delivery may need additional help from the clinical staff to attain comfortable and correct positioning of their infant for breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=see_link\">",
"     \"Anesthesia for cesarean delivery\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Positioning'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF POSTPARTUM CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum care of breastfeeding infants includes parental education and support, assessing the adequacy of breastfeeding, and identifying any problems of breastfeeding. Postnatal educational and support programs that promote breastfeeding should be provided to parents, before and during the birth hospitalization, and after discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the hospitalization, the initiation of breastfeeding is monitored by assessing the maternal progression of lactogenesis and the infant's intake. Mothers are instructed and evaluated on positioning of their infant, obtaining an adequate latch-on and milk transfer, recognizing their infant's feeding cues and signs of satiety, and assessing their infant's intake. Feeding on demand is dependent upon continuous rooming-in, which allows mothers and infants to remain together at all times. Problems identified in the hospital should be addressed at that time, and a documented plan for management after discharge should be communicated to both the parents and primary care provider. At discharge, a primary care appointment should be scheduled and postdischarge lactation resources provided. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanics of feeding'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H12\">",
"       'Demand feeding'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17\">",
"       'Assessment of intake'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      After the birth hospitalization, the infant-mother dyad should be evaluated 24 to 48 hours after discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. At that visit, assessment should include weight measurement, examination for any evidence of jaundice or dehydration, review of intake (ie, history of urine and stool output, and frequency and duration of feeding), maternal history for breast problems (eg, breast pain), and provision of additional lactation support",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      resources to the parents as needed. If possible, observation of breastfeeding including position, latch, and milk transfer is desirable, and should be done if there are concerns for inadequate breastfeeding. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanics of feeding'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"       \"Common problems of breastfeeding and weaning\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANICS OF FEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;New mothers, especially those who have never breastfed, should receive instructions from a trained professional on the mechanics of breastfeeding that include positioning the infant, latch-on, and milk transfer. During the hospitalization, documentation of assessment by a trained observer addressing the various mechanics of breastfeeding and monitoring the progression of lactogenesis should be performed each shift [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The department of pediatrics at Stanford School of medicine provides an excellent on-line guide for new mothers on the mechanics of breastfeeding (",
"    <a class=\"external\" href=\"file://newborns.stanford.edu/Breastfeeding/ABCs.html\">",
"     Stanford School of Medicine: ABCs of breastfeeding",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nursing mother must be in a comfortable position while breastfeeding her infant. To ensure proper latch-on, the infant should be positioned to face the mother's body such that the infant's mouth is opposite the mother's nipple with",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    neck slightly extended and the head, shoulders, and hips are in alignment (",
"    <a class=\"graphic graphic_figure graphicRef69936 \" href=\"UTD.htm?40/55/41855\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71940 \" href=\"UTD.htm?32/12/32975\">",
"     figure 2",
"    </a>",
"    ). For mothers who have undergone cesarean delivery, the \"football\" (also referred to as the clutch) and the side-by-side positions may be preferred as they avoid contact with the surgical incision (",
"    <a class=\"graphic graphic_figure graphicRef70124 \" href=\"UTD.htm?32/43/33471\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53668 \" href=\"UTD.htm?36/25/37265\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/21\">",
"     21",
"    </a>",
"    ]. The \"football\" position also is often used in preterm infants, because it allows for good control of the infant's head and visibility of the infant's mouth on the mother's breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/12/36040?source=see_link\">",
"     \"Breastfeeding the preterm infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Latch-on",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latch-on refers to the formation of a tight seal of the infant's lips around the nipple and a sufficient portion of contiguous mammary tissue, which allows efficient removal of milk during nursing. Latch-on is facilitated by supporting the breast in one hand with four fingers underneath and the thumb on top of the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/21\">",
"     21",
"    </a>",
"    ]. The infant must open",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    mouth widely, and grasp the entire nipple and as much of the areola as comfortably possible (",
"    <a class=\"graphic graphic_figure graphicRef69241 \" href=\"UTD.htm?40/62/41967\">",
"     figure 4",
"    </a>",
"    ). With a proper latch-on, the infant's tongue elongates the nipple and compresses the lactiferous sinuses beneath the areola against",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    hard palate, which facilitates access to milk ducts beyond the base of the nipple. The mother should feel a gentle undulating painless motion with each suck.",
"   </p>",
"   <p>",
"    The appearance of an adequate latch-on includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An angle of about 120 degrees between the top and bottom lip",
"     </li>",
"     <li>",
"      The lower lip (and, to a lesser extent, the upper lip) turned outward against the breast",
"     </li>",
"     <li>",
"      The chin and nose in close proximity to the breast",
"     </li>",
"     <li>",
"      Full cheeks",
"     </li>",
"     <li>",
"      Tongue extends over the lower dental ridge and is in visible contact with the breast if the lower lip is pulled away (",
"      <a class=\"graphic graphic_figure graphicRef63201 \" href=\"UTD.htm?8/47/8959\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Signs of poor latch-on include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Contact between the upper and lower lip at the corners of the mouth",
"     </li>",
"     <li>",
"      Sunken cheeks",
"     </li>",
"     <li>",
"      Clicking sounds that correspond to breaking suction",
"     </li>",
"     <li>",
"      Tongue not visible below the nipple when the lower lip is pulled down",
"     </li>",
"     <li>",
"      Creased nipple following nursing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Causes of poor latch-on include breast engorgement or nipple abnormalities that prevent the infant from drawing the surrounding tissue far enough into the mouth. Problems in the infant that may contribute to poor latch-on include ankyloglossia (ie, tight frenulum), difficulties with sucking or swallowing, and neurologic complications. There are case reports that maternal nipple piercing may be associated with difficulty in latching [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=see_link\">",
"     \"Sucking and swallowing disorders in the newborn\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Inverted nipples'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ankyloglossia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankyloglossia, also known as \"tongue-tie,\" occurs when the frenulum connecting the tongue to the floor of the mouth is tight and limits extension of the tongue. It is a relatively common finding in newborns and the majority of infants with tongue-tie are able to breastfeed without difficulty. However, breastfeeding problems (eg, poor latch, maternal nipple pain) are reported more frequently among infants with ankyloglossia than without ankyloglossia. Infants who have problems with breastfeeding after lactation is established should be examined for ankyloglossia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44615?source=see_link&amp;anchor=H5#H5\">",
"     \"Ankyloglossia (tongue-tie) in infants and children\", section on 'Breastfeeding problems'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inverted nipples",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important not to assume that an apparently inverted or otherwise irregular nipple will interfere with breastfeeding because infants generally are able to form a good latch-on even with the most irregularly shaped nipples. When nipple abnormalities are identified prenatally, mothers should receive lactation counseling from a qualified lactation consultant in the immediate postpartum period so that any latch problems can be addressed, and breastfeeding can be successfully initiated.",
"   </p>",
"   <p>",
"    Techniques used to assist latch in such cases include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjust of the infant's position to facilitate easy access.",
"     </li>",
"     <li>",
"      Use a pump or other device to draw out the nipple immediately before latch-on.",
"     </li>",
"     <li>",
"      Use of a thin-walled nipple shield for part or the entire nursing episode may increase milk transfer and facilitates sustained breast attachment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Milk transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficient transfer of milk requires coordination of suckling and swallowing. Audible swallowing is a reassuring indicator of successful milk transfer for most infants. However, it can be misleading, particularly in infants with neurologic impairment and disorganized feeding behaviors. The only reliable assessment of infant intake is a comparison of weights before and after feeding and growth over time.",
"   </p>",
"   <p>",
"    If the breast is not adequately stimulated by the infant, it is difficult to maintain the milk supply. Disorganized suckling may lead to poor growth. Signs of disorganized suckling include early release of the breast, spilling of milk from the mouth during feeding, coughing, or gagging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=see_link\">",
"     \"Sucking and swallowing disorders in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lactogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactogenesis takes place in two stages, secretory initiation (stage I), which occurs during the second half of pregnancy, and secretory activation (stage II), which occurs after delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=see_link&amp;anchor=H9#H9\">",
"     \"Physiology of lactation\", section on 'Lactogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stage II lactogenesis generally occurs between two and four days postpartum and is marked by the swelling of the mother's breasts and the onset of copious milk production. When the infant is nursing efficiently, the onset of stage II lactogenesis is followed rapidly by clearance of meconium and the transition to a typical mustard yellow stool.",
"   </p>",
"   <p>",
"    Stage II lactogenesis may be delayed until 7 to 10 postpartum days in some women, resulting in continued infant weight loss due to decreased milk production and is associated with an increased risk of breastfeeding failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/23\">",
"     23",
"    </a>",
"    ] . If lactogenesis is delayed beyond the fourth day postpartum, mother-infant dyads require careful monitoring and extra support [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/24\">",
"     24",
"    </a>",
"    ]. In general, the frequency of feeding is increased in order to facilitate lactogenesis progression. The clinician must balance the need to support the mother's continued efforts for successful breastfeeding with safeguarding her infant's health and growth. It may be necessary to provide supplemental milk (eg, bank donor milk or formula) if the infant's health is compromised by inadequate intake and efforts to improve lactation are ineffective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=see_link&amp;anchor=H9#H9\">",
"     \"Physiology of lactation\", section on 'Lactogenesis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H25\">",
"     'Supplementation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DEMAND FEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feeding on demand means that feedings are initiated in response to infant cues. Parents must learn to recognize signs of hunger and satiety and the readiness of their infant to feed. The rate at which these skills are acquired varies among individuals.",
"   </p>",
"   <p>",
"    The mother should offer both breasts at each feeding, and the first breast offered should be alternated so that each breast receives equal stimulation and drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Parental expectations",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-time parents rarely appreciate the intensity of care infants require, whether or not they breastfeed. Although they may assume that breastfeeding is responsible for the surprising amount of attention their infants demand, the time spent holding the infant is comparable for nursing and formula feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/25\">",
"     25",
"    </a>",
"    ]. Formula feeding requires additional time-consuming tasks that are not needed for breastfeeding, such as purchasing formula, preparing feeding, and washing of nipples and bottles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nursing frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nursing frequency is variable and may be as often as every hour. The frequency of demand depends upon factors including the maternal milk supply, efficiency of milk transfer, and the ability of the infant to modulate behavioral state. In the first one to two weeks postpartum, the average frequency of breastfeeding is 8 to 12 times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Frequency and duration of feeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The healthy term infant can modulate the frequency and duration of nursing if the mother responds to the infant's cues of hunger and satiety. Thorough emptying of the breast increases the delivery of hind milk, which has high fat content and promotes rapid infant growth. Thorough emptying is also critical for promoting the progression of lactogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=see_link&amp;anchor=H9#H9\">",
"     \"Physiology of lactation\", section on 'Lactogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the first postpartum week or until breastfeeding is established, mothers should wake sleeping infants to nurse if four hours have elapsed since the beginning of the last feeding. This will provide a safety net for infants who do not exhibit strong hunger signals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Feeding cues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feeding cues are behavioral changes that accompany hunger. A typical pattern of progression includes movement of the hands toward the mouth, sucking on fists and fingers, fussiness, agitation, flailing of the extremities, and, finally, loud, persistent crying. This sequence can last 45 minutes.",
"   </p>",
"   <p>",
"    Infants should be fed when they demonstrate early feeding cues that include hand to mouth activity, smacking lips, rooting, and eye and extremities movements while asleep. Feeding the infant in response to early cues is optimal, especially in the first postpartum week, because it conditions the mother's let-down reflex to early hunger cues and provides an opportunity for the nursing dyad to practice latch-on and nursing skills before the baby becomes agitated. It also avoids excessive agitation and crying and, thus, minimizes early weight loss and prevents maternal anxiety.",
"   </p>",
"   <p>",
"    Late hunger cues (eg, agitation, flailing of the arms and legs, and crying) may not occur in infants who are premature or ill, and lack the necessary energy reserves, or neurologic and muscular coordination. Infants who are less likely to awaken and vocalize when hungry are at risk for failure to thrive. The \"good\" newborn who sleeps long periods and rarely cries may present with poor weight gain within a few weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Signs of satiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Satiety is typically signaled by the infant's voluntary release of the nipple and relaxation of the facial muscles and hands. Infants younger than two to three months often fall asleep. Parents' assessment of satiety may be complicated by the soporific (sleepiness) effect of breastfeeding, the sensitivity of the infant's oral cavity to the nipple, and the stimulation of gastric motility by milk.",
"   </p>",
"   <p>",
"    Breastfeeding is soporific, and newborns may fall asleep almost immediately after attaching to the breast. It may take several days to weeks to maintain an appropriate awake state for duration sufficient to adequately transfer milk. In these cases, adequate intake cannot be assured by behavioral assessment and must be evaluated by weight gain and signs of good hydration (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Assessment of intake'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    An automatic suckling response is elicited as the nipple slides out of the infant's mouth. In the satiated infant, this response diminishes quickly, and the baby falls back to sleep. If the infant is not satiated, sucking intensifies, rooting behavior ensues, and the infant displays the progression of hunger cues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF INTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequacy of intake is based upon the frequency and duration of feeding, urine and stool output, and weight of the infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Frequency and duration of feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first postpartum week or until breastfeeding is established, mothers should nurse whenever the infant shows signs of hunger or when four hours have elapsed since the last feeding. This will usually result in 8 to 12 feedings in 24 hours. After the first week, the frequency of nursing decreases to seven to nine times per day by four weeks of age as maternal and infant nursing skills improve and milk volume increases. In one report, exclusively breastfed infants received an average of seven feedings per day at two months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of a feeding also depends in part upon efficiency. The time required to transfer the same volume of milk can range from 5 to 20 minutes for different mother-infant dyads. The duration of feeding on each breast decreases with maturation. It typically falls from 10 to 15 minutes soon after birth to 8 to 10 minutes at approximately one month of age.",
"   </p>",
"   <p>",
"    The maternal breastfeeding skills and comfort level, and the nursing abilities of newborns vary considerably. Thus, the assessment of appropriate frequency and duration of nursing for a mother-infant dyad depend upon the desired weight of the infant and signs of sufficient intake rather than a fixed schedule or timed feedings. In general, when milk production",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infant growth are inadequate, increasing nursing frequency should be the first intervention, and is usually successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is normal after delivery, and the expected loss is 5 to 7 percent of birth weight. Normal infants stop losing weight by five days of life and typically regain their birth weight by one to two weeks of age. Once breastfeeding is well-established, infants gain 15 to 40 g per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Excessive weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss beyond the normal amount is an indication of poor intake that requires medical attention and intervention. The American Academy of Pediatrics (AAP) recommends prompt assessment of the",
"    <span class=\"nowrap\">",
"     infant/mother",
"    </span>",
"    dyad if the infant loses more than 7 percent of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    birth weight (",
"    <a class=\"graphic graphic_table graphicRef78906 \" href=\"UTD.htm?9/1/9243\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These infants are at risk for developing hypernatremia (serum sodium &gt;150",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    jaundice. Although, the overall incidence of rehospitalization for dehydration in breastfed infants is low, ranging from 25 to 71 per 100,000 breastfed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], hypernatremic dehydration can result in life-threatening complications, such as acute renal failure, vascular thrombosis, shock, and seizures in rare cases of extreme weight loss greater than 12 percent of birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/27,29\">",
"     27,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, for infants with an excessive weight loss (&gt;7 percent of birth weight), prompt evaluation by a knowledgeable health care provider is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/19\">",
"     19",
"    </a>",
"    ]. The evaluation should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical history including a history of feeding, and urine and stool output.",
"     </li>",
"     <li>",
"      Physical examination of the infant (eg, signs of jaundice and hypovolemia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physical examination of mother's breast (eg, signs of engorgement). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"       \"Common problems of breastfeeding and weaning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Observation of a feeding (eg, adequacy of latch-on) and determination whether mother's milk supply is adequate or if there is inadequate milk transfer. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Latch-on'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link&amp;anchor=H115298521#H115298521\">",
"       \"Common problems of breastfeeding and weaning\", section on 'Inadequate milk intake'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Determination if breastfeeding should continue with supervision, or if supplementation is necessary. If the infant appears well, and the mother's milk production",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the infant's weight have increased in the previous 24 to 48 hours, continued observation without supplemental feeding may be appropriate. This avoids the unnecessary introduction of formula supplements, which may impede milk production. However, if there is no improvement in milk production or infant weight gain, supplementation with formula may be required. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Supplementation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the mother feels that her breasts are inadequately emptied after breastfeeding, expression of breast milk with a breast pump can be used after each breastfeeding session. Expressed breast milk can also be fed to the infant.",
"   </p>",
"   <p>",
"    In severe cases, intravenous fluids may be necessary to initially correct hypernatremia and severe hypovolemia. This was illustrated in a retrospective study of 3718 infants (&lt;29 days of age) admitted to a tertiary care center between 1997 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/30\">",
"     30",
"    </a>",
"    ]. The incidence of breastfeeding-associated hypernatremic hypovolemia due to inadequate milk intake was 1.9 percent. Three-quarters of affected infants had greater than 10 percent weight loss. Ninety percent of mothers were primiparous and were discharged within 48 hours after giving birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While medical evaluation and interventions (if needed) are initiated and completed, maternal education and support by knowledgeable health providers should be provided to ensure subsequent successful lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Prevention of excessive weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned previously, a post-discharge hospital visit should be scheduled within 48 hours to assess the infant's intake and weight, and assess and support lactation. Implementation of an early weighing program between 72 and 96 hours of life resulted in earlier identification of dehydration compared to historical controls (median day of life three versus six), which was less severe with lower percentage of weight losses (11 versus 15 percent) and smaller increases of serum sodium (147 versus 150",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Overview of postpartum care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Urine output",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of voids and quality of the urine are measures of the infant's hydration status and intake. Voiding increases from one void in the first 24 hours, to 2 or 3 in the second 24 hours, 4 to 6 during the third and fourth day, and to 6 to 8 on day 5 and after [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased frequency of voiding, dark yellow or orange urine, or brick-red urate crystals in the diaper often are signs of inadequate intake and should be further assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=see_link\">",
"     \"Fluid and electrolyte therapy in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Stools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who are successfully nursing should clear meconium and have transitional stools within approximately three days of birth, coincident with the onset of lactogenesis stage II (increased milk secretion) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/32\">",
"     32",
"    </a>",
"    ]. After day four, the majority of infants have three or more stools per day, which is often timed with feeding episodes. By the fifth postpartum day, stools should be pale yellow and seedy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Lactogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Delayed clearance of meconium indicates delayed or failed lactogenesis, poor lactation management, ineffective milk transfer, or rarely, intestinal obstruction associated with cystic fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Green frothy stools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stools that appear green and frothy sometimes occur in infants of mothers who produce copious milk and switch the infant from one breast to the other before much of the hind milk is completely extracted from the first breast. High fat content in the hind milk usually retards gut motility sufficiently so that the majority of milk lactose undergoes digestion in the small intestine. With less hind milk to slow motility, high concentrations of lactose reach the large bowel, where the action of bacterial flora creates excessive gas and frothy stools. Mothers should be advised to allow the infant to finish nursing on one breast before switching to the other, even if the child does not take the second breast.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplementation with formula should be avoided as it discourages the initiation and decreases the duration of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/4,33\">",
"     4,33",
"    </a>",
"    ]. Initiation of supplementation with banked human milk or commercial infant formula is",
"    <strong>",
"     only",
"    </strong>",
"    recommended when the infant has lost more than 7 percent of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    birth weight, exhibits signs of dehydration (eg, decreased urine output), or stool output is less than three small stools a day, and mother's milk supply remains limited [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/34\">",
"     34",
"    </a>",
"    ]. Glucose water or sterile water feedings should not be used, as they do not provide adequate nutrition. Supplemental milk may be given by cup, bottle, syringe, or supplemental nursing system.",
"   </p>",
"   <p>",
"    Any reduction in the frequency of breast emptying will decrease milk production and volume. So if the mother plans to continue breastfeeding, she should be encouraged to use a pump to empty her breasts after each nursing and each time a supplemental feeding is given. Any milk that is expressed should be fed to the infant. The additional stimulation to the breast will increase the milk supply and enhance the likelihood of successful breastfeeding.",
"   </p>",
"   <p>",
"    Formula supplementation can be combined with breastfeeding for varying lengths of time. However, formula supplementation without breast stimulation decreases breastfeeding frequency, leads to early weaning, and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     VITAMIN D",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all breast-fed infants, vitamin D supplementation (400",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    is recommended starting at hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H723639#H723639\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Vitamin D supplementation for infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192727406\">",
"    <span class=\"h1\">",
"     PACIFIER USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pacifier use is discouraged during the initiation of breastfeeding, it is associated with a reduced risk of sudden infant death syndrome. A systematic review (which was updated in 2012) reported no difference in the rate of exclusive or partial breastfeeding at three or four months between infants who were offered pacifiers compared to those who were not offered pacifiers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/37\">",
"     37",
"    </a>",
"    ]. These results support the use of a pacifier provided that it does not interfere with establishment of breastfeeding. The AAP recommends pacifier use after breastfeeding is established no earlier than 3 weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8217/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link&amp;anchor=H13238420#H13238420\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\", section on 'Protective factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=see_link\">",
"       \"Patient information: Breastfeeding (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=see_link\">",
"       \"Patient information: Deciding to breastfeed (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"       \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"       \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend exclusive breastfeeding for newborn infants because of its proven benefits for both infants and mothers (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"       \"Infant benefits of breastfeeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=see_link\">",
"       \"Maternal and economic benefits of breastfeeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      During the birth hospitalization, optimal care practice policy promotes breastfeeding as outlined in the criteria required for World Health Organization and the United Nations Children's Fund Baby-Friendly Hospital. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hospital environment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal delivery room care includes skin-to-skin contact of mother and infant, breastfeeding within the first hour after birth, and the delay of any unnecessary interventions until after this initial period of mother-infant interaction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Delivery room'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal post-delivery hospital routines include continuous rooming-in, on demand newborn feeding schedules, guidance to mothers on the successful initiation of breastfeeding (ie, mechanics of breastfeeding, demand feeding, and assessment of intake), and scheduling a primary care appointment 24 to 48 hours after discharge. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of postpartum care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanics of feeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Demand feeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Assessment of intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal post-discharge care includes evaluation within 24 to 48 hours with assessment of adequate fluid intake, examination for any evidence of jaundice or dehydration, detection of any breastfeeding problems, and provision of additional support",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      resources to the parents as needed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of postpartum care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Assessment of intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequacy of intake is based upon the frequency and duration of feeding, urine and stool output, and weight of the infant. Weight loss greater than 7 percent of birth weight generally is due to inadequate milk intake. These infants are at risk for developing dehydration, hypernatremia (serum sodium &gt;150",
"      <span class=\"nowrap\">",
"       mEq/L),",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      jaundice. These patients require prompt evaluation, and in some cases, fluid supplementation may be necessary. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Assessment of intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In breastfed infants, we recommend vitamin D supplementation (400",
"      <span class=\"nowrap\">",
"       IU/day)",
"      </span>",
"      starting in the first week of life (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H723639#H723639\">",
"       \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Vitamin D supplementation for infants'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. Global Strategy for Infant and Young Child Feeding (2003). Available at: www.who.int/nutrition/publications/infantfeeding/en/index.html (Accessed on April 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/2\">",
"      U.S. Preventive Services Task Force. Primary care interventions to promote breastfeeding: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/3\">",
"      Committee on Health Care for Underserved Women, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 361: Breastfeeding: maternal and infant aspects. Obstet Gynecol 2007; 109:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/4\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     Healthy People maternal, infant and child health 2020 goals file://healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicid=26 (Accessed on February 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/6\">",
"      Philipp BL, Merewood A, Miller LW, et al. Baby-friendly hospital initiative improves breastfeeding initiation rates in a US hospital setting. Pediatrics 2001; 108:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/7\">",
"      Saadeh R, Akr&eacute; J. Ten steps to successful breastfeeding: a summary of the rationale and scientific evidence. Birth 1996; 23:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/8\">",
"      Coutinho SB, de Lira PI, de Carvalho Lima M, Ashworth A. Comparison of the effect of two systems for the promotion of exclusive breastfeeding. Lancet 2005; 366:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/9\">",
"      Merewood A, Mehta SD, Chamberlain LB, et al. Breastfeeding rates in US Baby-Friendly hospitals: results of a national survey. Pediatrics 2005; 116:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/10\">",
"      Merten S, Dratva J, Ackermann-Liebrich U. Do baby-friendly hospitals influence breastfeeding duration on a national level? Pediatrics 2005; 116:e702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/11\">",
"      Kramer MS, Chalmers B, Hodnett ED, et al. Promotion of Breastfeeding Intervention Trial (PROBIT): a randomized trial in the Republic of Belarus. JAMA 2001; 285:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/12\">",
"      Perrine CG, Scanlon KS, Li R, et al. Baby-Friendly hospital practices and meeting exclusive breastfeeding intention. Pediatrics 2012; 130:54.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization, Division of Child Health and Development. Evidence for the ten steps to successful breastfeeding, World Health Organization, Geneva 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Breastfeeding-related maternity practices at hospitals and birth centers--United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: hospital practices to support breastfeeding--United States, 2007 and 2009. MMWR Morb Mortal Wkly Rep 2011; 60:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/16\">",
"      Prior E, Santhakumaran S, Gale C, et al. Breastfeeding after cesarean delivery: a systematic review and meta-analysis of world literature. Am J Clin Nutr 2012; 95:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/17\">",
"      McDonald SD, Pullenayegum E, Chapman B, et al. Prevalence and predictors of exclusive breastfeeding at hospital discharge. Obstet Gynecol 2012; 119:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/18\">",
"      Zanardo V, Pigozzo A, Wainer G, et al. Early lactation failure and formula adoption after elective caesarean delivery: cohort study. Arch Dis Child Fetal Neonatal Ed 2013; 98:F37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/19\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/20\">",
"      Hospital stay for healthy term newborns. American Academy of Pediatrics Committee on Fetus and Newborn. Pediatrics 1995; 96:788.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Breastfeeding. In: Nutrition Handbook, 6th ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove 2009. p.29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/22\">",
"      Garbin CP, Deacon JP, Rowan MK, et al. Association of nipple piercing with abnormal milk production and breastfeeding. JAMA 2009; 301:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/23\">",
"      Brownell E, Howard CR, Lawrence RA, Dozier AM. Delayed onset lactogenesis II predicts the cessation of any or exclusive breastfeeding. J Pediatr 2012; 161:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/24\">",
"      Neville MC, Morton J, Umemura S. Lactogenesis. The transition from pregnancy to lactation. Pediatr Clin North Am 2001; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/25\">",
"      Baildam EM, Hillier VF, Menon S, et al. Attention to infants in the first year. Child Care Health Dev 2000; 26:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/26\">",
"      Hammer LD, Bryson S, Agras WS. Development of feeding practices during the first 5 years of life. Arch Pediatr Adolesc Med 1999; 153:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/27\">",
"      Pelleboer RA, Bontemps ST, Verkerk PH, et al. A nationwide study on hospital admissions due to dehydration in exclusively breastfed infants in the Netherlands: its incidence, clinical characteristics, treatment and outcome. Acta Paediatr 2009; 98:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/28\">",
"      Oddie S, Richmond S, Coulthard M. Hypernatraemic dehydration and breast feeding: a population study. Arch Dis Child 2001; 85:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/29\">",
"      Shroff R, Hignett R, Pierce C, et al. Life-threatening hypernatraemic dehydration in breastfed babies. Arch Dis Child 2006; 91:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/30\">",
"      Moritz ML, Manole MD, Bogen DL, Ayus JC. Breastfeeding-associated hypernatremia: are we missing the diagnosis? Pediatrics 2005; 116:e343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/31\">",
"      Iyer NP, Srinivasan R, Evans K, et al. Impact of an early weighing policy on neonatal hypernatraemic dehydration and breast feeding. Arch Dis Child 2008; 93:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/32\">",
"      Neville MC. Anatomy and physiology of lactation. Pediatr Clin North Am 2001; 48:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/33\">",
"      Becker GE, Remmington S, Remmington T. Early additional food and fluids for healthy breastfed full-term infants. Cochrane Database Syst Rev 2011; :CD006462.",
"     </a>",
"    </li>",
"    <li>",
"     The Academy of Breastfeeding Medicine www.bfmed.org (Accessed on April 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/35\">",
"      H&ouml;rnell A, Hofvander Y, Kylberg E. Solids and formula: association with pattern and duration of breastfeeding. Pediatrics 2001; 107:E38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/36\">",
"      Holmes AV, Auinger P, Howard CR. Combination feeding of breast milk and formula: evidence for shorter breast-feeding duration from the National Health and Nutrition Examination Survey. J Pediatr 2011; 159:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8217/abstract/37\">",
"      Jaafar SH, Jahanfar S, Angolkar M, Ho JJ. Pacifier use versus no pacifier use in breastfeeding term infants for increasing duration of breastfeeding. Cochrane Database Syst Rev 2011; :CD007202.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4986 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8217=[""].join("\n");
var outline_f8_1_8217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HOSPITAL ENVIRONMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DELIVERY ROOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18294243\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF POSTPARTUM CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANICS OF FEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Latch-on",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ankyloglossia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inverted nipples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Milk transfer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lactogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DEMAND FEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Parental expectations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nursing frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Feeding cues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Signs of satiety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ASSESSMENT OF INTAKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Frequency and duration of feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Excessive weight loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Prevention of excessive weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Urine output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Stools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Green frothy stools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      VITAMIN D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192727406\">",
"      PACIFIER USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4986|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/55/41855\" title=\"figure 1\">",
"      Cradle position PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/12/32975\" title=\"figure 2\">",
"      Cross cradle position PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/43/33471\" title=\"figure 3\">",
"      Seated nursing position for breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/62/41967\" title=\"figure 4\">",
"      Latch on PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/47/8959\" title=\"figure 5\">",
"      Tongue protrusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4986|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/25/37265\" title=\"picture 1\">",
"      Breastfeeding side by side",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4986|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/1/9243\" title=\"table 1\">",
"      Early postnatal weight",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=related_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44615?source=related_link\">",
"      Ankyloglossia (tongue-tie) in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/12/36040?source=related_link\">",
"      Breastfeeding the preterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=related_link\">",
"      Fluid and electrolyte therapy in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=related_link\">",
"      Maternal and economic benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6727?source=related_link\">",
"      Nutritional composition of human milk for full-term infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=related_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=related_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=related_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=related_link\">",
"      Physiology of lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_1_8218="Disorders of fibrinogen";
var content_f8_1_8218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disorders of fibrinogen",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8218/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8218/contributors\">",
"     Caroline B&eacute;rub&eacute;, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8218/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8218/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/1/8218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/1/8218/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/1/8218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen circulates in the plasma at a concentration of approximately 200 to 400",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    with a half-life of four days and a catabolic rate of approximately 25 percent per day [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/1\">",
"     1",
"    </a>",
"    ]. Fibrinogen has numerous functional interactions and plays a pivotal role in the hemostatic balance:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is the substrate for fibrin clot formation.",
"     </li>",
"     <li>",
"      It binds to platelets to support platelet aggregation.",
"     </li>",
"     <li>",
"      It has a role in wound healing.",
"     </li>",
"     <li>",
"      The fibrin clot is a template for both thrombin binding and the fibrinolytic system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, any abnormality of fibrinogen (ie, hypofibrinogenemia, dysfibrinogenemia) may result in defects in one or more of these key functions. The final result of the balance between fibrin clot formation and fibrinolysis determines whether the clinical manifestations include bleeding, thrombosis, both, or neither.",
"   </p>",
"   <p>",
"    While the finding of a low level of circulating fibrinogen is commonly seen as a result of acquired disorders of coagulation (eg, acute disseminated intravascular coagulation), the presence of an abnormal fibrinogen (ie, dysfibrinogenemia) is a rare condition. It is usually suspected following the finding of a prolonged thrombin time or a low fibrinogen level. In a hospital-based practice, it is most commonly observed as an acquired disorder in patients with liver disease. Congenital dysfibrinogenemia is rare; the true incidence is unknown since many abnormal fibrinogens are clinically silent.",
"   </p>",
"   <p>",
"    This topic review will discuss the structure and function of fibrinogen, as well as the clinical manifestations, diagnosis, and management of congenital and acquired disorders of fibrinogen. Discussions concerning fibrinogen as an acute phase reactant, the relationship between elevated fibrinogen levels and cardiovascular disease, and abnormal fibrinolysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen disorders can be classified as quantitative or qualitative, congenital or acquired (",
"    <a class=\"graphic graphic_table graphicRef55144 \" href=\"UTD.htm?26/38/27243\">",
"     table 1",
"    </a>",
"    ). The following terms will be used here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysfibrinogenemia",
"      <strong>",
"       ���",
"      </strong>",
"      Presence of a dysfunctional fibrinogen molecule.",
"     </li>",
"     <li>",
"      Hypodysfibrinogenemia",
"      <strong>",
"       ���",
"      </strong>",
"      Inherited fibrinogens that are both functionally abnormal as well as associated with low plasma levels (&lt;150",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      as measured by immunologic techniques.",
"     </li>",
"     <li>",
"      Hypofibrinogenemia",
"      <strong>",
"       ���",
"      </strong>",
"      Any condition associated with a reduction in the circulating level of normal fibrinogen to &lt;150",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Afibrinogenemia",
"      <strong>",
"       ���",
"      </strong>",
"      A rare autosomal recessive condition in which there is a complete lack of circulating fibrinogen.",
"     </li>",
"     <li>",
"      Cryofibrinogenemia",
"      <strong>",
"       ���",
"      </strong>",
"      A phenomenon in which there is the presence in plasma, but not serum, of a fibrinogen that precipitates on exposure to low temperatures (eg, 4&deg;C).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FIBRINOGEN STRUCTURE AND FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human fibrinogen is a complex 340kD dimeric glycoprotein composed of two identical chains centrally connected by three disulfide bonds (",
"    <a class=\"graphic graphic_figure graphicRef68948 \" href=\"UTD.htm?37/25/38293\">",
"     figure 1",
"    </a>",
"    ). Each half consists of three polypeptide chains (ie, Aalpha, Bbeta, and gamma) coded by three different genes on chromosome 4 (FGA, FGB, FGG) and synthesized by hepatocytes. The assembly of fibrinogen takes place in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/2\">",
"     2",
"    </a>",
"    ]; carbohydrate side chains are added to the beta and gamma chains before the molecule is secreted into the plasma. A small pool of fibrinogen is stored in platelet alpha-granules. Plasma fibrinogen is internalized by a process mediated by",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa,",
"    </span>",
"    and can support platelet aggregation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link&amp;anchor=H4#H4\">",
"     \"Megakaryocyte biology and the production of platelets\", section on 'Specific platelet granules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The trinodular structure of fibrinogen can be described as a central E-region (containing the aminoterminal portions of the three polypeptide chains) and two D-regions (carboxyterminal portions) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/3\">",
"     3",
"    </a>",
"    ]. The complete amino acid sequence of fibrinogen has been determined as well as the location of residues that define the sites of some of the important functions, including fibrinopeptide cleavage, fibrin polymerization, factor XIIIa-mediated fibrin crosslinking, as well as its interaction with platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=see_link&amp;anchor=H2#H2\">",
"     \"Platelet biology\", section on 'Overview of platelet function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fibrinogen synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen synthesis is controlled at the level of transcription. The inducible component is mainly influenced by acute phase reactions. Fibrinogen biosynthesis increases with inflammation and stress, a process mediated by interleukin-6. Interleukin-6 enhances transcription of fibrinogen mRNA while interleukin-1 and tumor necrosis factor-alpha suppress fibrinogen synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acute phase response can elevate plasma fibrinogen by two- to 20-fold. The peak elevation in fibrinogen during the acute phase occurs by three to five days, with a gradual return to baseline following resolution of the inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Polymorphisms of the B-beta fibrinogen gene have been identified; some variants are associated with elevated plasma fibrinogen concentrations, especially in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Epidemiologic studies indicate that high fibrinogen levels are associated with increased risk of cardiovascular disease, stroke, and nonvascular mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H10122223#H10122223\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Coagulation factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9299647\">",
"    <span class=\"h2\">",
"     Conversion of fibrinogen to fibrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conversion of fibrinogen into insoluble fibrin can be divided into three distinct steps, as discussed in the following sections:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Fibrinopeptide cleavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;When thrombin binds to fibrinogen it cleaves fibrinopeptides A (FPA) and B (FPB) from the aminoterminal portions of the Aalpha and Bbeta chains at the Arg16-Gly17 and the Arg14-Gly15 bonds, respectively, facilitating optimal fibrin polymerization (",
"    <a class=\"graphic graphic_figure graphicRef68948 \" href=\"UTD.htm?37/25/38293\">",
"     figure 1",
"    </a>",
"    ). FPA release takes place earlier and faster than FPB release and is sufficient to induce clot formation, whereas isolated cleavage of FPB is not sufficient for this purpose.",
"   </p>",
"   <p>",
"    The resultant molecule, composed of a dimer of three polypeptide chains&mdash;alpha, beta, and gamma&mdash;is referred to as a fibrin monomer, the basic unit of fibrin formation. Any structural defect of the aminoterminal region can markedly impair thrombin binding, FPA or FPB release, as well as the rate of fibrin formation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/13\">",
"     13",
"    </a>",
"    ]. It is not surprising, therefore, that a high proportion of the abnormal fibrinogens have mutations involving this region. Even so, the majority of the affected subjects remain asymptomatic, although some have excessive bleeding manifestations, especially after surgery or childbirth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Fibrin polymerization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal fibrinogen, release of negatively charged FPA and FPB results in spontaneous fibrin monomer polymerization to form the fibrin clot. This process is initiated by complementary non-covalent binding of the polymerization sites at the D region of one molecule to the central E domain of an adjacent fibrin monomer, forming a two molecule-thick strand or protofibril. Polymerization sites are located on the aminoterminal portion of the A alpha and B beta chains (E-domain), and the carboxyterminal portion of the gamma chains (D-domain). This is followed by longitudinal growth (D-D contact between adjacent fibrin monomers) and branching to form the final fibrin network (",
"    <a class=\"graphic graphic_figure graphicRef62012 \" href=\"UTD.htm?20/39/21119\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/14\">",
"     14",
"    </a>",
"    ]. Mutations affecting these binding sites may delay fibrin polymerization and produce heterogeneous clinical manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fibrin crosslinking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor XIIIa-mediated crosslinking is the final step in fibrin clot formation. FXIII is activated by thrombin, and binds to fibrin to produce covalent bonds between D domains of the fibrin fibers (",
"    <a class=\"graphic graphic_figure graphicRef62012 \" href=\"UTD.htm?20/39/21119\">",
"     figure 2",
"    </a>",
"    ). These bonds involve gamma-gamma chain as well as alpha-alpha and alpha-gamma chain interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Crosslinking stabilizes the clot and makes the clot resistant to disruption. Defective crosslinking due to an abnormal fibrinogen molecule may affect the mechanical resistance of the clot and be responsible for delayed wound healing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wound dehiscence, similar to patients with FXIII deficiency. Alternatively, increased cross-linking might predispose to thromboembolic phenomena and cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Gamma-prime fibrinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased or decreased fibrinogen crosslinking may have important hemostatic effects, as supported by observations concerning a normally-occurring fibrinogen variant, gamma-prime fibrinogen. Approximately 8 to 15 percent of plasma fibrinogen contains a variant gamma chain (gamma-prime) resulting from alternative splicing, yielding gamma-prime fibrinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. This variant is associated with clots that are structurally different, with more extensive cross-linking and greater resistance to lysis.",
"   </p>",
"   <p>",
"    A study of patients undergoing coronary angiography has shown that levels of this variant fibrinogen were higher on average in coronary artery disease patients than in patients without coronary artery disease, and that this association was independent of total fibrinogen levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/22\">",
"     22",
"    </a>",
"    ]. A case-control study performed in patients with myocardial infarction has confirmed this association [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin is a template for the assembly and activation of the fibrinolytic system. Plasminogen, tissue-type plasminogen activator (t-PA), and alpha-2-plasmin inhibitor have binding sites on the fibrin clot. Mutations affecting those regions may result in defective plasmin generation and reduced fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/6\">",
"     6",
"    </a>",
"    ]. The rate of fibrinolysis is also influenced by the thickness of the fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, resistance to the action of plasmin can result from mutations in the C-terminus of the Aalpha chain associated with abnormal albumin binding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. These mechanisms explain the thrombophilic, rather than the hemorrhagic, phenotype in some of these individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link&amp;anchor=H2#H2\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'The fibrinolytic system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONGENITAL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital disorders of fibrinogen take the form of either the production of an abnormal fibrinogen (dysfibrinogenemia) or the complete lack of production of fibrinogen (afibrinogenemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/27\">",
"     27",
"    </a>",
"    ]. Each will be described below.",
"   </p>",
"   <p>",
"    Inherited dysfibrinogenemia is the result of mutations in the coding region of the fibrinogen FGA, FGB, or FGG genes. Over 400 affected families have been reported in the literature. Over 90 percent are point missense mutations, leading to the production of a dysfunctional protein product [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. An updated online database of fibrinogen mutations is available, which also provides data on their associated clinical manifestations:",
"    <a class=\"external\" href=\"file://www.geht.org/databaseang/fibrinogen\">",
"     Fibrinogen database",
"    </a>",
"    . These modifications result in alteration of fibrinopeptide release, fibrin polymerization, fibrin crosslinking, or fibrinolysis, and may be associated with a clinical phenotype, as discussed below.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Structure/function",
"    </span>",
"    correlations can be made for several of these mutations (",
"    <a class=\"graphic graphic_figure graphicRef51010 \" href=\"UTD.htm?42/15/43261\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/5,6,30\">",
"     5,6,30",
"    </a>",
"    ]. A significant number of these mutations are located at positions Aalpha 16 Arg (the FPA cleavage site) and gamma 275 Arg (the fibrin polymerization site) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/29\">",
"     29",
"    </a>",
"    ]. These mutations account for 45 percent of dysfibrinogenemia mutations. Overall, dysfibrinogenemias can be silent (55 percent), or lead to a hemorrhagic (25 percent) or thrombotic diathesis (10 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/28,31,32\">",
"     28,31,32",
"    </a>",
"    ]. About 2 percent of the mutations may be associated with both thrombotic and bleeding complications. Asymptomatic dysfibrinogenemia is often diagnosed incidentally following the finding of abnormal coagulation tests or as part of family screening studies.",
"   </p>",
"   <p>",
"    Inherited dysfibrinogenemias are named after the city where the patient was first identified or evaluated. Roman numerals are added after the city name when there are several dysfibrinogens from the same city (eg, Caracas V). With rare exceptions, the mode of inheritance of the congenital dysfibrinogenemias is autosomal dominant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thrombotic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfibrinogenemia is a rare cause of thrombophilia; the other more common causes of thrombophilia should be excluded before the patient is evaluated for the presence of an abnormal fibrinogen. The prevalence of congenital dysfibrinogenemia in patients with a history of venous thrombosis has been estimated at 0.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The true prevalence of thrombosis among patients with dysfibrinogenemia is unknown, but is estimated to be around 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/28,32\">",
"     28,32",
"    </a>",
"    ]. Venous thrombosis of the lower extremity dominates the clinical picture; arterial thrombosis or both",
"    <span class=\"nowrap\">",
"     venous/arterial",
"    </span>",
"    thrombosis have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/33\">",
"     33",
"    </a>",
"    ]. The findings of a registry of dysfibrinogenemia and thrombophilia established by the Scientific and Standardization Subcommittee on Fibrinogen of the International Society on Thrombosis and Haemostasis were published in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/32\">",
"     32",
"    </a>",
"    ]. The registry reported 26 cases with thrombosis at young age and gathered information on family members. The mean age of first thrombosis was 27 years. A highly convincing association between dysfibrinogenemia and thrombophilia could be established for five families (Caracas V, Melun, Naples, Paris V,",
"    <span class=\"nowrap\">",
"     Vlissinger/Frankfurt",
"    </span>",
"    IV). There was a high rate of pregnancy-related complications such as postpartum thrombosis and spontaneous abortions; 3 of the 26 families experienced severe postpartum bleeding (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Pregnancy complications'",
"    </a>",
"    below). Fibrinogen concentrations were normal or low.",
"   </p>",
"   <p>",
"    Resistance to fibrinolysis due to the presence of an abnormal fibrinogen is a potential mechanism in the development of chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary embolism. Five patients with dysfibrinogenemias were identified in a cohort of 33 patients with CTEPH. Functional studies showed abnormal fibrin structure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resistance to lysis in all five [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hemorrhagic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fibrinogen levels less than 50 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    have a higher frequency of bleeding complications. Bleeding is also associated with fibrinogen mutations impairing fibrinopeptide release or fibrin monomer polymerization. Most bleeding manifestations are moderate, but some can be severe.",
"   </p>",
"   <p>",
"    The clinical presentation is heterogeneous, and may include epistaxis, menorrhagia, easy bruisability, soft tissue hemorrhage, postoperative bleeding, antepartum and postpartum bleeding, as well as hematomas and hemarthrosis. Bleeding often manifests after trauma, surgery, or during the postpartum period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Silent mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Half of the reported cases of dysfibrinogenemia remain asymptomatic as observed in family members who share the defect with the proband.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other disease manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary renal amyloidosis ��� Renal amyloidosis secondary to deposition in the kidney of a mutant fibrinogen alpha chain has been reported. Inheritance is autosomal dominant and most affected individuals develop renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/35-42\">",
"       35-42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H2#H2\">",
"       \"An overview of amyloidosis\", section on 'Pathogenesis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link&amp;anchor=H13#H13\">",
"       \"Renal amyloidosis\", section on 'Hereditary renal amyloidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatic storage disease ��� In four hypofibrinogenemia mutations, all located in exon 8 of the fibrinogen gamma gene, the abnormal fibrinogen may remain within the endoplasmic reticulum of the hepatocyte, leading to a form of hepatic storage disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/43-46\">",
"       43-46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dysfibrinogenemia can rarely cause delayed wound healing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wound dehiscence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Congenital afibrinogenemia/hypofibrinogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Afibrinogenemia, or a complete or virtually complete lack of circulating fibrinogen, is a rare condition, most often with autosomal recessive inheritance in association with consanguinity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. The estimated incidence is one per million in the general population. Hemorrhagic manifestations vary from minimal to catastrophic, and may include fatal umbilical cord hemorrhage as the first disease manifestation. In later life, the disorder may be associated with bleeding from mucosal surfaces (eg, epistaxis, menorrhagia, gastrointestinal bleeding), hemorrhage into muscles and joints, intracranial bleeding, spontaneous abortions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spontaneous splenic rupture.",
"   </p>",
"   <p>",
"    The vast majority of patients with afibrinogenemia are homozygous or compound heterozygous for truncating mutations in the fibrinogen alpha chain gene [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/51\">",
"     51",
"    </a>",
"    ], while patients with hypofibrinogenemia are usually asymptomatic carriers (heterozygotes) of afibrinogenemia mutations. Comprehensive reviews of the molecular mechanisms of congenital hypo- and a-fibrinogenemia have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heterogeneity of the disease was confirmed by the observations of a survey of 100 patients with congenital hypo- or a-fibrinogenemia. The annual incidence of bleeding episodes was 0.7, with a range from zero to 16.5 episodes per year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is established by demonstrating trace or absent immunoreactive fibrinogen in the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with hypofibrinogenemia are usually asymptomatic, except during pregnancy or when exposed to trauma. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pregnancy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal fibrinogen concentration and function are both critical for successful pregnancy outcome. Women with quantitative or qualitative fibrinogen abnormalities have an increased incidence of bleeding and thrombotic complications, recurrent spontaneous abortions, and abruptio placentae [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/32,56\">",
"     32,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen does not appear to be necessary for fertilization and initial implantation. However, fibrinogen plays a fundamental role in maintaining the integrity of placental insertion. As an example, homozygous, Aalpha chain-deficient mutant mice have fatal uterine bleeding around the tenth day of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/57\">",
"     57",
"    </a>",
"    ]. In humans, congenital hypo- or afibrinogenemia is associated with excessive bleeding and early recurrent miscarriages at five to six weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/58\">",
"     58",
"    </a>",
"    ]. The risk of postpartum bleeding is also increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital dysfibrinogenemias are associated with spontaneous abortion and postpartum venous thrombosis. In a registry of familial dysfibrinogenemia and thrombophilia, 15 female probands had a total of 34 normal deliveries. However, 24 spontaneous abortions, six stillbirths, and postpartum thromboses were also observed in seven of these 15 women. One woman developed thrombosis both during pregnancy and in the postpartum period. In contrast, two women with hypodysfibrinogenemia had excessive postpartum bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ACQUIRED DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acquired dysfibrinogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical conditions can lead to the production of an abnormal fibrinogen:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of acquired dysfibrinogenemia is liver disease. It is observed in the majority of patients with cirrhosis, acute or chronic hepatitis, and also in those with metastatic hepatoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/59-64\">",
"     59-64",
"    </a>",
"    ]. Fibrinogen dysfunction in this setting is manifested by prolongation of thrombin and reptilase times; fibrinogen levels are normal when measured by immunologic methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858451#H5858451\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Fibrinogen and individual factor levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The abnormal fibrinogen in this setting is characterized by an increased content of sialic acid residues and delayed fibrin polymerization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Both cleavage of the A and B fibrinopeptides and the crosslinking of fibrin by factor XIII are normal. Removal of the sialic acid from the abnormal fibrinogen normalizes the thrombin time and corrects the polymerization defect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/65\">",
"     65",
"    </a>",
"    ]. Normal fetal fibrinogen also exhibits an increased content of sialic acid residues and similar laboratory changes are found [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the abnormal fibrinogen seen in liver disease is associated with an increased bleeding risk is difficult to evaluate, since most of these individuals have other associated abnormalities of hemostasis (eg, thrombocytopenia, diminished synthesis of other coagulation factors)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other causes for bleeding (eg, varices, peptic ulceration). No increase in thrombotic risk has been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired dysfibrinogenemia has also been reported in association with renal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/67\">",
"     67",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/68\">",
"     68",
"    </a>",
"    ], and biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/61\">",
"     61",
"    </a>",
"    ], and in one case resulted in red cell aggregation, digital arterial occlusion, and digital gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/69\">",
"     69",
"    </a>",
"    ]. The abnormal fibrinogen may disappear with treatment of the underlying condition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/67\">",
"     67",
"    </a>",
"    ], or may disappear spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fibrinogen antibodies or inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies inhibiting specific functions of fibrinogen have been described. These antibodies can block fibrinopeptide release, fibrin monomer polymerization, or fibrin crosslinking. They have been reported in systemic lupus erythematosus, ulcerative colitis, multiple myeloma, therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , or without any underlying condition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/31,70\">",
"     31,70",
"    </a>",
"    ]. Presence of such antibodies is more commonly associated with bleeding manifestations. Clinical thrombosis associated with fibrinogen autoantibodies has been reported, although many of those patients had other risk factors for thrombosis.",
"   </p>",
"   <p>",
"    Antibodies can also be clinically silent, such as in one patient in whom the antibody interfered with fibrinopeptide B release [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/71\">",
"     71",
"    </a>",
"    ]. Blockage of fibrinopeptide A release seems to be associated with the most severe clinical manifestations. Spontaneous remissions have been reported.",
"   </p>",
"   <p>",
"    Fibrin sealant (fibrin glue) has been used during various surgical procedures for decades. Patients exposed to fibrin glue prepared from",
"    <strong>",
"     bovine",
"    </strong>",
"    sources can develop antibodies against bovine fibrinogen, which may cross-react with human fibrinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/72\">",
"     72",
"    </a>",
"    ]. Current FDA-approved commercial fibrin sealants made of",
"    <strong>",
"     human",
"    </strong>",
"    coagulant factors (Hemaseel APR or Tisseel kit VH) should eliminate this potential complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link&amp;anchor=H6#H6\">",
"     \"Fibrin sealant\", section on 'Source of thrombin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hypofibrinogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low levels of fibrinogen may occur when there is reduced synthesis or increased turnover of fibrinogen. As an example, patients with hepatic failure or decompensated cirrhosis may have low levels of fibrinogen for a number of reasons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858465#H5858465\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Fibrinogen abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Production of an abnormal fibrinogen (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Liver disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Decreased hepatic synthesis",
"     </li>",
"     <li>",
"      Increased turnover (consumption) due to the concomitant presence of disseminated intravascular coagulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fibrinogen is an acute phase reactant, with levels increasing as part of the acute inflammatory response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .) Thus, a plasma fibrinogen of 200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    although within the normal range, may represent a significant",
"    <strong>",
"     decrease",
"    </strong>",
"    in a patient whose baseline level, because of underlying malignancy, sepsis, or inflammation, should be 800",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common clinical condition associated with hypofibrinogenemia is",
"      <strong>",
"       acute",
"      </strong>",
"      disseminated intravascular coagulation (DIC), a disorder in which there is an excessive turnover of fibrinogen, due to increased consumption (",
"      <a class=\"graphic graphic_algorithm graphicRef78959 \" href=\"UTD.htm?32/4/32846\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"       \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"      </a>",
"      .) Plasma levels of fibrinogen are usually normal or increased in chronic DIC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Less common causes of hypofibrinogenemia include administration of drugs that may impair hepatic synthetic function, such as L-asparaginase [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/73,74\">",
"       73,74",
"      </a>",
"      ] and valproic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary fibrinolytic states leading to hypofibrinogenemia are rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link\">",
"       \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cryofibrinogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryofibrinogenemia refers to the presence in plasma (but not serum) of an abnormal cold-insoluble protein, composed of a combination of fibrinogen, fibrin, and fibronectin. This condition is seen most frequently in autoimmune disorders, malignancy, thrombotic disorders, and infections (eg, hepatitis C virus infection), and may be accompanied by disseminated intravascular coagulation. Symptoms, when present, include sensitivity to cold, Raynaud's phenomenon, purpura, urticaria, skin ulcerations or gangrene, and arterial or venous thromboses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7576?source=see_link\">",
"     \"Cryofibrinogenemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6298531\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders involving fibrinogen are rare but should be considered in any patient with a history of hemorrhage or thrombosis in whom the common causes have been ruled out. Global screening tests, such as whole blood clotting time, prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT) all require the production of a fibrin clot as an end point, and will be abnormally prolonged in patients with hypofibrinogenemia or afibrinogenemia. An abnormal PT, aPTT,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    TT in patients with afibrinogenemia will correct completely on addition of normal plasma or purified fibrinogen. Thus, these tests are highly sensitive for the presence of a fibrinogen disorder, but lack specificity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H32#H32\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Prolonged PT and aPTT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial screening tests for dysfibrinogenemia should include the fibrinogen concentration, as determined by both immunologic (antigenic) and clotting methods (\"clottable\" fibrinogen), thrombin time (TT), and reptilase time (RT) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/76\">",
"     76",
"    </a>",
"    ]. The TT is the more sensitive screening test, but its specificity is poor, since other more common causes for a prolonged thrombin time must first be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the reported congenital dysfibrinogenemias have a prolonged TT and RT and should be detected by these tests. A normal or shortened TT has been reported only with fibrinogens Oslo I and Valhalla [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The functional assay for fibrinogen is based upon the rate of fibrin formation in a clotting assay. The Clauss method, which uses a high concentration of thrombin added to citrated plasma, is the most commonly used, but other tests are available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Such assays measure only the fibrinogen that is incorporated into the in vitro clot, and may give misleading information since the abnormal fibrinogen may not be incorporated into the clot",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    may inhibit clotting of normal uninvolved fibrinogen molecules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6298538\">",
"    <span class=\"h2\">",
"     Specific diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inherited disorders involving fibrinogen are diagnosed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Afibrinogenemia/hypofibrinogenemia",
"       </strong>",
"      </span>",
"      ��� This diagnosis is established by demonstrating trace or absent immunoreactive fibrinogen in the plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/48\">",
"       48",
"      </a>",
"      ]. The vast majority of patients with afibrinogenemia are homozygous or compound heterozygous for truncating mutations in the fibrinogen alpha chain gene [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/51\">",
"       51",
"      </a>",
"      ], while patients with hypofibrinogenemia are usually asymptomatic carriers (heterozygotes) of afibrinogenemia mutations.",
"     </li>",
"     <li>",
"      <strong>",
"       Dysfibrinogenemia",
"      </strong>",
"      ��� In the dysfibrinogenemias, levels of functional fibrinogen (ie, clottable fibrinogen) are usually low or normal but the fibrinogen concentration is usually normal or elevated when measured immunologically (eg, radial immunodiffusion, enzyme-linked immunosorbent assay, or nephelometry). This difference reflects the presence of fibrinogen with impaired polymerization, resulting in a low ratio of functional to immunologic fibrinogen.",
"     </li>",
"     <li>",
"      <strong>",
"       Inherited dysfibrinogenemia",
"      </strong>",
"      &mdash; Inherited dysfibrinogenemia can be documented by the presence of similar laboratory abnormalities among family members. The specific diagnosis requires the demonstration of an abnormal protein or DNA sequence or characterization of the functional defect. A proposed flowchart for mutation identification can be found in a review of congenital fibrinogen disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/79\">",
"       79",
"      </a>",
"      ]. Such testing, as well as assays for fibrinogen electrophoretic migration, fibrinopeptide release, and fibrin monomer aggregation, is generally available only in research laboratories.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6298614\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of fibrinogen may be suspected most directly when there is a prolongation of the thrombin time. Conditions that can prolong the thrombin time that do not directly involve fibrinogen include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , a direct thrombin inhibitor, or heparan-like compound in the blood sample",
"     </li>",
"     <li>",
"      Presence of",
"      <span class=\"nowrap\">",
"       fibrin/fibrinogen",
"      </span>",
"      degradation products",
"     </li>",
"     <li>",
"      Presence of bovine thrombin antibodies from prior exposure to bovine thrombin",
"     </li>",
"     <li>",
"      High concentrations of serum proteins (eg, multiple myeloma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11520614\">",
"    <span class=\"h2\">",
"     General treatment principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with dysfibrinogenemia are asymptomatic and do not require treatment. For the remainder, there is considerable variability in their clinical manifestations and management must be individualized. Despite replacement with normal fibrinogen, the abnormal fibrinogen may act in a dominant manner, preventing fibrin generation from the added normal fibrinogen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a known history of previous bleeding should receive fibrinogen replacement prior to surgery. Replacement therapy is also effective when active bleeding is present. Prophylactic therapy is recommended for pregnant women (see",
"      <a class=\"local\" href=\"#H32\">",
"       'Pregnancy'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Most of the recommendations for replacement therapy in fibrinogen disorders are derived from observations in patients with afibrinogenemia. The goal is to increase fibrinogen concentration to above 50 to 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in non-surgical settings and to approximately 100 to 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for surgical prophylaxis in order to achieve normal hemostasis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/49,80\">",
"       49,80",
"      </a>",
"      ]. Sources of fibrinogen for clinical use include cryoprecipitate, fresh frozen plasma, and, where available, fibrinogen concentrates [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The United Kingdom Hemophilia Doctors&rsquo; Organisation published recommendations for the management of rare coagulation disorders, including fibrinogen deficiency. In the case of bleeding, fibrinogen levels should be maintained",
"      <strong>",
"       above 100",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"      </strong>",
"      until hemostasis is achieved, then maintained above 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      until wound healing is complete [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen replacement therapy has changed the natural history of pregnancy in patients with afibrinogenemia. The first case of a successful pregnancy in a woman with afibrinogenemia was reported in 1985, using fibrinogen infusion during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/83\">",
"     83",
"    </a>",
"    ]. Prophylaxis with fibrinogen replacement improved obstetrical outcome and prevented postpartum hemorrhage.",
"   </p>",
"   <p>",
"    Guidelines for replacement therapy are based upon the correlation between measured fibrinogen levels and bleeding episodes or fetal loss in a small number of women with afibrinogenemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/80,82,84-87\">",
"     80,82,84-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the following approach in women with afibrinogenemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Replacement therapy should be initiated as soon as pregnancy is confirmed, starting as early as week four or five of gestation, and continued throughout pregnancy and labor.",
"     </li>",
"     <li>",
"      The optimal target fibrinogen level based on experience derived from reported cases is a target trough of 100",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Fibrinogen level should be monitored weekly. Fibrinogen requirements increase significantly with the number of weeks of gestation secondary to increased clearance. It ranges from 2 g twice weekly during the first trimester to 5 g three to four times per week at term [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During labor, the fibrinogen target is at least 150 to 200",
"      <span class=\"nowrap\">",
"       mg/dL;",
"      </span>",
"      a continuous infusion may prevent placental abruption. These levels should be maintained for 24 hours postpartum.",
"     </li>",
"     <li>",
"      After 24 hours, fibrinogen levels above 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      should be maintained until the wounds have healed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the data from pregnant women with congenital afibrinogenemia, it is possible that recurrent abortion in women with dysfibrinogenemia may be prevented by the use of prophylactic fibrinogen replacement. Whether such replacement therapy is beneficial is largely unknown, and there is the potential for an increased risk of thrombosis. One report described successful pregnancy in three of four related women with a history of recurrent pregnancy loss who were treated with continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/20/14659?source=see_link\">",
"     fibrinogen concentrate",
"    </a>",
"    therapy initiated as early as possible during pregnancy (ie, at diagnosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a registry of patients with a thrombophilic dysfibrinogen, 7 of 15 women developed postpartum thrombosis during a total of 34 normal deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, prophylactic postpartum anticoagulation should be considered in these high-risk women. Fibrinogen replacement should be administered only in the presence of bleeding. In the same registry, two patients developed postpartum hemorrhage in the setting of hypodysfibrinogenemia. The patient's previous clinical history (ie, thrombosis or bleeding) should be used to guide the treatment of these women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11520852\">",
"    <span class=\"h2\">",
"     Available treatment modalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11520860\">",
"    <span class=\"h3\">",
"     Cryoprecipitate and FFP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoprecipitate (cryo) is the main source of fibrinogen in the United States. Fresh frozen plasma also contains fibrinogen and is sometimes used as an alternative, although larger volumes must be infused. The availability of fibrinogen concentrates may change this practice [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One unit of cryo contains all of the fibrinogen present in one unit of whole blood (approximately 200 to 400 mg) in a volume of 10 to 15 mL. In the average patient, each unit raises the plasma fibrinogen concentration by approximately 7 to 10",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    with a half-life of two to four days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of plasma components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For minor episodes of bleeding, 1 unit of cryo per 10 kg of body weight is usually sufficient. For major surgical procedures or serious injuries, requirements may increase to 1 unit per 5 kg. As noted above, the goal is to increase the fibrinogen concentration to more than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in order to achieve normal hemostasis, although higher levels may be required in some patients (eg, surgery, pregnancy) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/80\">",
"       80",
"      </a>",
"      ]. The fibrinogen level should be determined daily; subsequent doses are based upon the fibrinogen level obtained immediately before infusion, as well as prior effectiveness in achieving hemostasis.",
"     </li>",
"     <li>",
"      A maintenance dose of approximately one-third of the initial dose is infused daily, based upon a catabolic rate of 25 percent per day and an extravascular distribution of 30 percent. The duration of therapy can vary from a few doses to up to two to three weeks following major surgery.",
"     </li>",
"     <li>",
"      Complications of replacement therapy include allergic reactions, transmission of infectious disease, and thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/90,91\">",
"       90,91",
"      </a>",
"      ]. Rare patients with afibrinogenemia have developed antifibrinogen antibodies following replacement therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/92,93\">",
"       92,93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11520867\">",
"    <span class=\"h3\">",
"     Fibrinogen concentrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of virally-inactivated human fibrinogen concentrates are available in Europe and other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/49,89,94,95\">",
"     49,89,94,95",
"    </a>",
"    ]. A virally-inactivated human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/20/14659?source=see_link\">",
"     fibrinogen concentrate",
"    </a>",
"    (RiaSTAP, CSL Behring) prepared from human pooled plasma has been approved for use in the treatment of acute bleeding episodes in patients with congenital afibrinogenemia and hypofibrinogenemia. The recommended dose of fibrinogen concentrate (mg) is determined as follows:",
"   </p>",
"   <p>",
"    Dose (mg) = [Target fibrinogen level",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    &ndash; measured fibrinogen level] &divide; 1.7 x body weight (kg)",
"   </p>",
"   <p>",
"    If the patient's fibrinogen level is not known, a dose of 70",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    has been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/96\">",
"     96",
"    </a>",
"    ]. In a study of two formulations in 14 patients with afibrinogenemia, the median half-lives for fibrinogen activity and antigen were 77 and 88 hours, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11520874\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless there is a contraindication to its use, patients with thrombotic complications resulting from an abnormal fibrinogen should receive anticoagulation therapy. The optimal duration of anticoagulation therapy in these patients is unknown. As with all anticoagulants, the possible reduction in thrombotic episodes should be weighed against the higher risk of bleeding.",
"   </p>",
"   <p>",
"    Management decisions should be based upon the presence of risk factors for bleeding (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    ), the severity and the number of prior thrombotic events, and the phenotype of the family history. Due to the small number of affected patients, there are no data to support the use of anticoagulation in patients with a known thrombophilic dysfibrinogen who have",
"    <strong>",
"     not",
"    </strong>",
"    had a thromboembolic event. All patients should be educated about thrombotic risk factors (eg, surgery, pregnancy, oral contraceptives, immobilization) that might potentiate their underlying thrombophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Acquired thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11520881\">",
"    <span class=\"h3\">",
"     Antifibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the potential thrombogenic effect of systemic antifibrinolytic therapy, agents such as epsilon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    may be used with caution in patients with dysfibrinogenemia and bleeding, but should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with dysfibrinogenemia and thrombosis. Local treatment with these agents (eg, 5 percent mouthwash solution 10 mL four times daily for 7 to 10 days) may be useful in patients undergoing oral or dental surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/1/8218/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9299846\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen (normal level: 200 to 400",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    is the substrate for fibrin clot formation, binds to platelets to support platelet aggregation, has a role in wound healing, and is a template for both thrombin binding and the fibrinolytic system. The final result of the balance between fibrin clot formation and fibrinolysis determines whether the clinical manifestations of an abnormal fibrinogen include bleeding, thrombosis, both, or neither. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Fibrinogen structure and function'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited abnormalities of fibrinogen (afibrinogenemia, inherited dysfibrinogenemia) are uncommon, and include thrombotic, hemorrhagic, and clinically silent variants. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Congenital disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired abnormalities of fibrinogen are relatively common, and are mainly seen in patients with liver disease (dysfibrinogenemia), disseminated intravascular coagulation (hypofibrinogenemia), or associated with medications. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Acquired disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Diagnosis",
"      </strong>",
"      ��� An abnormality of fibrinogen is suspected in a patient with bleeding or thrombosis in whom most of the common causes have been ruled out. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Global screening tests, such whole blood clotting time, prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT) all require the production of a fibrin clot as an end point, and will be abnormally prolonged in patients with hypo- or afibrinogenemia.",
"     </li>",
"     <li>",
"      Abnormal tests results in patients with afibrinogenemia will correct completely on addition of normal plasma or purified fibrinogen.",
"     </li>",
"     <li>",
"      Most individuals with dysfibrinogenemia have a discrepancy between the level of clottable fibrinogen and that detected by immunologic assay, resulting in a low ratio of functional to immunologic fibrinogen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Treatment",
"      </strong>",
"      ��� Sources of fibrinogen for clinical use include cryoprecipitate, fresh frozen plasma (FFP), and fibrinogen concentrates; the latter, if available, is the preferred product. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with bleeding due to hypo- or afibrinogenemia, we recommend that one of these agents be employed to increase fibrinogen concentration to approximately 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Higher levels may be required during surgery and labor. (See",
"      <a class=\"local\" href=\"#H11520614\">",
"       'General treatment principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       Tranexamic acid",
"      </a>",
"      or epsilon",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      administered as mouth rinse can be useful to prevent bleeding after dental extraction, avoiding the need for blood products.",
"     </li>",
"     <li>",
"      Unless there is a contraindication to its use, patients with thrombotic complications resulting from an abnormal fibrinogen should receive anticoagulation therapy. The optimal duration of anticoagulation therapy in these patients is unknown. (See",
"      <a class=\"local\" href=\"#H11520874\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/1\">",
"      Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol 1972; 22:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/2\">",
"      Tennent GA, Brennan SO, Stangou AJ, et al. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/3\">",
"      Medved L, Weisel JW, Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 7:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/4\">",
"      Doolittle RF. Fibrinogen and fibrin. Sci Am 1981; 245:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/5\">",
"      Everse SJ, Spraggon G, Doolittle RF. A three-dimensional consideration of variant human fibrinogens. Thromb Haemost 1998; 80:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/6\">",
"      Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999; 25:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/7\">",
"      Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/8\">",
"      Green F, Humphries S. Control of plasma fibrinogen levels. Baillieres Clin Haematol 1989; 2:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/9\">",
"      Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/10\">",
"      Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993; 22:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/11\">",
"      Behague I, Poirier O, Nicaud V, et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 1996; 93:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/12\">",
"      Lee AJ, Fowkes FG, Lowe GD, et al. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost 1999; 81:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/13\">",
"      Martinez J. Congenital dysfibrinogenemia. Curr Opin Hematol 1997; 4:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/14\">",
"      Chernysh IN, Weisel JW. Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood 2008; 111:4854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/15\">",
"      Standeven KF, Carter AM, Grant PJ, et al. Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/16\">",
"      Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/17\">",
"      Ajjan R, Lim BC, Standeven KF, et al. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 2008; 111:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/18\">",
"      Falls LA, Farrell DH. Resistance of gammaA/gamma' fibrin clots to fibrinolysis. J Biol Chem 1997; 272:14251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/19\">",
"      Cooper AV, Standeven KF, Ari&euml;ns RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003; 102:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/20\">",
"      Collet JP, Nagaswami C, Farrell DH, et al. Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol 2004; 24:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/21\">",
"      Uitte de Willige S, Standeven KF, Philippou H, Ari&euml;ns RA. The pleiotropic role of the fibrinogen gamma' chain in hemostasis. Blood 2009; 114:3994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/22\">",
"      Lovely RS, Falls LA, Al-Mondhiry HA, et al. Association of gammaA/gamma' fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/23\">",
"      Mannila MN, Lovely RS, Kazmierczak SC, et al. Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007; 5:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/24\">",
"      Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267:24259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/25\">",
"      Wada Y, Lord ST. A correlation between thrombotic disease and a specific fibrinogen abnormality (A alpha 554 Arg--&gt;Cys) in two unrelated kindred, Dusart and Chapel Hill III. Blood 1994; 84:3709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/26\">",
"      Sugo T, Nakamikawa C, Takebe M, et al. Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila. Blood 1998; 91:3282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/27\">",
"      Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008; 14:1151.",
"     </a>",
"    </li>",
"    <li>",
"     Ebert RF. Index of variant human fibrinogen, CRC Press, Boca Raton 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/29\">",
"      Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/30\">",
"      Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114:249.",
"     </a>",
"    </li>",
"    <li>",
"     McDonagh J. Dysfibrinogenemia and other disorders of fibrinogen structure or function. In: Hemostasis and Thrombosis. Basic principles and clinical practice, 4th ed, Colman R, Hirsh J, Marder V, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.855.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/32\">",
"      Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/33\">",
"      Hamano A, Mimuro J, Aoshima M, et al. Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of gammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism. Blood 2004; 103:3045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/34\">",
"      Morris TA, Marsh JJ, Chiles PG, et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009; 114:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/35\">",
"      Benson MD, Liepnieks J, Uemichi T, et al. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet 1993; 3:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/36\">",
"      Uemichi T, Liepnieks JJ, Benson MD. Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest 1994; 93:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/37\">",
"      Uemichi T, Liepnieks JJ, Alexander F, Benson MD. The molecular basis of renal amyloidosis in Irish-American and Polish-Canadian kindreds. QJM 1996; 89:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/38\">",
"      Uemichi T, Liepnieks JJ, Yamada T, et al. A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. Blood 1996; 87:4197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/39\">",
"      Uemichi T, Liepnieks JJ, Gertz MA, Benson MD. Fibrinogen A alpha chain Leu 554: an African-American kindred with late onset renal amyloidosis. Amyloid 1998; 5:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/40\">",
"      Hamidi Asl L, Liepnieks JJ, Uemichi T, et al. Renal amyloidosis with a frame shift mutation in fibrinogen aalpha-chain gene producing a novel amyloid protein. Blood 1997; 90:4799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/41\">",
"      Hamidi Asl L, Fournier V, Billerey C, et al. Fibrinogen A alpha chain mutation (Arg554 Leu) associated with hereditary renal amyloidosis in a French family. Amyloid 1998; 5:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/42\">",
"      de Carvalho M, Linke RP, Domingos F, et al. Mutant fibrinogen A-alpha-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid 2004; 11:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/43\">",
"      Brennan SO, Maghzal G, Shneider BL, et al. Novel fibrinogen gamma375 Arg--&gt;Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/44\">",
"      Brennan SO, Wyatt J, Medicina D, et al. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly--&gt;Arg mutation. Am J Pathol 2000; 157:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/45\">",
"      Dib N, Quelin F, Ternisien C, et al. Fibrinogen angers with a new deletion (gamma GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. J Thromb Haemost 2007; 5:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/46\">",
"      Brennan SO, Davis RL, Conard K, et al. Novel fibrinogen mutation &gamma;314Thr&rarr;Pro (fibrinogen AI duPont) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia. Liver Int 2010; 30:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/47\">",
"      Mammen EF. Seminars in Thrombosis and Hemostasis. Semin Thromb Hemost 1983; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/48\">",
"      al-Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol 1994; 46:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/49\">",
"      Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/50\">",
"      Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/51\">",
"      Spena S, Duga S, Asselta R, et al. Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen Bbeta-chain gene causing activation of cryptic splice sites. Blood 2002; 100:4478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/52\">",
"      Maghzal GJ, Brennan SO, Homer VM, George PM. The molecular mechanisms of congenital hypofibrinogenaemia. Cell Mol Life Sci 2004; 61:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/53\">",
"      Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 5 Suppl 1:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/54\">",
"      Neerman-Arbez M, de Moerloose P. Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations. Hum Mutat 2007; 28:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/55\">",
"      Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/56\">",
"      Goodwin TM. Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv 1989; 44:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/57\">",
"      Suh TT, Holmb&auml;ck K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/58\">",
"      Ayg&ouml;ren-P&uuml;rs&uuml;n E, Martinez Saguer I, Rusicke E, et al. Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions. Am J Hematol 2007; 82:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/59\">",
"      Ballard JO, Kelly GA, Kukrika MD, et al. Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy. Cancer 1981; 48:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/60\">",
"      Gralnick HR, Givelber H, Abrams E. Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. N Engl J Med 1978; 299:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/61\">",
"      Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/62\">",
"      Rega&ntilde;&oacute;n E, Vila V, Aznar J, et al. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia. Thromb Res 1987; 46:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/63\">",
"      von Felten A, Straub PW, Frick PG. Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation. N Engl J Med 1969; 280:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/64\">",
"      Mammen EF. Coagulopathies of liver disease. Clin Lab Med 1994; 14:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/65\">",
"      Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983; 61:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/66\">",
"      Galanakis D, Martinez J, McDevitt C. The role of sialic acid on human fetal fibrinogen function. Symposium on fibrinogen. Ann N Y Acad Sci 1983; 408:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/67\">",
"      Dawson NA, Barr CF, Alving BM. Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. Am J Med 1985; 78:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/68\">",
"      Aurousseau MH, Levacher S, B&eacute;n&eacute;ton C, et al. [Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isotretinoin therapy]. Rev Med Interne 1995; 16:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/69\">",
"      Kwaan HC, Levin M, Sakurai S, et al. Digital ischemia and gangrene due to red blood cell aggregation induced by acquired dysfibrinogenemia. J Vasc Surg 1997; 26:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/70\">",
"      Dear A, Brennan SO, Sheat MJ, et al. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain. Haematologica 2007; 92:e111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/71\">",
"      Nawarawong W, Wyshock E, Meloni FJ, et al. The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. Br J Haematol 1991; 79:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/72\">",
"      Chouhan VD, De La Cadena RA, Nagaswami C, et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997; 77:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/73\">",
"      Gralnick HR, Henderson E. Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment. Cancer 1971; 27:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/74\">",
"      Whitecar JP Jr, Bodey GP, Harris JE, Freireich EJ. L-asparaginase. N Engl J Med 1970; 282:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/75\">",
"      Hauser E, Seidl R, Freilinger M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 1996; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/76\">",
"      Verhovsek M, Moffat KA, Hayward CP. Laboratory testing for fibrinogen abnormalities. Am J Hematol 2008; 83:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/77\">",
"      CLAUSS A. [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 1957; 17:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/78\">",
"      Mackie IJ, Kitchen S, Machin SJ, et al. Guidelines on fibrinogen assays. Br J Haematol 2003; 121:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/79\">",
"      de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009; 35:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/80\">",
"      Bornikova L, Peyvandi F, Allen G, et al. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/81\">",
"      Rahe-Meyer N, S&oslash;rensen B. For: Fibrinogen concentrate for management of bleeding. J Thromb Haemost 2011; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/82\">",
"      Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/83\">",
"      Inamoto Y, Terao T. First report of case of congenital afibrinogenemia with successful delivery. Am J Obstet Gynecol 1985; 153:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/84\">",
"      Grech H, Majumdar G, Lawrie AS, Savidge GF. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature. Br J Haematol 1991; 78:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/85\">",
"      Trehan AK, Fergusson IL. Congenital afibrinogenaemia and successful pregnancy outcome. Case report. Br J Obstet Gynaecol 1991; 98:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/86\">",
"      Kobayashi T, Kanayama N, Tokunaga N, et al. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/87\">",
"      Mensah PK, Oppenheimer C, Watson C, Pavord S. Congenital afibrinogenaemia in pregnancy. Haemophilia 2011; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/88\">",
"      Miesbach W, Galanakis D, Scharrer I. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis 2009; 20:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/89\">",
"      S&oslash;rensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/90\">",
"      Cronin C, Fitzpatrick D, Temperley I. Multiple pulmonary emboli in a patient with afibrinogenaemia. Acta Haematol 1988; 79:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/91\">",
"      MacKinnon HH, Fekete JF. Congenital afibrinogenemia. Vascular changes and multiple thromboses induced by fibrinogen infusions and contraceptive medication. Can Med Assoc J 1971; 104:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/92\">",
"      DE VRIES A, ROSENBERG T, KOCHWA S, BOSS JH. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med 1961; 30:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/93\">",
"      M&eacute;nach&eacute; D. Congenital fibrinogen abnormalities. Ann N Y Acad Sci 1983; 408:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/94\">",
"      Peyvandi F, Palla R. Fibrinogen concentrates. Clin Adv Hematol Oncol 2009; 7:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/95\">",
"      Manco-Johnson MJ, Dimichele D, Castaman G, et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost 2009; 7:2064.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribing information is available on the FDA website. www.fda.gov/cber/label/riastapLB.pdf (Accessed on January 23, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/1/8218/abstract/97\">",
"      Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada. CMAJ 1995; 153:147.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1321 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8218=[""].join("\n");
var outline_f8_1_8218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9299846\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FIBRINOGEN STRUCTURE AND FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fibrinogen synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9299647\">",
"      Conversion of fibrinogen to fibrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Fibrinopeptide cleavage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Fibrin polymerization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fibrin crosslinking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gamma-prime fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONGENITAL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thrombotic variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hemorrhagic variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Silent mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Congenital afibrinogenemia/hypofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ACQUIRED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acquired dysfibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fibrinogen antibodies or inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hypofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cryofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6298531\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6298538\">",
"      Specific diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6298614\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11520614\">",
"      General treatment principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11520852\">",
"      Available treatment modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11520860\">",
"      - Cryoprecipitate and FFP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11520867\">",
"      - Fibrinogen concentrate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11520874\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11520881\">",
"      - Antifibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9299846\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1321\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1321|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/4/32846\" title=\"algorithm 1\">",
"      Pathophysiology of DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1321|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/25/38293\" title=\"figure 1\">",
"      Fibrinogen molecule schematic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/39/21119\" title=\"figure 2\">",
"      Fibrin polymerization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/15/43261\" title=\"figure 3\">",
"      Gene map fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1321|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/38/27243\" title=\"table 1\">",
"      Fibrinogen disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7576?source=related_link\">",
"      Cryofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_1_8219="Indications for anti-(D) immune globulin";
var content_f8_1_8219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for administration of anti-(D) immune globulin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        At 28 weeks of gestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous abortion, threatened abortion, induced abortion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invasive procedures: genetic amniocentesis; chorionic villus sampling; multi-fetal reduction; fetal blood sampling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydatidiform mole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal death in the second or third trimester",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt trauma to the abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antepartum hemorrhage in the second or third trimester (eg, placenta previa or abruption)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        External cephalic version",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8219=[""].join("\n");
var outline_f8_1_8219=null;
var title_f8_1_8220="Sexual maturity rating of secondary sexual characteristics";
var content_f8_1_8220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sexual maturity rating (Tanner stages) of secondary sexual characteristics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Boys - Development of external genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 1: Prepubertal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 2: Enlargement of scrotum and testes; scrotum skin reddens and changes in texture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 3: Enlargement of penis (length at first); further growth of testes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 4: Increased size of penis with growth in breadth and development of glans; testes and scrotum larger, scrotum skin darker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 5: Adult genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Girls - Breast development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 1: Prepubertal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 2: Breast bud stage with elevation of breast and papilla; enlargement of areola",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 3: Further enlargement of breast and areola; no separation of their contour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 4: Areola and papilla form a secondary mound above level of breast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 5: Mature stage: projection of papilla only, related to recession of areola",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Boys and girls - Pubic hair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 1: Prepubertal (can see velus hair similar to abdominal wall)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 2: Sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 3: Darker, coarser and more curled hair, spreading sparsely over junction of pubes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 4: Hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 5: Adult in type and quantity, with horizontal distribution (\"feminine\")",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8220=[""].join("\n");
var outline_f8_1_8220=null;
var title_f8_1_8221="Wheezing frequency and causes";
var content_f8_1_8221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spectrum and frequency of causes of wheezing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 200px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spectrum and frequency of causes of wheeze in patients referred to a pulmonary clinic.",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br>",
"      * PNDS: post nasal drip syndrome.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8221=[""].join("\n");
var outline_f8_1_8221=null;
var title_f8_1_8222="Lepore and Kenya hemoglobins";
var content_f8_1_8222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Genesis of Lepore and Kenya hemoglobins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These figures illustrate the unequal crossing-over which underlies the production of the Lepore and Kenya hemoglobins. For ease in understanding, each \"newly created\" gene has been given a separate color. Gene segments which are composed of joined portions from two different genes are shown in parentheses. Panel (A): unequal crossing-over between the beta gene locus of one chromosome and the delta gene locus of the other yields the genes for Lepore (red) and anti-Lepore (green) hemoglobins. Panel (B): unequal crossing-over between the beta gene locus of one chromosome and the A(gamma) gene locus of the other yields the genes for Kenya (red) and anti-Kenya (green) hemoglobins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Benz EJ, Jr. The hemoglobinopathies. In: Textbook of Internal Medicine, Kelly WN, DeVita VT (Eds), JB Lippincott, Philadelphia 1988. Copyright &copy; 1988 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8222=[""].join("\n");
var outline_f8_1_8222=null;
var title_f8_1_8223="Normal leukocyte movement - no inflammatory stimulus";
var content_f8_1_8223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/60382/nl_conv.mp4?title=Normal+leukocyte+movement+-+no+inflammatory+stimulus\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal leukocyte movement, no inflammatory stimulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Amos Etzioni.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_1_8223=[""].join("\n");
var outline_f8_1_8223=null;
